https://www.novartis.com/
2024-03-08T09:13:42+01:00
daily
1.0
https://www.novartis.com/about/board-directors/william-t-winters
2024-01-25T13:46:06+01:00
daily
1.0
https://www.novartis.com/about/board-directors/ton-buechner
2024-01-25T14:49:48+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/harry-kirsch
2024-01-25T09:07:41+01:00
daily
1.0
https://www.novartis.com/about/board-directors/simon-moroney
2024-01-24T15:09:47+01:00
daily
1.0
https://www.novartis.com/about/board-directors/patrice-bula
2024-01-25T13:32:12+01:00
daily
1.0
https://www.novartis.com/about/board-directors/nancy-c-andrews
2024-01-29T13:40:51+01:00
daily
1.0
https://www.novartis.com/about/board-directors/joerg-reinhardt
2024-01-25T14:57:21+01:00
daily
1.0
https://www.novartis.com/about/board-directors/frans-van-houten
2024-02-13T10:54:22+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/karen-hale
2024-01-25T09:06:05+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/klaus-moosmayer
2024-01-25T09:03:54+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/lutz-hegemann
2024-01-25T09:09:20+01:00
daily
1.0
https://www.novartis.com/about/board-directors/elizabeth-liz-doherty
2024-01-29T13:41:30+01:00
daily
1.0
https://www.novartis.com/about/board-directors/charlotte-pamer-wieser
2024-01-25T09:27:38+01:00
daily
1.0
https://www.novartis.com/about/board-directors/charles-l-sawyers
2024-01-29T13:39:52+01:00
daily
1.0
https://www.novartis.com/about/board-directors/bridgette-heller
2024-01-25T13:53:37+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/vasant-narasimhan
2024-01-25T09:17:45+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/steffen-lang
2024-01-29T13:45:30+01:00
daily
1.0
https://www.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/julie-chauvet
2023-10-24T09:39:54+02:00
daily
1.0
https://www.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/vincent-vanwijnsberghe
2021-09-22T12:30:02+02:00
daily
1.0
https://www.novartis.com/about/novartis-and-european-union-eu/novartis-eu-public-affairs-team/sarah-moundir
2024-02-13T13:57:56+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/rob-kowalski
2024-01-25T08:53:44+01:00
daily
1.0
https://www.novartis.com/about/board-directors/daniel-hochstrasser
2024-01-25T13:56:05+01:00
daily
1.0
https://www.novartis.com/about/board-directors/ana-de-pro-gonzalo
2024-01-24T15:48:27+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/victor-bulto
2024-01-25T08:51:57+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/kees-roks
2024-01-25T09:09:43+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/shreeram-aradhye
2024-01-25T08:49:29+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/aharon-ronny-gal-phd
2024-01-25T09:05:28+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/fiona-marshall
2024-01-25T09:08:43+01:00
daily
1.0
https://www.novartis.com/about/board-directors/john-d-young
2024-01-25T13:13:57+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/michelle-weese
2024-01-25T09:10:01+01:00
daily
1.0
https://www.novartis.com/about/executive-committee/patrick-horber-md
2024-01-25T09:07:54+01:00
daily
1.0
https://www.novartis.com/clinicaltrials/study/nct04597411
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03872778
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04174157
2024-02-15T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06142383
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06142357
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06121349
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06042478
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06031844
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06019637
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06006559
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06004661
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06004453
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05996835
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05985915
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05983198
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05977322
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05976243
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05976230
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05948943
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05943522
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05921994
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05900141
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05888493
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05885555
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05870579
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05853458
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05849298
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05838768
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05803941
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05798117
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05776888
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05767034
2024-03-16T16:45:39+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05764265
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05758415
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05755386
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05750628
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05739383
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05726838
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05722522
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05703516
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05697146
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05682378
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05678959
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05677451
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05670106
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05666804
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05658003
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05653349
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05653219
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05648968
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05639114
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05634967
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05631795
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05630001
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05626257
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05624749
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05622708
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05621733
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05592990
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05576792
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05569174
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05562934
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05562466
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05552469
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05548062
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05544929
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05541341
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05524051
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05513001
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05497284
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05462990
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05462873
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05456191
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05445843
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05432388
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05429502
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05415072
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05399992
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05397496
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05388916
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05384587
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05380453
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05362903
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05360446
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05358249
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05350072
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05349214
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05344469
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05335876
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05304949
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05301907
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05294289
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05293470
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05285904
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05275868
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05274425
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05268289
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05266495
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05266469
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05252585
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05230537
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05222529
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05217810
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05201066
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05161195
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05156281
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05147220
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05142696
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05132075
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05126277
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05118230
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05110196
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05109728
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05090371
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05090033
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05084638
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05073120
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05038735
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05022342
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04985487
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04967248
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04961619
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04946305
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04943497
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04940052
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04933552
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04930094
2024-03-16T16:45:39+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04926818
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04925479
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04903197
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04889430
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04886258
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04878432
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04877522
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04873934
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04857372
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04817618
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04814368
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04797000
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04788615
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04747613
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04712721
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04699188
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04675931
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04666272
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04657822
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04641442
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04638647
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04589650
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04575025
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04557462
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04546633
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04543331
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04486716
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04480853
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04230148
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04094311
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct04058756
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03975829
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03960840
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03955445
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03876769
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03827798
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03650114
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03591510
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03474965
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03340506
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03114319
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct03040973
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct02934568
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct02584933
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct02445222
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct02386800
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct01892722
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct01285479
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06262919
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06097663
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05827081
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05329623
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06251986
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06157086
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05809986
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06053801
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05172596
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06130540
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05646381
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct06275724
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05939414
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/clinicaltrials/study/nct05842954
2024-03-16T15:00:08+01:00
0.5
https://www.novartis.com/news/media-library/manufacturing-facility-stein-ch
2021-10-11T09:11:49+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-production-and-manufacturing-b-roll-video
2022-10-25T06:14:34+02:00
daily
1.0
https://www.novartis.com/news/media-library/karen-l-hale
2022-04-04T07:08:03+02:00
daily
1.0
https://www.novartis.com/news/media-library/what-non-alcoholic-steatohepatitis-nash
2021-08-16T07:56:01+02:00
daily
1.0
https://www.novartis.com/news/media-library/access-fact-sheet
2021-08-16T09:06:09+02:00
daily
1.0
https://www.novartis.com/news/media-library/healthy-family-fact-sheet
2021-08-16T09:09:08+02:00
daily
1.0
https://www.novartis.com/news/media-library/thalassemia-backgrounder
2021-08-16T07:59:01+02:00
daily
1.0
https://www.novartis.com/news/media-library/sickle-cell-disease-backgrounder
2021-08-16T08:02:11+02:00
daily
1.0
https://www.novartis.com/news/media-library/chronic-iron-overload-backgrounder
2021-08-16T08:04:21+02:00
daily
1.0
https://www.novartis.com/news/media-library/myelodysplastic-syndromes-mds-backgrounder
2021-08-16T08:06:45+02:00
daily
1.0
https://www.novartis.com/news/media-library/anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-interactive-media-guide
2021-08-16T08:09:04+02:00
daily
1.0
https://www.novartis.com/news/media-library/neuroendocrine-tumors-expert-media-guide
2021-08-16T08:11:30+02:00
daily
1.0
https://www.novartis.com/news/media-library/leprosy
2021-08-16T08:13:18+02:00
daily
1.0
https://www.novartis.com/news/media-library/reimagining-management-sickle-cell-disease-africa
2021-08-16T08:14:54+02:00
daily
1.0
https://www.novartis.com/news/media-library/malaria
2022-03-15T09:27:38+01:00
daily
1.0
https://www.novartis.com/news/media-library/chagas-disease
2021-08-16T08:18:29+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-access-fact-sheet
2021-08-03T20:09:53+02:00
daily
1.0
https://www.novartis.com/news/media-library/chronic-myeloid-leukemia-today-and-tomorrow-visual-fact-sheet
2021-08-10T19:47:12+02:00
daily
1.0
https://www.novartis.com/news/media-library/renal-cell-carcinoma-rcc-fact-sheet
2021-08-10T19:48:06+02:00
daily
1.0
https://www.novartis.com/news/media-library/early-versus-advanced-breast-cancer-list
2021-08-10T19:49:03+02:00
daily
1.0
https://www.novartis.com/news/media-library/frontal-view-gehry-building
2021-08-16T09:15:42+02:00
daily
1.0
https://www.novartis.com/news/media-library/gehry-building-from-distance
2021-08-16T09:17:04+02:00
daily
1.0
https://www.novartis.com/news/media-library/tables-and-chairs-next-green-space
2021-08-16T09:19:39+02:00
daily
1.0
https://www.novartis.com/news/media-library/steffen-lang-phd
2023-03-16T09:44:41+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-logo
2021-10-19T15:46:43+02:00
daily
1.0
https://www.novartis.com/news/media-library/frans-van-houten
2021-08-16T10:14:04+02:00
daily
1.0
https://www.novartis.com/news/media-library/charlotte-pamer-wieser-phd
2021-08-16T10:16:06+02:00
daily
1.0
https://www.novartis.com/news/media-library/william-t-winters
2021-08-16T10:25:10+02:00
daily
1.0
https://www.novartis.com/news/media-library/charles-l-sawyers-md
2021-08-16T10:26:47+02:00
daily
1.0
https://www.novartis.com/news/media-library/elizabeth-liz-doherty
2021-08-16T10:31:06+02:00
daily
1.0
https://www.novartis.com/news/media-library/ton-buechner
2021-08-16T10:33:29+02:00
daily
1.0
https://www.novartis.com/news/media-library/nancy-c-andrews-md-phd
2021-08-16T10:35:02+02:00
daily
1.0
https://www.novartis.com/news/media-library/joerg-reinhardt-phd
2021-08-16T10:38:44+02:00
daily
1.0
https://www.novartis.com/news/media-library/vasant-vas-narasimhan-md
2022-04-04T07:02:47+02:00
daily
1.0
https://www.novartis.com/news/media-library/trees-casting-shadows-along-fabrikstrasse
2021-08-13T07:10:42+02:00
daily
1.0
https://www.novartis.com/news/media-library/harry-kirsch
2022-04-04T07:07:49+02:00
daily
1.0
https://www.novartis.com/news/media-library/antimalarial-pills
2021-08-16T10:49:45+02:00
daily
1.0
https://www.novartis.com/news/media-library/antimalarial-raw-material
2021-08-16T10:51:23+02:00
daily
1.0
https://www.novartis.com/news/media-library/artemisinin-combination-therapy-act
2021-08-16T10:54:29+02:00
daily
1.0
https://www.novartis.com/news/media-library/artemisinin-extraction
2021-08-16T10:58:31+02:00
daily
1.0
https://www.novartis.com/news/media-library/farmer-harvesting-artemisia-annua
2021-08-16T11:01:56+02:00
daily
1.0
https://www.novartis.com/news/media-library/malaria-diagnostic-test
2023-03-16T09:47:10+01:00
daily
1.0
https://www.novartis.com/news/media-library/malaria-prevention
2023-03-16T09:46:49+01:00
daily
1.0
https://www.novartis.com/news/media-library/malaria-researchers-nairobi-kenya
2021-08-16T11:13:03+02:00
daily
1.0
https://www.novartis.com/news/media-library/mode-action-cgrp-receptor-blocker
2021-08-16T11:28:31+02:00
daily
1.0
https://www.novartis.com/news/media-library/patients-frozen-t-cells
2021-08-16T11:39:02+02:00
daily
1.0
https://www.novartis.com/news/media-library/sms-life
2021-08-16T13:19:23+02:00
daily
1.0
https://www.novartis.com/news/media-library/sms-life-training-session
2021-08-16T13:22:00+02:00
daily
1.0
https://www.novartis.com/news/media-library/t-cell-arrival-novartis-manufacturing-facility
2021-08-16T13:23:31+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-fabrikstrasse-novartis-hq
2021-08-16T13:24:57+02:00
daily
1.0
https://www.novartis.com/news/media-library/worldwide-distribution-center-novartis-antimalarial-basel-switzerland
2021-08-16T13:30:21+02:00
daily
1.0
https://www.novartis.com/news/media-library/young-malaria-patient
2023-03-16T09:45:27+01:00
daily
1.0
https://www.novartis.com/news/media-library/cancer-2030-growing-global-crisis
2021-08-16T13:35:05+02:00
daily
1.0
https://www.novartis.com/news/media-library/sickle-cell-world-assessment-survey-sway-results
2021-08-16T13:35:58+02:00
daily
1.0
https://www.novartis.com/news/media-library/new-era-medicine
2021-08-16T13:37:09+02:00
daily
1.0
https://www.novartis.com/news/media-library/cell-and-gene-key-focus-areas
2021-08-16T13:40:35+02:00
daily
1.0
https://www.novartis.com/news/media-library/introduction-cell-and-gene-therapy
2021-08-16T13:42:42+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-financial-results-q3-2018-infographic
2021-08-16T13:44:09+02:00
daily
1.0
https://www.novartis.com/news/media-library/klaus-moosmayer-phd
2022-04-04T07:07:06+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-financial-results-q2-2018-infographic
2021-08-12T06:34:21+02:00
daily
1.0
https://www.novartis.com/news/media-library/impact-migraine
2021-08-12T06:51:56+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-financial-results-q1-2018-infographic
2021-08-12T07:26:12+02:00
daily
1.0
https://www.novartis.com/news/media-library/spinal-muscular-atrophy-sma-infographic
2021-08-13T13:21:00+02:00
daily
1.0
https://www.novartis.com/news/media-library/inflammation-and-cardiovascular-risk
2021-08-12T07:45:54+02:00
daily
1.0
https://www.novartis.com/news/media-library/measuring-inflammation-and-role-hscrp
2021-08-16T07:42:14+02:00
daily
1.0
https://www.novartis.com/news/media-library/chimeric-antigen-receptor-t-cell-car-t-therapy
2021-08-16T13:45:57+02:00
daily
1.0
https://www.novartis.com/news/media-library/chronic-iron-overload-infographic
2021-08-12T07:55:14+02:00
daily
1.0
https://www.novartis.com/news/media-library/chronic-myleoid-leukemia-meet-milestones-matter-one-pager
2021-08-12T07:57:02+02:00
daily
1.0
https://www.novartis.com/news/media-library/facts-about-melanoma-infographic
2021-08-12T08:03:57+02:00
daily
1.0
https://www.novartis.com/news/media-library/chronic-iron-overload-complications-infographic
2021-08-12T08:04:00+02:00
daily
1.0
https://www.novartis.com/news/media-library/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-disease-state-infographic
2021-08-12T08:09:48+02:00
daily
1.0
https://www.novartis.com/news/media-library/about-noncommunicable-diseases-infographic
2021-08-12T08:15:02+02:00
daily
1.0
https://www.novartis.com/news/media-library/access-ncd-treatment-infographic
2021-08-12T08:16:03+02:00
daily
1.0
https://www.novartis.com/news/media-library/understanding-chronic-myeloid-leukemia-infographic
2021-08-12T08:19:53+02:00
daily
1.0
https://www.novartis.com/news/media-library/gastrointestinal-neuroendocrine-tumors-infographic
2021-08-12T08:27:54+02:00
daily
1.0
https://www.novartis.com/news/media-library/pancreatic-neuroendocrine-tumors-infographic
2021-08-12T08:36:26+02:00
daily
1.0
https://www.novartis.com/news/media-library/lung-neuroendocrine-tumors-infographic
2021-08-12T08:44:12+02:00
daily
1.0
https://www.novartis.com/news/media-library/tuberous-sclerosis-complex-patient-journey-infographic
2021-08-12T08:52:12+02:00
daily
1.0
https://www.novartis.com/news/media-library/advanced-soft-tissue-sarcoma-infographic
2021-08-12T08:52:41+02:00
daily
1.0
https://www.novartis.com/news/media-library/tuberous-sclerosis-complex-common-threads-infographic
2021-08-12T09:04:26+02:00
daily
1.0
https://www.novartis.com/news/media-library/renal-cell-carcinoma-infographic
2021-08-12T09:06:05+02:00
daily
1.0
https://www.novartis.com/news/media-library/embarking-young-adulthood-tsc-monitoring-manifestations-over-time
2021-08-12T09:06:40+02:00
daily
1.0
https://www.novartis.com/news/media-library/psychological-social-impact-advanced-breast-cancer
2021-08-12T09:12:17+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-us-report-2020
2021-08-12T09:14:45+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-esg-report-2020
2021-08-12T09:28:05+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-annual-report-2020
2021-08-12T09:30:15+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-annual-report-2019
2021-08-16T08:35:26+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-us-report-2019
2021-08-12T09:53:11+02:00
daily
1.0
https://www.novartis.com/news/media-library/malaria-futures-central-africa
2021-08-12T09:58:22+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-esg-report-2019
2021-08-12T10:03:08+02:00
daily
1.0
https://www.novartis.com/news/media-library/malaria-futures-asia
2021-08-12T10:23:17+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-social-business-report-2018
2021-08-12T10:29:05+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-us-report-2018
2021-08-12T10:35:50+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-report-2018
2022-02-01T18:02:31+01:00
daily
1.0
https://www.novartis.com/news/media-library/malaria-futures-africa
2021-08-12T10:46:32+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-annual-report-2018
2021-08-12T10:50:03+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-annual-report-2017
2021-08-12T10:50:20+02:00
daily
1.0
https://www.novartis.com/news/media-library/healthy-family-10-year-report
2021-08-12T10:54:45+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-access-two-year-report
2021-08-12T10:59:27+02:00
daily
1.0
https://www.novartis.com/news/media-library/corporate-responsibility-report-2017
2021-08-12T10:59:36+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-access-one-year-report
2021-08-12T11:08:28+02:00
daily
1.0
https://www.novartis.com/news/media-library/building-trust-society-our-priorities
2021-08-16T09:02:11+02:00
daily
1.0
https://www.novartis.com/news/media-library/strengthening-our-global-health-corporate-responsibility-function
2021-08-13T08:18:24+02:00
daily
1.0
https://www.novartis.com/news/media-library/spinal-muscular-atrophy-sma-factsheet
2021-08-13T08:51:52+02:00
daily
1.0
https://www.novartis.com/news/media-library/heart-failure-hospitalization-why-moment-matters
2021-08-13T08:46:29+02:00
daily
1.0
https://www.novartis.com/news/media-library/about-migraine
2021-08-13T08:55:50+02:00
daily
1.0
https://www.novartis.com/news/media-library/diffuse-large-b-cell-lymphoma-dlbcl
2021-08-13T09:01:52+02:00
daily
1.0
https://www.novartis.com/news/media-library/acute-lymphoblastic-leukemia-all
2021-08-13T09:46:11+02:00
daily
1.0
https://www.novartis.com/news/media-library/acute-lymphoblastic-leukemia-fact-sheet
2021-08-13T09:51:42+02:00
daily
1.0
https://www.novartis.com/news/media-library/advancing-global-health
2021-08-13T10:03:30+02:00
daily
1.0
https://www.novartis.com/news/media-library/chronic-myeloid-leukemia-background-fact-sheet
2021-08-12T11:55:53+02:00
daily
1.0
https://www.novartis.com/news/media-library/science-behind-car-t-cell-therapy
2023-03-16T09:47:33+01:00
daily
1.0
https://www.novartis.com/news/media-library/manufacturing-car-t-cell-therapies-novartis-approach
2021-08-12T13:13:50+02:00
daily
1.0
https://www.novartis.com/news/media-library/lutz-hegemann-md-phd
2023-08-04T10:30:21+02:00
daily
1.0
https://www.novartis.com/news/media-library/bridgette-heller
2021-08-12T14:40:41+02:00
daily
1.0
https://www.novartis.com/news/media-library/simon-moroney-dphil
2023-03-16T09:47:55+01:00
daily
1.0
https://www.novartis.com/news/media-library/bad-sackingen-novartis-stein-switzerland
2021-08-12T14:54:42+02:00
daily
1.0
https://www.novartis.com/news/media-library/operator-culture-medium-bag
2021-08-12T14:58:17+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-site-stein-switzerland
2021-08-12T15:02:35+02:00
daily
1.0
https://www.novartis.com/news/media-library/marc-boutin
2021-10-05T14:35:43+02:00
daily
1.0
https://www.novartis.com/news/media-library/operators-clean-room
2021-08-13T06:19:14+02:00
daily
1.0
https://www.novartis.com/news/media-library/operator-labels-culture-plates
2021-08-13T06:23:38+02:00
daily
1.0
https://www.novartis.com/news/media-library/operator-prepares-connecting-hose
2021-08-13T06:25:22+02:00
daily
1.0
https://www.novartis.com/news/media-library/patrice-bula
2022-03-03T10:25:30+01:00
daily
1.0
https://www.novartis.com/news/media-library/people-park
2021-08-13T06:31:31+02:00
daily
1.0
https://www.novartis.com/news/media-library/break-park
2021-08-13T06:33:14+02:00
daily
1.0
https://www.novartis.com/news/media-library/operator-performs-process-operation-biosafety-cabinet
2021-08-13T06:36:44+02:00
daily
1.0
https://www.novartis.com/news/media-library/grocery-shop-staircase
2021-08-13T06:40:11+02:00
daily
1.0
https://www.novartis.com/news/media-library/staircase-fabrikstrasse-6-peter-markli
2023-03-30T09:37:14+02:00
daily
1.0
https://www.novartis.com/news/media-library/avenue-trees-along-fabrikstrasse
2021-08-13T07:03:30+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-fabrikstrasse-6-peter-markli-trees
2023-03-30T09:30:01+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-staircase-gehry-building
2021-08-13T07:25:15+02:00
daily
1.0
https://www.novartis.com/news/media-library/first-results-from-global-net-survey-part-1-time-diagnosis
2021-08-13T07:51:07+02:00
daily
1.0
https://www.novartis.com/news/media-library/tackling-chronic-disease-novartis-access
2021-10-12T11:24:54+02:00
daily
1.0
https://www.novartis.com/news/media-library/results-from-first-global-net-survey-part-2-net-patient-experience
2021-08-13T08:32:41+02:00
daily
1.0
https://www.novartis.com/news/media-library/what-polycythemia-vera
2023-03-15T14:10:34+01:00
daily
1.0
https://www.novartis.com/news/media-library/how-polycythemia-vera-diagnosed
2021-08-13T07:59:25+02:00
daily
1.0
https://www.novartis.com/news/media-library/what-are-symptoms-and-complications-polycythemia-vera
2021-08-13T08:11:00+02:00
daily
1.0
https://www.novartis.com/news/media-library/tsc-common-threads-future-outlook-tsc
2021-08-13T08:18:13+02:00
daily
1.0
https://www.novartis.com/news/media-library/tsc-common-threads-grandia-family-story
2021-08-13T08:33:10+02:00
daily
1.0
https://www.novartis.com/news/media-library/tsc-talk-did-you-know
2021-08-13T08:33:26+02:00
daily
1.0
https://www.novartis.com/news/media-library/tsc-common-threads-tsc-affects-each-person-differently
2021-08-13T08:40:12+02:00
daily
1.0
https://www.novartis.com/news/media-library/tsc-common-threads-moss-family
2021-08-13T08:44:35+02:00
daily
1.0
https://www.novartis.com/news/media-library/tsc-common-threads-life-tsc
2021-08-13T08:46:09+02:00
daily
1.0
https://www.novartis.com/news/media-library/acute-myeloid-leukemia-unique-needs-patients-and-caregivers
2021-08-13T08:52:07+02:00
daily
1.0
https://www.novartis.com/news/media-library/alk-non-small-cell-lung-cancer-patient-video-anne-marie
2021-08-13T08:57:10+02:00
daily
1.0
https://www.novartis.com/news/media-library/alk-non-small-cell-lung-cancer-patient-video-miriam-joel
2021-08-13T09:06:36+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-access-how-well-expand-access-healthcare
2021-08-13T09:12:50+02:00
daily
1.0
https://www.novartis.com/news/media-library/experts-gather-explore-response-chronic-illness-poor-countries
2021-08-13T09:12:01+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-and-international-red-cross-partner-provide-medicines-syrian-refugees
2021-08-13T09:18:38+02:00
daily
1.0
https://www.novartis.com/news/media-library/museum-ms
2021-08-13T09:21:24+02:00
daily
1.0
https://www.novartis.com/news/media-library/what-do-you-know-about-noncommunicable-diseases
2021-08-13T09:27:29+02:00
daily
1.0
https://www.novartis.com/news/media-library/about-erenumab-amg-334
2021-09-09T10:48:41+02:00
daily
1.0
https://www.novartis.com/news/media-library/erenumab-amg-334-key-clinical-trials-numbers
2021-09-09T10:48:29+02:00
daily
1.0
https://www.novartis.com/news/media-library/how-does-acz885-work
2021-09-09T10:48:16+02:00
daily
1.0
https://www.novartis.com/news/media-library/juliet-clinical-trial
2021-09-09T10:48:04+02:00
daily
1.0
https://www.novartis.com/news/media-library/kymriah-tisagenlecleucel-children-and-young-adults-b-cell-all-refractory-or-relapsed-least-twice
2022-10-20T11:02:08+02:00
daily
1.0
https://www.novartis.com/news/media-library/rth258-brolucizumab-clinical-trials
2021-09-09T10:47:38+02:00
daily
1.0
https://www.novartis.com/news/media-library/kymriah-tisagenlecleucel-suspension-intravenous-infusion
2022-10-20T10:55:43+02:00
daily
1.0
https://www.novartis.com/news/media-library/interleukin-17-il-17a-inflammatory-joint-disease
2021-09-09T10:47:10+02:00
daily
1.0
https://www.novartis.com/news/media-library/interleukin-17-il-17a-psoriasis
2021-09-09T10:46:13+02:00
daily
1.0
https://www.novartis.com/news/media-library/rob-kowalski
2022-04-04T07:07:27+02:00
daily
1.0
https://www.novartis.com/news/media-library/managing-tsc-transition-adult-care
2021-10-06T09:33:37+02:00
daily
1.0
https://www.novartis.com/news/media-library/nibr-basel
2022-10-25T06:12:17+02:00
daily
1.0
https://www.novartis.com/news/media-library/nibr-cambridge-united-states
2022-10-25T06:11:34+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-animated-logo
2022-10-25T06:10:55+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-forum-1-and-fabrikstrasse-novartis-campus-basel
2021-12-07T14:30:18+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-fabrikstrasse-15-novartis-campus-basel
2021-12-07T10:11:08+01:00
daily
1.0
https://www.novartis.com/news/media-library/outside-meeting-space-novartis-campus-basel
2021-12-08T09:48:37+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-asklepios-8-along-rhine-riverbank-novartis-campus-basel
2021-12-07T14:29:09+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-towards-asklepios-8-and-dreirosenbruckebasel-novartis-campus-basel
2021-12-07T14:37:40+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-banting-1-and-novartis-campus-basel
2021-12-13T10:14:35+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-banting-1
2021-12-13T10:14:45+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-novartis-campus-and-banting-1-basel
2021-12-13T10:14:23+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-banting-1-and-fabrikstrasse-novartis-campus-basel
2022-01-26T15:09:13+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-banting-1-and-fabrikstrasse-6-passing-cyclist-novartis-campus-basel
2022-01-26T15:18:29+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-banting-1-and-fabrikstrasse-6-novartis-campus-basel
2022-01-26T15:18:03+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-annual-report-2021
2022-02-01T23:17:40+01:00
daily
1.0
https://www.novartis.com/news/media-library/ana-de-pro-gonzalo
2022-03-04T14:59:28+01:00
daily
1.0
https://www.novartis.com/news/media-library/daniel-hochstrasser
2023-03-16T09:45:06+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-novartis-campus-forum-1-banting-1-and-fabrikstrasse
2022-04-05T15:44:31+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-pavillon-banting-1-background
2022-04-05T15:45:07+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-pavillon-novartis-campus-and-banting-1-background
2022-04-05T15:45:58+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-from-novartis-campus-towards-novartis-pavillon-and-basel-alongside-rhine-river
2022-04-05T15:46:51+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-from-novartis-campus-towards-novartis-pavillon-and-basel
2022-04-05T15:48:12+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-pavillon-located-park-south-novartis-campus
2022-04-05T15:51:10+02:00
daily
1.0
https://www.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon-artwork-semiconductor-0
2022-04-05T15:50:05+02:00
daily
1.0
https://www.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon-artwork-semiconductor
2022-04-05T15:52:08+02:00
daily
1.0
https://www.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon-0
2022-04-05T15:52:45+02:00
daily
1.0
https://www.novartis.com/news/media-library/illumination-zero-energy-media-facade-novartis-pavillon
2022-04-05T15:53:35+02:00
daily
1.0
https://www.novartis.com/news/media-library/organic-solar-cell-led-core-which-builds-illuminating-skin-novartis-pavillon
2022-04-05T15:54:18+02:00
daily
1.0
https://www.novartis.com/news/media-library/schoolhub-ground-floor-novartis-pavillon
2022-04-05T15:54:52+02:00
daily
1.0
https://www.novartis.com/news/media-library/interior-view-ground-floor-novartis-pavillon
2022-04-05T15:55:19+02:00
daily
1.0
https://www.novartis.com/news/media-library/welcome-wall-and-staircase-exhibition-wonders-medicine-novartis-pavillon
2022-04-05T15:56:13+02:00
daily
1.0
https://www.novartis.com/news/media-library/welcome-wall-novartis-pavillon
2022-04-05T15:56:39+02:00
daily
1.0
https://www.novartis.com/news/media-library/content-area-fragility-life-wonders-medicine-exhibition-novartis-pavillon
2022-04-05T15:57:24+02:00
daily
1.0
https://www.novartis.com/news/media-library/victor-bulto
2023-10-04T12:01:30+02:00
daily
1.0
https://www.novartis.com/news/media-library/kees-roks
2022-05-02T11:41:28+02:00
daily
1.0
https://www.novartis.com/news/media-library/shreeram-aradhye-md
2023-10-04T12:00:45+02:00
daily
1.0
https://www.novartis.com/news/media-library/crizanlizumab-clinical-setting-from-international-managed-access-program-map
2022-06-17T12:20:56+02:00
daily
1.0
https://www.novartis.com/news/media-library/aharon-ronny-gal-phd
2022-09-12T14:17:27+02:00
daily
1.0
https://www.novartis.com/news/media-library/about-gene-therapy
2022-08-12T09:29:48+02:00
daily
1.0
https://www.novartis.com/news/media-library/gene-therapy-manufacturing-north-carolina
2022-08-12T09:34:45+02:00
daily
1.0
https://www.novartis.com/news/media-library/about-novartis-gene-therapies
2022-10-03T10:34:29+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-gene-therapies-manufacturing-process
2022-10-03T10:31:51+02:00
daily
1.0
https://www.novartis.com/news/media-library/screen-unseen-newborn-screening-sma
2022-08-12T09:22:53+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-aav-platform
2022-10-03T10:28:58+02:00
daily
1.0
https://www.novartis.com/news/media-library/spinal-muscular-atrophy
2022-08-12T09:33:04+02:00
daily
1.0
https://www.novartis.com/news/media-library/scientist-laboratory-banting-1-office-space-background
2022-09-05T16:45:45+02:00
daily
1.0
https://www.novartis.com/news/media-library/scientists-fermentation-hub-banting-1
2022-09-05T16:45:37+02:00
daily
1.0
https://www.novartis.com/news/media-library/fermentation-hub-banting-1-where-natural-products-and-biomolecules-can-be-produced
2022-09-05T16:45:29+02:00
daily
1.0
https://www.novartis.com/news/media-library/scientists-one-state-art-laboratories-banting-1
2022-09-05T16:45:14+02:00
daily
1.0
https://www.novartis.com/news/media-library/scientists-laboratory-banting-1-where-global-discovery-chemistry-group-based
2022-09-05T16:45:05+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-asklepios-building-oscillation-bench-front
2022-10-27T11:02:48+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-pavillon-located-park-south-novartis-campus-0
2022-10-27T11:06:14+02:00
daily
1.0
https://www.novartis.com/news/media-library/park-south-novartis-campus-view-novartis-pavillon
2022-10-27T11:24:37+02:00
daily
1.0
https://www.novartis.com/news/media-library/laboratory-building-virchow-6-novartis-campus
2022-10-27T11:07:29+02:00
daily
1.0
https://www.novartis.com/news/media-library/architects-map-novartis-campus-english-version
2022-10-27T10:30:25+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-gehry-building-green-and-fabrikstrasse-novartis-campus-basel
2022-10-27T11:08:06+02:00
daily
1.0
https://www.novartis.com/news/media-library/fiona-h-marshall-phd
2023-10-04T11:57:56+02:00
daily
1.0
https://www.novartis.com/news/media-library/how-novartis-contributing-fight-against-malaria
2022-11-23T07:44:14+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-annual-report-2022
2023-02-02T12:55:12+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-integrated-report-2022
2023-02-17T18:02:34+01:00
daily
1.0
https://www.novartis.com/news/media-library/52-week-results-cosentyx-hidradenitis-suppurativa-summary
2023-02-08T07:37:04+01:00
daily
1.0
https://www.novartis.com/news/media-library/production-process-rna-therapies-schweizerhalle-switzerland
2023-02-16T15:31:34+01:00
daily
1.0
https://www.novartis.com/news/media-library/view-rna-production-schweizerhalle-switzerland
2023-02-16T15:31:52+01:00
daily
1.0
https://www.novartis.com/news/media-library/manufacturing-rna-therapies-schweizerhalle-switzerland
2023-02-16T15:31:43+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-integrierter-geschaftsbericht-2022
2023-02-17T18:02:26+01:00
daily
1.0
https://www.novartis.com/news/media-library/john-d-young
2023-03-07T12:21:40+01:00
daily
1.0
https://www.novartis.com/news/media-library/main-entrance-novartis-pavillon
2023-03-30T09:27:34+02:00
daily
1.0
https://www.novartis.com/news/media-library/birds-eye-view-novartis-pavillon
2023-03-30T09:28:12+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-from-kleinbasel-towards-novartis-campus-basel
2023-03-30T09:32:11+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-novartis-pavillon-towards-dreirosenbrucke-and-city-center
2023-03-30T09:27:40+02:00
daily
1.0
https://www.novartis.com/news/media-library/view-from-hohlweg-passing-under-novartis-pavillon
2023-03-30T09:28:05+02:00
daily
1.0
https://www.novartis.com/news/media-library/wonders-medicine-exhibition-novartis-pavillon
2023-03-30T09:28:27+02:00
daily
1.0
https://www.novartis.com/news/media-library/wonders-medicine-exhibition-from-lab-patient-novartis-pavillon
2023-03-30T09:28:34+02:00
daily
1.0
https://www.novartis.com/news/media-library/wonders-medicine-exhibition-from-lab-patient-novartis-pavillon-0
2023-03-30T09:28:41+02:00
daily
1.0
https://www.novartis.com/news/media-library/wonders-medicine-exhibition-steps-through-time-novartis-pavillon
2023-03-30T09:28:48+02:00
daily
1.0
https://www.novartis.com/news/media-library/wonders-medicine-exhibition-future-healthcare-novartis-pavillon
2023-03-30T09:28:54+02:00
daily
1.0
https://www.novartis.com/news/media-library/schoolhub-novartis-pavillon
2023-03-30T09:27:21+02:00
daily
1.0
https://www.novartis.com/news/media-library/pedestrian-path-trees-novartis-campus-basel
2023-03-30T09:29:01+02:00
daily
1.0
https://www.novartis.com/news/media-library/fabrikstrasse-4-sanaa-novartis-campus-basel
2023-03-30T09:29:07+02:00
daily
1.0
https://www.novartis.com/news/media-library/fabrikstrasse-28-tadao-ando-and-artwork-richard-serra-novartis-campus-basel
2023-03-30T09:29:15+02:00
daily
1.0
https://www.novartis.com/news/media-library/fabrikstrasse-12-vittorio-magnago-lampugnani-novartis-campus-basel
2023-03-30T09:29:22+02:00
daily
1.0
https://www.novartis.com/news/media-library/banting-1-and-artwork-structure-life-claudia-comte-novartis-campus-basel
2023-03-30T09:29:30+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-campus-basel-switzerland
2023-06-05T15:07:42+02:00
daily
1.0
https://www.novartis.com/news/media-library/michelle-weese
2023-08-11T11:53:02+02:00
daily
1.0
https://www.novartis.com/news/media-library/cardiovascular-disease-victorion-media-summary
2023-09-12T16:34:03+02:00
daily
1.0
https://www.novartis.com/news/media-library/cardiovascular-disease-numbers
2023-09-12T16:34:25+02:00
daily
1.0
https://www.novartis.com/news/media-library/cardiovascular-disease-orion-8-media-summary
2023-09-12T16:33:45+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-vertical
2023-10-23T13:22:46+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-from-main-gate-novartis-campus-basel-vertical
2023-10-23T13:20:28+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-from-park-south-novartis-campus-basel-vertical
2023-10-23T13:41:25+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-vertical-0
2023-10-23T13:43:21+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-vertical-1
2023-10-23T13:45:14+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-logo-banting-1-building-novartis-campus-basel-horizontal
2023-10-23T13:46:50+02:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-logo-through-colorful-facade-forum-3-novartis-campus-basel-vertical
2023-10-23T13:50:02+02:00
daily
1.0
https://www.novartis.com/news/media-library/access-medicines-eu-member-states
2023-11-23T11:49:50+01:00
daily
1.0
https://www.novartis.com/news/media-library/intellectual-property-including-regulatory-data-protection-rdp
2023-11-23T11:50:00+01:00
daily
1.0
https://www.novartis.com/news/media-library/regulatory-ema
2023-11-23T11:50:11+01:00
daily
1.0
https://www.novartis.com/news/media-library/orphan-medicinal-products-pediatrics
2023-11-23T11:50:21+01:00
daily
1.0
https://www.novartis.com/news/media-library/security-supply
2023-11-23T11:50:31+01:00
daily
1.0
https://www.novartis.com/news/media-library/vasant-vas-narasimhan-md-0
2023-11-28T15:42:41+01:00
daily
1.0
https://www.novartis.com/news/media-library/vasant-vas-narasimhan-md-1
2023-11-28T15:42:21+01:00
daily
1.0
https://www.novartis.com/news/media-library/fiona-h-marshall-phd-0
2023-11-28T11:24:41+01:00
daily
1.0
https://www.novartis.com/news/media-library/fiona-h-marshall-phd-1
2023-11-28T15:39:29+01:00
daily
1.0
https://www.novartis.com/news/media-library/harry-kirsch-0
2023-11-28T15:38:25+01:00
daily
1.0
https://www.novartis.com/news/media-library/harry-kirsch-1
2023-11-28T15:38:02+01:00
daily
1.0
https://www.novartis.com/news/media-library/aharon-ronny-gal-phd-0
2023-11-28T15:37:39+01:00
daily
1.0
https://www.novartis.com/news/media-library/aharon-ronny-gal-phd-1
2023-11-28T15:37:17+01:00
daily
1.0
https://www.novartis.com/news/media-library/rob-kowalski-0
2023-11-28T15:36:48+01:00
daily
1.0
https://www.novartis.com/news/media-library/rob-kowalski-1
2023-11-28T15:36:26+01:00
daily
1.0
https://www.novartis.com/news/media-library/shreeram-aradhye-md-0
2023-11-28T15:36:01+01:00
daily
1.0
https://www.novartis.com/news/media-library/shreeram-aradhye-md-1
2023-11-28T15:35:37+01:00
daily
1.0
https://www.novartis.com/news/media-library/victor-bulto-0
2023-11-28T15:34:45+01:00
daily
1.0
https://www.novartis.com/news/media-library/victor-bulto-1
2023-11-28T15:35:09+01:00
daily
1.0
https://www.novartis.com/news/media-library/steffen-lang-phd-0
2023-11-28T15:34:12+01:00
daily
1.0
https://www.novartis.com/news/media-library/steffen-lang-phd-1
2023-11-28T14:36:26+01:00
daily
1.0
https://www.novartis.com/news/media-library/klaus-moosmayer-phd-0
2023-11-28T14:56:56+01:00
daily
1.0
https://www.novartis.com/news/media-library/klaus-moosmayer-phd-1
2023-11-28T14:58:31+01:00
daily
1.0
https://www.novartis.com/news/media-library/lutz-hegemann-md-phd-0
2023-11-28T15:05:54+01:00
daily
1.0
https://www.novartis.com/news/media-library/lutz-hegemann-md-phd-1
2023-11-28T15:07:29+01:00
daily
1.0
https://www.novartis.com/news/media-library/kees-roks-0
2023-11-28T15:13:38+01:00
daily
1.0
https://www.novartis.com/news/media-library/kees-roks-1
2023-11-28T15:15:12+01:00
daily
1.0
https://www.novartis.com/news/media-library/karen-l-hale-0
2023-11-28T15:24:55+01:00
daily
1.0
https://www.novartis.com/news/media-library/karen-l-hale-1
2023-11-28T15:26:33+01:00
daily
1.0
https://www.novartis.com/news/media-library/karen-l-hale-2
2023-11-28T15:28:19+01:00
daily
1.0
https://www.novartis.com/news/media-library/michelle-weese-0
2023-11-29T13:46:39+01:00
daily
1.0
https://www.novartis.com/news/media-library/patrick-horber-md
2023-11-30T13:24:01+01:00
daily
1.0
https://www.novartis.com/news/media-library/patrick-horber-md-0
2023-12-05T08:22:40+01:00
daily
1.0
https://www.novartis.com/news/media-library/patrick-horber-md-1
2023-12-05T08:23:08+01:00
daily
1.0
https://www.novartis.com/news/media-library/patrick-horber-md-2
2023-12-05T08:23:25+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-integrated-report-2023
2024-01-30T18:26:35+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-annual-report-2023
2024-01-30T18:24:37+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-radioligand-therapy-rlt-manufacturing
2024-02-13T08:47:54+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-society-integrierter-geschaftsbericht-2023
2024-02-16T14:10:26+01:00
daily
1.0
https://www.novartis.com/news/media-library/quality-control-environmental-monitoring-radioligand-therapy-rlt-manufacturing
2024-03-13T08:52:33+01:00
daily
1.0
https://www.novartis.com/news/media-library/specialized-equipment-manufacture-radioligand-therapy-rlt
2024-03-13T08:53:34+01:00
daily
1.0
https://www.novartis.com/news/media-library/refrigeration-room-novartis-radioligand-therapy-rlt-manufacturing-facility
2024-03-13T08:54:18+01:00
daily
1.0
https://www.novartis.com/news/media-library/radioligand-therapy-rlt-production-line
2024-03-13T08:54:58+01:00
daily
1.0
https://www.novartis.com/news/media-library/novartis-radioligand-therapy-rlt-manufacturing-facility
2024-03-13T08:55:44+01:00
daily
1.0
https://www.novartis.com/news/in-the-news/pandemic-has-been-reset-pharmas-reputation
2021-09-10T11:48:12+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/moving-towards-next-normal
2021-09-21T06:27:55+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/enabling-stable-supply-medicines-during-covid-19
2021-09-21T06:31:00+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/overcoming-manufacturing-challenges
2021-09-21T06:32:37+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/proactive-scenario-planning-and-supply-risk-management
2021-09-21T06:34:17+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/supply-chain-organization-during-covid-19-pandemic
2021-09-21T06:41:10+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/coronavirus-giving-health-and-pharma-companies-chance-woo-tech-talent
2021-09-21T06:45:22+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/pharmas-pandemic-response-could-help-attract-tech-talent
2021-09-21T06:46:39+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/new-era-healthcare-innovation
2021-09-21T07:06:57+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/developing-drugs-during-pandemic
2021-09-21T07:18:38+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/breaking-through-glass-ceiling-spring-women-artificial-intelligence
2021-09-21T07:22:02+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/curious-advantage-curiosity-ceo-and-chief-people-and-organization-officer-perspective
2021-09-21T08:04:19+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-pharmaceuticals-head-chief-marie-france-tschudin-rethinking-drug-launch-formula
2021-09-21T08:06:23+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-ceo-vasant-narasimhan-building-trust-society
2021-09-21T08:13:48+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/how-be-boss-unbossed-company
2021-09-21T08:19:04+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/medicines-and-transformative-effect
2021-09-21T08:21:17+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/its-time-pivot-towards-transformational-innovation
2021-09-21T08:24:03+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-flipping-pyramid-explains-steven-baert
2021-09-21T08:35:41+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/fortunes-most-admired-pharmaceutical-companies-2019
2021-09-21T08:38:15+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/science-and-business-innovative-medicines
2021-09-21T08:40:12+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/how-long-till-final-world-malaria-day
2021-09-21T08:49:00+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-and-government-cameroon-sign-agreement-fight-chronic-diseases
2021-09-21T08:51:03+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/changing-world
2021-09-21T08:53:08+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/increasing-access-ncd-treatments-uganda
2021-09-21T08:54:55+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-and-government-pakistan-sign-memorandum-understanding
2021-09-21T08:56:49+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-perspective-key-fighting-chronic-disease-south-east-asia-young-people
2021-09-21T09:20:52+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-perspective-how-smart-partnerships-can-help-us-fight-chronic-disease-africa
2021-09-21T09:22:24+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/what-really-driving-malaria-control-personal-accountability-and-passion-community-health-workers
2021-09-21T09:29:59+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/juncture-malaria-eradication
2021-09-21T09:37:46+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/world-malaria-report-2016-keeping-momentum
2021-09-21T09:39:51+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-perspectives-pharma-partners-african-countries-chronic-diseases
2021-09-21T09:56:36+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/confronting-next-global-health-challenge
2021-09-21T11:30:46+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/new-strategies-improving-access-lower-income-countries
2021-09-21T11:32:26+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/tackling-chronic-disease-novartis-access
2021-09-21T11:33:48+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/price-drugs-should-reflect-value-they-deliver
2021-09-21T11:44:56+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-perspectives-making-medicines-affordable-worlds-poorest-people
2021-09-21T11:53:19+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/reigniting-passion-science
2021-09-21T12:11:48+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-perspectives-how-new-business-models-can-help-fight-chronic-diseases
2021-09-21T12:27:19+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-perspectives-kenyas-new-health-care-battle
2021-09-21T12:34:39+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/perfecting-access-through-embedded-sustainability-pooling-resources-and-consolidating-expertise
2021-09-21T12:41:10+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/expanding-access-healthcare-what-will-it-really-take
2021-09-21T13:21:30+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/malarias-deadly-comeback
2021-09-21T13:23:04+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-perspectives-expanding-access-healthcare-what-will-it-really-take
2021-09-21T13:27:15+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-hosts-second-stakeholder-dialogue
2021-09-21T13:29:32+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-perspectives-fighting-africas-future-epidemics
2021-09-21T13:33:33+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/beautiful-medicine-rediscover-power-natures-exquisite-complexity
2021-09-21T13:34:45+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/crispr-genome-editing-fuels-cancer-drug-discovery
2021-09-21T13:36:04+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-perspectives-tailoring-tactics-tackle-chronic-disease-low-income-countries
2021-09-29T12:08:07+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/joe-jimenez-how-improve-healthcare
2021-09-21T13:44:51+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-access-one-year-report
2021-09-29T10:40:29+02:00
daily
1.0
https://www.novartis.com/news/in-the-news/novartis-ceo-outlines-how-improve-pandemic-preparedness-warns-another-one-bound-happen
2021-10-04T16:58:46+02:00
daily
1.0
https://www.novartis.com/careers/career-search/job-details/391405br/responsable-grands-comptes-hemato-cell-gene-est-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391480br/specialist-content-compliance-monitoring
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391498br/senior-key-account-manager-neuroscience
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391514br/delegue-hospitalier-neuro-nouvelle-aquitaine-hf
2024-02-09T15:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391542br/dir-integrated-insights-gep-net
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391543br/dir-commercial-analytics-rltprostate
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391544br/dir-integrated-insights-rlt-platform
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391547br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-06T07:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391551br/medical-advisor
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390135br/medical-representative-nsw-south-wollongong-sth-highlands
2024-03-14T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391462br/head-kam-new-commercial-opportunities
2024-03-11T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/369405br/data-solution-architect-sr-manager
2024-03-13T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383935br/senior-study-leader
2024-03-07T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386844br/global-gfcc-sme-senior-manager-pin-pca
2024-03-14T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387308br/commissioning-qualification-engineer
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388201br/medical-science-liaison-breast-cancer
2024-03-04T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388103br/director-salesforce-data-cloud-technical-product-lead
2024-03-14T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388358br/engineering-lead-trd-rlt
2024-03-13T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388532br/senior-study-leader
2024-03-05T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388643br/field-project-manager-radioligand-therapy
2024-02-06T17:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389435br/senior-buyer-german-indirect-procurement
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389461br/director-regional-search-evaluation
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389764br/laboratorijski-analitik-mzd
2024-03-13T17:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389782br/technicien-de-production-cq-saint-cloud-hf
2024-03-05T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389799br/novartis-country-quality-head-central-eastern-europe-cluster-mfd
2024-03-12T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390286br/legal-traineeship-novartis-corporate-functions
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390577br/pricing-manager
2024-03-14T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390948br/ast-specialist-mfd
2024-03-06T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391094br/legal-trainee-development-and-innovative-medicines
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391157br/senior-medical-director
2024-02-20T15:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391305br/direct-tax-process-lead
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391468br/senior-regulatory-affairs-associate
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391478br/hse-lead-rlt-cn
2024-03-07T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391452br/territory-business-executive
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391453br/product-specialist
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391455br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-15T09:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/367533br/senior-scientist-small-scale-sirna-analytics-processing-80-100
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/378718br/network-manager-dwm-ost-deutschland
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383527br/sourcing-manager-it-digital
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383770br/clinical-development-director-cardio-renal-metabolic
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384809br/global-head-clinical-quantitative-sciences
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386988br/global-category-manager-it-procurement-outsourcing
2024-03-12T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389836br/tehnik-vzdrzevanja-mzd
2024-03-05T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390889br/tactical-planner
2024-02-27T11:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390947br/executive-medical-director-us-medical-program-head-allergy
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391059br/assoc-dir-ddit-ops-data-science
2024-03-05T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391108br/accounting-lead-mfd
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391130br/it-commercial-excellence-sr-manager
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391254br/medical-science-liaison-manager-mwd-baden-wurttemberg
2024-02-22T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391378br/customer-engagement-partner-solid-tumor-ta
2024-03-04T11:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391379br/customer-engagement-partner-immunology
2024-03-04T11:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391380br/senior-principal-clinical-data-scientist-project-data-manager
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391389br/assocdirector-visualization
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391407br/novartis-executive-advisors-lead
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391413br/director-portfolio-analytics
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391416br/assoc-director-erp-sap-btp-s4hana
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391424br/senior-specialistsap-abap-btps4hana
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/374705br/specialiste-contrat-hf
2024-03-06T21:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383782br/senior-financial-reporting-and-accounting-specialist-tehcnical
2024-02-14T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385625br/quality-assurance-operations-manager
2024-02-08T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387549br/laboratorijski-analitik-ekspert-mzd
2024-03-07T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387900br/senior-scientist
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388915br/functional-trainer
2024-02-16T09:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389023br/responsable-grands-comptes-ophta-centre-est-hf
2024-02-13T11:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389222br/senior-global-program-regulatory-manager-cardio-renal-metabolism
2024-02-27T23:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389854br/territory-business-executive
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390023br/study-and-site-operations-study-start-manager
2024-02-23T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390168br/senior-scientist-iii-vivo-pharmacology-80-100
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390189br/rheumatology-institutional-sales-specialist-mi-and-oh-remote
2024-03-03T17:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390204br/service-applications-manager-sap-operations
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390409br/global-esg-reporting-analyst
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390880br/country-medical-affairs-head-im
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391175br/ad-access-reimbursement-radioligand-therapy-remote-memphis-tn
2024-03-09T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391304br/qa-compliance-operations-lead-rlt-cn
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391313br/associate-director-ml-engineeringaws-sagemaker-azure-mlops
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391315br/responsable-grands-comptes-hemato-maladies-rares-sud-est-bfc-aura-hf
2024-02-13T11:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391324br/product-steward-mfd
2024-03-07T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391355br/director-integrated-evidence-planning-2-positions
2024-03-11T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391345br/snr-specialistappian-low-code-bpm-automation
2024-02-27T09:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391347br/hr-business-partner-12-monate-mwd
2024-02-21T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391349br/chef-de-produit-dermatologie
2024-03-08T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391363br/senior-product-specialist-heart-failure-melaka
2024-03-08T03:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382933br/senior-process-expert-mfd
2024-02-19T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384003br/global-procurement-head-category-warehousing-distribution
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384220br/principal-scientist-vivo-pharmacologyb-cell-therapies-80-100
2024-03-08T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385833br/associate-director-aiml-products
2024-03-14T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386887br/associate-director-itot-lead
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386891br/associate-director-itot-lead
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387911br/chef-de-produit-senior-tumeurs-solides-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389137br/senior-statistical-programmer
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389474br/senior-medical-information-manager-ii
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389956br/warehouse-logistics-expert-mwd
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390150br/senior-business-analyst-japanese-speaker
2024-02-27T05:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390166br/qa-evaluation-and-integration-lead
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390595br/field-medical-excellence-lead
2024-02-22T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390781br/medical-da-lead
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390806br/coordinateur-strategy-operations-hf
2024-03-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391012br/cell-processing-specialist-temporary-2-years-contract
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391070br/research-scientist-immuno-oncology-cell-and-gene-therapy
2024-03-04T23:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391112br/fra-analyst-mfd
2024-03-01T09:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391120br/hospital-sales-representative-ta-cardiovascular-dwm-gebiet-heilbr
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391183br/responsable-grands-comptes-neuro-bfc-aura-hf
2024-02-13T11:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391201br/warehouse-executive
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391207br/local-gcppv-auditor
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391216br/senior-financial-compliance-manager
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391228br/supply-demand-manager
2024-02-23T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391248br/technicien-services-techniques-utilites-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391256br/ad-access-reimbursement-radioligand-therapy-remote-detroit-mi
2024-03-07T23:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391257br/ad-access-reimbursement-radioligand-therapy-remote-lexington-ky
2024-03-07T23:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391258br/ad-access-reimbursement-radioligand-therapy-remote-nashville-tn
2024-03-07T23:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391268br/senior-process-expert-fmd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391278br/responsable-grands-comptes-neuro-normandie-bretagne-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391284br/disease-area-partner-hematology-cairo
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/369935br/22-principal-clinical-data-scientist-trial-data-managerproject-data
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/369937br/senior-clinical-data-scientist-trial-data-manager
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/369943br/sr-principal-clinical-data-scientist-project-data-manager
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/370976br/22-principal-statistical-programmer
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/370990br/23-senior-statistical-programmer
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/381885br/senior-tax-analyst-state-local-tax
2024-03-15T23:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/381886br/manager-state-local-tax
2024-03-15T23:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383647br/head-protective-security-asia-pacific
2024-02-19T11:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384123br/brand-lead-solid-tumors-madridbarcelona
2024-03-05T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386479br/real-estate-lead-data-technology
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386838br/rlt-sasayamaassociate-scm-planner
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386980br/srlead-agile-coach
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387664br/rwe-team-lead
2024-03-06T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388236br/technical-product-manager-veeva-crm
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388403br/financial-reporting-and-accounting-fra-analyst-mfd
2024-03-01T09:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389070br/pharmacovigilance-governance-manager-fmd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389458br/lead-senior-lead-rwe-bio-statistics-specialist
2024-03-05T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389462br/sr-cluster-procurement-manager-lmm-apma
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389542br/ad-disease-and-clinical-specialist-mn-ia-remote
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389793br/manufacturing-systems-expert
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389852br/sr-spec-ddit-dev-bp-gco
2024-03-08T11:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389951br/expert-science-technology-80-100
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389995br/responsable-comptabilite-generale-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390419br/expert-science-technology-mfd
2024-03-01T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390422br/health-and-safety-hse-officer
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390748br/storage-engineering-associate-director
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390750br/windows-engineering-expert
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390950br/disease-area-partner-immunology-cairo
2024-03-03T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390975br/procurement-manager
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390977br/expert-technique-utilites-propres-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391056br/senior-expert-science-technology
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391147br/ad-access-reimbursement-radioligand-therapy-remote-milwaukee-wi
2024-03-07T23:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391082br/internship-pharmacometrics
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391090br/data-steward
2024-03-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391095br/technical-data-architect-officer
2024-03-05T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391100br/qiyuesheyuanzongwuashisutantozhangkaizhecaiyong
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391103br/qiyuesheyuankurinikarutoraiaru-ashisutanto-ctazhangkaizhecaiyong
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391104br/director-data-analytics-platforms-architect
2024-02-20T17:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391125br/responsable-grands-comptes-onco-region-ouest
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391129br/sr-specialistsap-basis-aws
2024-02-07T07:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391150br/associate-director-sap-basis-operations-s4hana
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391154br/ad-access-reimbursement-radioligand-therapy-remote-albany-ny
2024-02-20T21:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391155br/assoc-dir-sol-architect-automation
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391158br/ad-access-reimbursement-radioligand-therapy-remote-boston-ma
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391161br/ad-access-reimbursement-radioligand-therapy-remote-pittsburgh-pa
2024-03-09T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391163br/assoc-dir-platform-analytics-architect
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391164br/ad-access-reimbursement-radioligand-therapy-remote-washington-dc
2024-03-09T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391166br/ad-access-reimbursement-radioligand-therapy-remote-charlotte-nc
2024-03-09T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391169br/ad-access-reimbursement-radioligand-therapy-remote-tampa-fl
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391173br/ad-access-reimbursement-radioligand-therapy-remote-miami-fl
2024-03-09T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391185br/executive-personnel-specialist
2024-03-03T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391188br/disease-area-partner-heart-failure-sharkia
2024-03-14T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391190br/disease-area-partner-heart-failure-beheira
2024-03-14T13:01:07+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391191br/disease-area-partner-heart-failure-beni-suef
2024-03-14T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391192br/responsable-grands-comptes-neuro-centre-val-de-loire-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391193br/disease-area-partner-heart-failure-aswan
2024-03-14T13:01:07+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391197br/life-cycle-manager
2024-02-16T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382976br/regional-senior-manager-erc-operations
2024-03-05T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385749br/lead-ta-medical-specialty
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386145br/assoc-dir-ddit-ops-sol-architecture
2024-02-19T11:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387241br/senior-study-leader
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387530br/continuous-improvement-engineer-mfd
2024-02-12T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387537br/production-support-engineer-mfd
2024-02-12T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388177br/principal-scientist-cadd
2024-03-11T21:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389739br/principal-biostatistician
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390181br/external-materials-planner-morris-plains-site-ljubljana
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390196br/executive-director-launch-excellence
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390424br/general-coordinating-expert-acd
2024-03-07T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391073br/head-ra-mow-new-product-strategy
2024-03-07T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390730br/cq-engineer-emsr
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390929br/qc-supervisor
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390967br/principal-statistical-programmer
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390991br/qc-analyst-i-temporary-2-years-contract
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390993br/qc-analyst-i-temporary-1-year-contract
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391014br/qc-lab-analyst-i-temp
2024-02-16T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391017br/chef-de-projet-ingenierie-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387466br/medical-lead-new-products
2024-03-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390953br/study-start-manager
2024-02-21T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390956br/associate-medical-advisor-neuroscience
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388907br/head-market-access
2024-02-07T11:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386927br/shift-lead-ii
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388361br/sr-regulatory-affairs-specialist
2024-02-26T15:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388543br/clinical-research-medical-advisor
2024-02-26T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388801br/senior-regulatory-affairs-manager
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389126br/strategy-bd-manager
2024-02-23T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389444br/technicien-de-production-controle-qualite-saint-genis-pouilly-hf
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389673br/senior-people-organization-business-partner-site
2024-02-23T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390210br/senior-infrastructure-engineering-aws-expert
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390248br/qa-documentation-coordinator-mfd
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390761br/gcp-team-lead-basel
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390824br/senior-technical-transfer-lead
2024-02-19T05:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390888br/senior-regulatory-writer
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390893br/director-search-evaluation
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390906br/qiyuesheyuanzhangkaizhecaiyong
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390921br/qualified-person-qp
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390941br/ed-access-reimbursement-nps-radioligand-therapy-remote-nj
2024-03-12T21:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390937br/people-partner-site
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390938br/rd-access-reimbursement-nps-radioligand-therapy-west-remote-az
2024-03-12T21:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390939br/rd-access-reimbursement-nps-radioligand-therapy-southeast-remote-ga
2024-03-12T21:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390946br/marketing-account-manager-and-engagement
2024-03-01T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/379318br/elektrotechniker-mwd
2024-03-07T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383895br/global-procurement-category-manager-infrastructure-and-security
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385760br/qc-specialist-mfd
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387667br/production-head
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388569br/medical-director-nephrologygenetic-diseases-translational-medicine
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389529br/customer-service-team-lead-molecular-imaging-mwd
2024-02-19T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390328br/sr-supply-demand-planner
2024-03-05T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389961br/clinical-operations-program-head
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390540br/pharmaziepraktikant-wmd-im-bereich-manufacturing-ab-marzapril
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390865br/global-process-owner-requisition-order-remote-usa
2024-03-08T23:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390859br/senior-expert-structural-bioinformatician
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390786br/regional-business-manager
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390788br/senior-specialist-integration-platform-bods-and-informatica
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390789br/senior-specialistsap-bwhana
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390818br/commissioning-qualification-specialist
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390846br/associate-director-solution-design-erp-supply-chain-management
2024-02-14T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390866br/private-access-manager
2024-03-07T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385607br/seniorclinical-development-medical-director-renal-80-100
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387793br/pnh-specialist-multiple-locations-may-be-considered
2024-03-07T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388022br/associate-director-biotherapeutic-engineering
2024-03-13T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388021br/associate-director-xrna-therapeutics
2024-03-13T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390368br/senior-medical-information-manager-ii
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390700br/managerassociate-msl
2024-03-04T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390727br/senior-scientific-writer-ii
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390728br/expert-scientific-writer
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390738br/assoc-dir-ddit-dev-technical-solution-delivery-gco
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390747br/sales-value-associate-toluca
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390774br/senior-scientist-quality-control-analytics-sun-wed-7am-530pm
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390777br/senior-scientist-quality-control-analytics-wed-sat-7am-530pm
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390778br/senior-scientist-quality-control-analytics-wed-sat-230pm-1am
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383066br/global-operational-excellence-director
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383768br/senior-global-program-clinical-head
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384527br/r2r-senior-specialist-gl-reporting
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389267br/engineer-multidiscipline-i-mfd-automation
2024-03-12T09:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389413br/cq-engineer-ii-mfd
2024-03-12T09:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389472br/rewards-manager
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390679br/snr-ra-compliance-associate
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390588br/medical-representative
2024-03-15T03:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390604br/stagiaires-chef-de-projets-meetings-congres-et-evenements
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390605br/stagiaires-chef-de-projets-meetings-congres-et-evenements
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390611br/manager-system-operations
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390615br/operater-mzd
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390621br/equipment-specialist-iii
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390632br/senior-specialist-power-apps
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390639br/senior-principal-scientist-computational-medicinal-chemistry
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390641br/computational-medicinal-chemistsenior-expert-data-science
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390665br/associate-director-rare-renal-training-remote
2024-03-12T21:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390669br/medical-science-liaison-msl-allergy-derm-ky-sw-oh-remote
2024-03-06T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385901br/netzwerkmanager-mwd-neuroscience-gebiet-mitte
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387431br/technicien-de-production-cq-marseille-hf
2024-03-04T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388658br/clinical-development-medical-director-nuclear-medicine
2024-03-08T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389521br/qa-operations-expert-fmd
2024-02-27T15:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390044br/starshiy-inzhener-tekhnolog-po-processu-upakovki
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390412br/associate-director-thought-leader-liaison-allergy-new-england
2024-02-26T17:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390469br/oncology-specialist-rlt-prostate-ann-arbor-mi-remote
2024-03-12T15:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390485br/scientist-quality-control-sun-wed-7am-530pm
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390504br/expert-science-technology-nitrosamine-scientist-ard
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390506br/area-manager-ha-noi
2024-02-23T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390509br/associate-director-sap-pp-pm
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390520br/medical-excellence-strategic-advisor-manager
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390522br/stage-chef-de-produit-oncologie
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390542br/associate-scientist-hours-wed-sat-230pm-100am
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390556br/scientist-quality-control-wed-sat-230pm-100am
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383173br/manager-new-product-dwm-focus-radioligandtherapy-rlt
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390198br/associate-dir-business-relationship-mgmt
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/379770br/medical-scientific-liaison-msl-dwm-berlin
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383898br/sr-specialistaws-cloud-formationpythonterraform-eks
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385750br/head-corporate-archives
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388928br/director-enterprise-architect-apd
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389477br/directoritil-salesforce
2024-02-20T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390343br/senior-expert-science-technology
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390364br/stage-excellence-medicale
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390373br/director-ldc-program-test-manager-sap-erp
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390377br/documentation-specialist-gmp-fmd-teilzeit-60-kundl-tirol
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390380br/associate-director-solution-delivery-sap-fico
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/380285br/da-solution-delivery-integration-lead
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/381718br/sr-prin-clinical-data-scientist-prog-data-mgr
2024-03-05T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382621br/clinical-development-medical-director-radioligand-imagingtherapy
2024-03-08T09:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386084br/clinical-document-mgmt-inspection-capa-and-risk-oversight-manager
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386248br/solutions-delivery-lead-mdm
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386247br/mdm-products-lead
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386629br/medical-science-liaison-onc-prostate-radioligand-therapies-sd-or-oc-ca
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387160br/medical-director-nephrologygenetic-diseases-translational-medicine
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389056br/responsable-marketing-rlt-radioligand-therapy-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390047br/reliability-engineer
2024-02-13T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390230br/sr-digital-operation-excellence
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390241br/sr-rlt-medical-launch-liaison
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390283br/business-execution-manager-mwd
2024-02-28T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387623br/ingenieur-biotech-purification-hf-cdd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388688br/site-quality-head
2024-02-20T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389433br/cloud-infrastructure-architect
2024-03-01T17:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389957br/mechatroniker-abfullung-inspektion-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389958br/mechaniker-abfullung-inspektion-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390043br/manufacturing-projects-engineer
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390116br/operations-manager-site
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/381487br/curation-expert
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387868br/biochemicalchemical-engineer-early-talent-program
2024-03-04T11:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388717br/qc-analyst-i
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389981br/netzwerkmanager-mwd-ta-cardio-region-berlin
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383853br/senior-clinical-project-manager
2024-03-04T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383978br/lead-or-senior-lead-medical-solid
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384238br/clinical-document-management-technology-team-lead
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384282br/time-service-delivery-expert-german-speaking
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384496br/hire-retire-services-expert-hr-services-german-speaking
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385020br/country-communications-engagement-head
2024-02-20T09:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387781br/first-line-manager-mwd-ta-neuroscience-regionth-sn-ni
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387968br/legal-trainee-legal-procurement-datadigital-it
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389256br/scientist-mst-senior-fmd
2024-02-28T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389752br/community-key-account-manager-south-east-london-12-month-ftc
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389960br/netzwerkmanager-mwd-ta-prostate-cancer-region-rp-und-saarland
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386223br/senior-analystsap-fi-implementation
2024-02-21T17:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388014br/ad-access-reimbursement-nps-crm-peoria-il-remote
2024-03-05T03:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389432br/hcp-engagement-expert-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389811br/senior-global-head-clinical-development-equity
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389823br/digitaldevice-data-scientist
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389827br/regional-htavalue-specialist
2024-02-19T23:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386265br/director-commercial-it-architecture-advanced-therapies
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388058br/business-process-analyst-license-mgmt
2024-03-11T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389685br/global-mobility-leader-americas
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389683br/menedzher-po-rabote-s-klyuchevymi-klientami-tula-ateroskleroz
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389712br/sr-application-expertveeva-vaultcrm
2024-02-27T15:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389726br/senior-material-planning-supervisor
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384331br/quality-operations-manager
2024-03-08T11:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385873br/process-specialist
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385882br/novartis-kurtkoy-site-general-application
2024-03-08T11:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389601br/senior-cluster-procurement-manager-german
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/379575br/associate-director-gdd-technical-rd-mzd
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382684br/strategic-materials-lifecycle-manager
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382935br/finance-manager-im-japan
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385879br/people-partner
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386440br/associate-director-cloud-security-architect
2024-03-07T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387767br/manufacturing-systems-expert-mfd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388304br/sso-feasibility-manager
2024-03-04T17:02:37+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389481br/medical-lead-cardiology
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389503br/assoc-director-automationrpa
2024-03-14T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389515br/senior-clinical-data-scientist
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388851br/expert-validation-senior-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388202br/onderhoudstechnieker
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/377160br/field-excellence-incentives-manager-dwm
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/377503br/business-insights-manager-wmd
2024-02-28T17:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388578br/medical-science-liaison-msl-solid-tumor-oncology-st-louis-mo-remote
2024-03-06T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388652br/medical-science-liaison-msl-solid-tumor-oncology-houston-tx
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386345br/senior-expert-biologics-analytical-operations-mfd
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388827br/process-engineer-mfd
2024-02-09T15:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389179br/senior-expert-science-technology
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387226br/executive-director-trans-med-neuroscience-neurodegeneration
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388520br/critical-reagent-manager
2024-03-12T19:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389145br/regionalnyy-menedzher-kardiologiya-moskva
2024-03-01T11:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388317br/medical-science-liaison-msl-renal-nephrology-heartland-remote
2024-03-09T03:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388619br/medical-science-liaison-manager-mwd-cardio-regionostdeutschland
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383462br/chef-de-projet-data-hf
2024-03-08T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387829br/expert-electricite-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388718br/senior-process-expert-fmd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388901br/healthcare-solutions-lead
2024-03-05T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388923br/crm-japan-program-clinical-head
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388168br/project-engineer-mfd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/372600br/director-ethics-risk-compliance-integrated-marketing-advisor
2024-03-08T21:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384884br/lead-medical-device-risk-management-control-strategy-engineer-fmd
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388542br/ast-expert-mwd
2024-03-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388530br/senior-specialist-itom-event-management-cloudsnow-discovery
2024-02-20T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388540br/assc-director-servicenow
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388553br/sr-specialistsnow-operations-soxaudit
2024-02-26T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388561br/brand-manager-solid-tumors
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388416br/senior-specialist-knowledge-management
2024-03-05T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383499br/senior-consultant-pmo
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388223br/postdoc-bioprocess-modelling-new-technologies-mfd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388272br/technicien-de-production-biotech-hf
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388315br/bioprocess-engineer-iiiiii-downstream-fillfinish-2-2-3-day-shift
2024-02-23T23:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388195br/vendor-category-expert
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387496br/inzhener-po-obsluzhivaniyu-proizvodstvennogo-oborudovaniya-i-planirovaniyu
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386267br/commercial-it-domain-architect
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385896br/labortechnikerin-mst-mwd-kundl-tirol
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387812br/maintenance-coordinator-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/365067br/public-affairs-manager-mwd
2024-03-12T15:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/377387br/senior-public-affairs-manager-dwm
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386008br/cardiovascular-institutional-sales-specialist-denver-westco-remote
2024-03-08T21:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387674br/senior-specialistsap-bpc
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387609br/sr-specialist-network-engineering
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386319br/senior-brand-manager
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386320br/senior-brand-manager
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386403br/senior-brand-manager
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386406br/market-access-manager
2024-03-04T13:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386815br/medical-manager-oncology
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386818br/medical-sciences-liaison
2024-02-21T05:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387418br/marketing-lead-cardiovascular
2024-02-25T15:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387465br/manager-retail-e-commerce-platformdianshangjingli
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/381510br/japan-program-head
2024-03-06T07:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385454br/chemielabortechniker-qc-analyst-ii-mwd-tirol-osterreich
2024-03-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385606br/lead-software-developer-r-remote
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/374288br/cell-culture-lead-mfd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383937br/cardiologist-physician-scientist-translational-medicine
2024-03-07T21:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387109br/laborantin-mikrobiologie-mwd-tirol-osterreich
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384967br/clinical-program-leader
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386009br/clinical-program-leader
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386692br/rlt-sasayamafinance-manager-business-planning-and-analysis
2024-03-08T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386694br/rlt-sasayamahse-health-safety-environment-head
2024-03-08T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386698br/rlt-sasayamaautomation-manager
2024-03-05T05:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386700br/rlt-sasayamatechnical-systems-lead
2024-03-05T05:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387232br/e2e-supply-network-planning-manager-mfd
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386830br/produktionsmitarbeiter-mwd-kundl-tirol
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384631br/msl-manager
2024-02-22T05:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386757br/lehrling-fur-den-lehrberuf-mechatronik-fertigungstechnik-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386657br/labeling-manager-japan
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/379140br/cybersecurity-solutions-architect-global-drug-development-team
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384820br/lehrling-fur-den-lehrberuf-pharmatechnologie-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384822br/lehrling-fur-den-lehrberuf-mechatronik-automatisierungstechnik-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384823br/lehrling-fur-den-lehrberuf-labortechnik-chemie-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384824br/lehrling-fur-den-lehrberuf-elektrotechnik-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384825br/lehrling-fur-den-lehrberuf-chemieverfahrenstechnik-mwd
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384888br/process-expert-wed-sat-2nd-shift
2024-02-29T23:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385923br/medical-director-rheumatology-autoimmune-translational-medicine
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383771br/clinical-development-medical-director
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383772br/sr-clinical-development-medical-director
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385748br/apprenti-pharmacien-hf-saint-genis-pouilly
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385753br/apprenti-pharmacien-hf-saint-cloud
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385754br/apprenti-pharmacien-hf-marseille
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385757br/apprenti-pharmacien-european-raw-materials-hf-bethune
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385791br/cardiovascular-territory-account-specialist-fremont-remote
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385396br/especialista-en-radiofarmacia
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383989br/japan-program-manager
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384547br/medical-director-translational-medicine-neuroscience
2024-03-05T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383790br/technical-accounting-senior-specialist
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383306br/srsales-manager
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/379141br/cybersecurity-solutions-architect-mergers-acquisitions
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/363942br/clinical-document-management-technology-release-manager
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/377209br/global-program-clinical-head-rheumatology
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/356163br/maschinenbediener-mwd-im-bereich-pharmazeutische-produktion
2024-02-06T07:32:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/345502br/technical-operator-mwd
2024-03-07T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391564br/assoc-dir-funct-security-architect
2024-03-14T13:01:07+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391585br/customer-service-assistant-cdd-hf
2024-02-06T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391590br/assoc-dir-ddit-ies-cloud-engineering
2024-02-21T09:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/375415br/expert-clinical-research-associate-hungaryhome-based
2024-03-13T17:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388151br/quality-assurance-head-nordics
2024-02-06T17:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391626br/translational-research-lab-based-scientist
2024-02-06T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391121br/itot-automation-engineer
2024-02-06T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391122br/itot-site-lead
2024-02-06T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391635br/specialist-automation-information-technology-operational-technology
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390214br/record-report-sr-specialist-centroamerica
2024-03-14T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390310br/medical-science-liaison-onc-prostate-radioligand-therapies-chicago
2024-03-06T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390300br/medical-science-liaison-onc-prostate-radioligand-therapies-los-angeles
2024-02-07T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390301br/medical-science-liaison-onc-prostate-radioligand-therapies-dallas
2024-02-07T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390306br/medical-science-liaison-onc-prostate-radioligand-therapies-oh-remote
2024-03-06T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390315br/medical-science-liaison-onc-prostate-radioligand-therapies-mpls-remote
2024-03-06T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391647br/access-reimbursement-manager-renal-remote-los-angeles-ca
2024-03-06T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386176br/medical-science-liaison
2024-03-13T05:01:07+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391653br/adsr-principal-scientist-cadd
2024-03-11T23:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390350br/country-medical-head-ap-leprosy
2024-03-11T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390383br/gcp-bioanalysis-senior-scientist-iii
2024-02-07T07:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390531br/senior-scientist-pks-vivo-preclinical-pkadme
2024-02-07T07:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383374br/data-science-manager
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391627br/quality-control-supervisor
2024-02-21T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391681br/production-technician
2024-02-08T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391625br/quality-control-technician
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391678br/sr-manager-integrated-insights
2024-02-07T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391709br/product-cost-planning-manager
2024-03-05T05:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386432br/prozessmitarbeiter
2024-02-07T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389115br/seniorglobal-regulatory-manager
2024-02-22T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388232br/container-platform-kubernetes-sr-specialist
2024-03-05T21:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/375810br/associate-director-ddit-im-data-products
2024-03-12T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386081br/clinical-document-management-process-user-support-team-lead
2024-02-07T21:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388235br/clinical-document-management-reference-model-manager
2024-02-07T21:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387775br/technical-product-owner-data-analytics
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390654br/planning-logistics-specialist-2nd-shift
2024-03-13T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391641br/specialist-automation-information-technology-operational-technology
2024-03-14T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391730br/investor-relations-strategic-analyst-communications-director
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391740br/senior-or-expert-clinical-scientist-translational-medicine-nbr
2024-02-08T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391757br/data-science-intern
2024-03-12T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/357636br/werkstudent-der-pharmazeutischen-produktion-mwd
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391612br/quality-assurance-specialist
2024-02-23T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391633br/microbiological-supervisor
2024-02-16T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391716br/senior-specialist-data-science
2024-02-08T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391809br/associate-director-commercial-erp-solution-design
2024-02-26T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388162br/quality-compliance-lead
2024-03-06T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388941br/sr-business-analyst-salesforce-data-cloud
2024-03-14T19:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389998br/ai-architect-developer-x2
2024-03-12T15:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391616br/isc-security-solutions-architect-us
2024-02-27T19:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391821br/supervisor-manufacturing-nights
2024-02-08T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391822br/quality-assurance-engineering-specialist
2024-03-15T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390574br/senior-study-leader
2024-03-14T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391830br/vendor-program-lead
2024-02-09T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391832br/operations-executive-commercial-excellence
2024-03-11T03:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391833br/principal-biostatistician
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390562br/principal-scientist-drug-discovery-glomerulonephritis-80-100
2024-02-09T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391836br/qa-supplier-management-specialist-ii-mfd
2024-03-12T09:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391838br/senior-principal-biostatistician
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387956br/head-sales-and-marketing-breast-cancer
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390770br/senior-specialistsnowflake-admin-iaac
2024-02-09T09:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386321br/laboratorijski-analitik-mzd
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391683br/operational-scheduler-wmd
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391763br/consultant-pmo
2024-03-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391844br/head-integrated-health-solutions-value-access-key-accounts
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390622br/director-it-security-policy-framework-data-digital-it
2024-02-09T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391859br/pharmaziepraktikant-wmd-mst-ab-01042024-oder-fruher
2024-02-09T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388079br/health-care-analytics-manager-mwd
2024-02-09T15:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391430br/senior-legal-counsel-datadigital-and-it-fmd
2024-02-09T15:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391864br/people-organization-hr-internship-fmd
2024-02-09T15:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391886br/supervizor-lc-ms
2024-02-13T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391525br/process-validation-expert
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391693br/product-steward
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391878br/executive-director-process-development-cell-therapy
2024-02-09T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391900br/sr-specialist-visualization-automation
2024-02-09T21:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387088br/assoc-dir-platform-svcs-developer
2024-02-10T17:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391918br/research-scientist-veterinary-medicine
2024-02-10T21:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390014br/government-relations-public-policy-manager
2024-02-12T05:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387765br/group-product-manager
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390555br/technicien-support-maintenance-journee-hf
2024-02-12T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389665br/data-engineering-manager
2024-02-12T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390933br/operational-scheduler
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/363916br/clinical-document-management-reference-model-manager
2024-02-12T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/363935br/clinical-document-management-process-standards-manager
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/363938br/clinical-document-management-process-user-support-team-lead
2024-02-12T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388985br/production-aid-temporary
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390754br/validation-expert
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391958br/warehouse-and-distribution-manager
2024-03-07T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391959br/director-ddit-analytics-products
2024-03-08T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385935br/director-launch-co-pilot
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391818br/quality-assurance-validation-specialist
2024-03-15T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391891br/assoc-dir-solutions-delivery-lead-mdm
2024-03-05T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391996br/manager-quality-assurance-operations
2024-02-12T21:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392006br/rlt-drug-product-project-leader-dppl-mfd
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392007br/rlt-formulation-project-leader-mfd
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392011br/rlt-analytical-project-leader-mfd
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392016br/rlt-analytical-expert-mfd
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/381813br/junior-radiation-safety-expert
2024-03-13T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391881br/regional-va-bp-lead
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392042br/associate-directorsap-mdg
2024-02-13T11:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391978br/san-block-storage-engineer
2024-02-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392075br/onderhoudstechnieker-pharma
2024-03-06T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/378407br/bpa-analyst
2024-03-14T21:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391581br/chemielabortechniker-qc-analyst-ii-mwd-kundl-tirol
2024-02-13T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392110br/director-quantitative-solutions-engineering
2024-02-13T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392112br/director-analytical-project-lead
2024-02-13T21:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392113br/senior-cluster-procurement-manager-belgium-italy
2024-02-13T21:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391046br/radioligand-therapy-specialist-mid-atlantic-mdnjde
2024-02-13T21:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391037br/radioligand-therapy-specialist-rocky-mountains-utwyco-nv-az-id
2024-02-13T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391038br/radioligand-therapy-specialist-texasnm
2024-02-13T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391040br/radioligand-therapy-specialist-mid-west-miok-io-nd-sd-ne-ks
2024-02-13T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391043br/radioligand-therapy-specialist-gulf-coast-al-ms-la-ar
2024-02-13T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391044br/radioligand-therapy-specialist-south-florida
2024-02-13T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391045br/radioligand-therapy-specialist-georgianorth-florida
2024-02-13T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/374865br/director-data-science-ai-research-chemistry
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391033br/radioligand-therapy-specialist-northern-california
2024-02-13T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392125br/principal-lab-it-engineer
2024-03-06T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392140br/data-steward
2024-02-14T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392143br/senior-knowledge-management-strategist
2024-03-14T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385870br/dir-ddit-isc-ent-architect-net-sec
2024-03-14T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389390br/principal-rwe-research-analyst
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391869br/medical-manager-breast-cancer
2024-02-29T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391948br/assistante-de-direction-hf
2024-02-14T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392159br/analyst-social-media-listening
2024-02-14T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392162br/manager-gprm-japan
2024-02-22T09:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391793br/ldc-buying-channels-adopt-manager
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392180br/assoc-director-science-technology-cell-therapy-process-analytics
2024-02-14T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392181br/site-quality-head
2024-02-14T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392187br/senior-patient-access-lead
2024-02-14T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391901br/associate-director-congress-management-and-association-relations
2024-03-08T09:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391835br/medical-head-governance-excellence
2024-03-01T05:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390517br/data-quality-analyst
2024-02-20T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392210br/medical-representative
2024-02-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392211br/medical-representative
2024-02-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385973br/sr-spec-ddit-isc-ies
2024-03-12T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387640br/medical-safety-lead
2024-03-13T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390891br/customer-engagement-manager-dermatology
2024-03-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392217br/mmdm-textdesign-expert
2024-03-05T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392227br/senior-medical-information-manager-i
2024-02-15T11:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383072br/director-data-science
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392061br/global-people-and-organization-hr-business-partner-fmd
2024-02-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392234br/analyst-competitive-intelligence-manufacturing
2024-02-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392236br/analyst-competitive-intelligence
2024-02-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392237br/senior-analyst-competitive-intelligence
2024-02-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392238br/automation-engineer-senior-specialist
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392241br/automation-engineering-associate-director
2024-02-28T17:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392243br/production-planning-senior-specialist
2024-02-27T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392250br/global-program-regulatory-manager-lcm
2024-02-15T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391255br/director-quantitative-safety-statistician
2024-03-12T19:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392245br/financial-master-data-specialist
2024-02-16T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392255br/cardiovascular-territory-account-specialist-fresno-south-remote
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392265br/head-medical-affairs
2024-03-06T07:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391426br/vendor-category-expert
2024-02-15T17:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387779br/technical-transfer-lead-medical-device-fmd
2024-02-20T21:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385944br/expert-science-technology-process-analytics
2024-02-15T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392306br/manager-ra-cmc-manager-japan
2024-02-20T09:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390361br/operations-manager-arogya-parivar
2024-03-11T07:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392224br/laboratorijski-analitik-mzd
2024-03-07T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392309br/buyer-mandarin-speaker
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392311br/buyer-japanese-speaker
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390590br/medical-lead-oncology-hematology
2024-03-07T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391783br/heor-manager-nordic-countries
2024-03-13T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391808br/customer-engagement-manager-north-east-netherlands
2024-03-04T17:02:37+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392164br/associate-director-solution-delivery-mfd
2024-02-16T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392321br/cooperative-study-program-bwl-healthcare-management-dhbw
2024-02-28T15:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392322br/cooperative-study-program-bwl-human-resources-management-dhbw
2024-02-28T15:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392323br/cooperative-study-program-bwl-digital-business-managementdhbw
2024-02-28T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391001br/computerized-systems-and-qualification-engineer
2024-02-16T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392337br/gestionnaire-adv-transport-cdd-saint-genis-pouilly-01
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392376br/territory-business-executive
2024-03-14T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392377br/territory-business-executive
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391061br/health-safety-environment-expert-process-safety
2024-02-19T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386897br/xianyuzhurenxianyuzhuguan
2024-03-04T05:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392381br/pipeline-manager
2024-02-18T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392382br/senior-regulatory-writer
2024-03-07T03:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392384br/immunology-japan-program-clinical-head
2024-02-18T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392386br/specialist-environmental-health-and-safety
2024-03-08T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392393br/knowledge-management-reporting-lead
2024-02-19T09:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391584br/medical-science-liaison-manager-mwd-hessen-rlp-saarland
2024-02-21T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392398br/territory-business-executive
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392401br/territory-business-executive
2024-03-13T07:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392248br/innovation-manager
2024-02-19T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392399br/senior-manager-ethics-risk-compliance-and-assurance
2024-03-07T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392420br/information-security-awareness-senior-specialist
2024-03-01T13:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392424br/apprenti-technicien-de-production-hf-saint-genis-pouilly
2024-02-19T15:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392426br/apprenti-technicien-de-production-hf-bethune
2024-02-19T15:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392429br/apprenti-technicien-de-production-hf-saint-cloud
2024-02-19T15:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392431br/apprenti-technicien-de-production-hf-troyes
2024-02-19T15:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392432br/apprenti-technicien-de-production-hf-marseille
2024-02-19T15:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392324br/production-planning-associate-director
2024-02-27T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392443br/specialist-solution-design-qlik-sense-aws-data-warehouse
2024-02-19T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392455br/sr-leadstrategic-planning
2024-02-20T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392456br/healthcare-solution-lead
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392457br/senior-lead-early-medical
2024-02-20T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/374978br/it-business-analyst-regulatory-affairs
2024-03-15T09:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392467br/associate-director
2024-02-20T09:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392468br/associate-director
2024-02-20T09:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392469br/associate-director
2024-02-20T09:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392471br/director-platforms-analytics-aws
2024-02-20T09:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392472br/associate-director
2024-02-20T09:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392466br/payroll-services-head-emea
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392484br/ta-head-oncology
2024-02-20T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392497br/head-dpdai-china
2024-02-20T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392501br/sr-manager-analytical-formulation-development
2024-02-20T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392504br/customer-engagement-lead
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392516br/medical-safety-processes-projects-lead
2024-03-12T09:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392340br/maintenance-technician-instrumentation
2024-02-20T15:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392408br/gxp-metrics-manager
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392421br/kierownik-ds-kluczowych-klientow-neurologia
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392517br/digital-health-innovation-manager
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392536br/snr-spec-platform-analytics-ai-machine-learning-aws-mlops
2024-02-20T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392550br/associate-director-institutional-multiple
2024-02-20T23:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392552br/associate-director-institutional-chargebacks
2024-02-20T23:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392551br/associate-director-managed-care-multiple
2024-02-20T23:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392558br/director-ethics-risk-compliance-advisor-corporate-functions
2024-03-07T21:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392029br/medical-representative-cardiovascular-mornington-peninsula
2024-03-10T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392010br/addirector-bio-cancer-therapeutics-dual-posting
2024-03-06T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385632br/country-patient-safety-head
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392569br/oncology-sales-specialist-melanoma-atlanta-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392574br/sr-spec-ddit-dev-technical-design-regulatory-affairs
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387980br/sr-spec-ddit-ies-cloud-engineerin
2024-02-29T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391482br/senior-tax-operations-specialist
2024-02-21T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392526br/pop-governance-manager-hf
2024-02-21T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392582br/clinical-research-associate
2024-02-21T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392585br/praktikant-mwd-der-internen-und-externen-kommunikation
2024-02-21T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392586br/junior-process-expert
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392219br/public-affairs-patient-access-senior-manager
2024-02-21T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392415br/qa-operations-expert-mfd
2024-02-21T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392463br/tm-academy-fellow-preclinical-safety
2024-03-01T11:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392464br/tm-academy-fellow-data-science
2024-03-01T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392577br/discovery-postdoctoral-fellow-immunology
2024-02-21T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392600br/senior-heor-lead
2024-03-08T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392605br/disease-area-partner-ascvd-greater-cairo
2024-03-14T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392618br/clinical-bio-specimen-senior-scientist
2024-02-21T17:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392621br/snr-specialist-snow-platform-services
2024-02-21T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392623br/research-scientist-ii-cell-pharmacology-cvm
2024-02-21T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392637br/record-report-sr-specialist
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392638br/site-head-health-safety-environment
2024-02-21T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392639br/time-management-expert-temporary
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392640br/time-service-specialist-temporary
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392643br/assoc-director-science-technology-cell-therapy-process-development
2024-02-21T21:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392646br/gcp-laboratory-compliance-lead
2024-02-21T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392649br/digital-workspace-manager-brazil
2024-03-04T19:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392655br/utility-engineer-i
2024-02-22T05:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392657br/assoc-director-ddit-apd-shared-services
2024-02-27T05:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385080br/r2r-senior-specialist-gl-reporting
2024-02-22T09:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386288br/key-account-manager
2024-03-12T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391834br/hire-retire-services-expert
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392661br/associate-supply-chain-manager
2024-02-22T09:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392662br/sr-spec-ddit-gf-soldel-treasury
2024-02-22T09:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392617br/postdoc-functional-genomics
2024-02-22T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392671br/associate-director-lan-sol-architect-czech-republic-spain-india
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392674br/manufacturing-systems-expert-mwd-teilzeit-50
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392683br/process-expert
2024-02-22T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392048br/discovery-postdoc-data-science
2024-02-22T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392518br/specialist-life-cycle-implementation
2024-02-22T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392519br/specialist-life-cycle-implementation
2024-02-22T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392686br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-02-22T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392697br/sr-spec-ddit-ies-cloud-engineering
2024-02-29T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389526br/technical-steward
2024-02-22T17:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390414br/medical-directorsenior-medical-director-radiopharmaceuticals-rlt
2024-02-22T17:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392260br/therapeutic-area-biomarker-leadbiomarker-strategy-immunology
2024-02-22T17:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392549br/head-operations-country-development-qa
2024-03-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392676br/payroll-services-senior-expert-italian
2024-03-04T17:02:37+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392703br/access-and-reimbursement-manager-immunology-indianapolis-remote
2024-02-26T17:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388926br/administrative-professional-mfd
2024-02-22T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392553br/payroll-analyst-temporary-12-months
2024-03-07T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392706br/senior-transparency-associate
2024-03-08T11:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392710br/associate-director-ddit-dev-gco
2024-03-08T09:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392713br/director-innovation-lab-ai-innovation-lead
2024-02-22T21:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392717br/senior-privacy-counsel-us
2024-02-23T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385341br/planning-logistics-specialist-1st-shift
2024-02-23T03:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392038br/medical-lead-cmlchronic-myelogenous-leukemia
2024-03-12T03:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392724br/xianyuzhurenxianyuzhuguan
2024-03-08T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382732br/security-solution-architect
2024-03-07T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392727br/technicien-de-production-centrale-de-pesee-hf
2024-02-23T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392752br/senior-fra-gl-specialist-south
2024-02-23T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385036br/senior-cad-designer-mfd-medical-device
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392524br/operational-excellence-expert-mfd
2024-02-23T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392763br/cvm-therapeutic-area-biomarker-lead
2024-02-23T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392770br/chef-de-produit-cardio-hf
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389544br/ad-disease-and-clinical-specialist-raleigh-remote
2024-02-23T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392748br/associate-director-clinical-trial-acceleration
2024-02-23T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392784br/reimbursement-specialist-1
2024-02-24T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392785br/director-nps-program-strategy-management-immunology
2024-02-24T17:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392790br/senior-vendor-program-manager
2024-02-24T17:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392793br/ad-experience-personalization-optimization
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392797br/regionalnyy-kommercheskiy-menedzher-kazan
2024-02-25T15:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392798br/regionalnyy-kommercheskiy-menedzher-tyumen
2024-02-25T15:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392799br/regionalnyy-kommercheskiy-menedzher-vladivostok
2024-02-25T15:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392800br/regionalnyy-kommercheskiy-menedzher-yaroslavl
2024-02-25T15:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392801br/regionalnyy-kommercheskiy-menedzher-tver
2024-02-25T15:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392802br/regionalnyy-kommercheskiy-menedzher-novosibirsk
2024-02-25T15:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392803br/regionalnyy-kommercheskiy-menedzher-nizhniy-novgorod
2024-02-25T15:00:40+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392303br/cell-processing-specialist-i-sun-thur-pm
2024-02-25T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392815br/gcp-bioanalysis-principal-scientist
2024-03-11T23:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392814br/gcp-lab-associate
2024-03-11T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392824br/associate-country-qa-compliance
2024-02-26T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392825br/associate-country-qa-operations-core-products
2024-02-26T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387803br/sales-representative-hematology-central
2024-02-26T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392838br/global-digital-fra-automation-lead
2024-02-26T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392842br/key-account-executive-lipids-johor
2024-02-26T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392849br/hire-retire-services-expert-japanese
2024-02-26T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392705br/senior-scientist-vitro-radiobiology-80-100
2024-02-26T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392869br/associate-supply-chain-performance-manager
2024-02-26T15:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392874br/ad-market-access-contracting-analytics-multiple-positions-remote
2024-03-08T21:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392875br/postgraduatepostdoc-manufacturing-unit-galenic
2024-02-28T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392597br/quality-manager-qualified-person-gmp
2024-02-26T17:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392839br/discovery-postdoctoral-fellow-glomerulonephritis
2024-02-26T17:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392877br/msc-student-proc-dev-new-technologies
2024-02-26T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392895br/bioinformatician-data-scientist-computational-biologist
2024-02-26T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392901br/strategic-manager
2024-02-26T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388539br/key-account-manager-east-scotland-ne-england-newcastle-area
2024-03-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392912br/team-lead-reimbursement-specialist-team
2024-02-26T23:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392898br/valueaccess-commercial-dev-head
2024-02-27T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392914br/medical-science-liaison-prostate-radioligand-therapies-me-nh-vt-ny
2024-03-06T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392915br/planning-and-logistics-lead
2024-02-27T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392916br/medical-science-liaison-msl-solid-tumor-oncology-miami-fl
2024-03-06T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392924br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-02-27T05:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392452br/representante-de-ventas
2024-02-27T05:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392899br/medical-director-translational-medicine-neuroscience
2024-02-27T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392928br/data-steward
2024-03-06T07:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392941br/management-report-senior-specialist
2024-02-27T11:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392957br/medical-science-liaison-hemato-voronezh
2024-02-27T11:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391985br/director-im-arch-int-marketing-customer-engagement
2024-02-27T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392731br/medical-director-dermatology-translational-medicine
2024-02-27T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392841br/hire-retire-services-expert-indonesian-speaker
2024-02-27T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392699br/regional-director-radioligand-therapy-western-us
2024-02-27T15:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392981br/praktikum-im-bereich-automation-engineering
2024-03-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392988br/associate-director-us-market-access-strategy-remote
2024-02-27T17:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392736br/process-expert
2024-02-27T17:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392997br/territorialnyy-kommercheskiy-menedzher-kazan
2024-02-27T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392998br/territorialnyy-kommercheskiy-menedzher-novosibirsk
2024-02-27T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392911br/director-us-market-access-strategy-remote-1of-2
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393006br/bioprocess-engineer-i-upstream-nights
2024-02-27T21:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393009br/business-data-migration-expert-commercial-2-positions
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393010br/business-data-migration-expert-manufacturing
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393036br/sr-product-manager
2024-02-28T05:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393037br/sso-contracting-specialist
2024-02-28T05:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393039br/gaojiyiyaodaibiao-zishenchanpinzhuguan
2024-02-28T09:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393052br/sales-manager-oncology
2024-02-28T09:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393067br/sr-specialist-hcmworkday-config-implementation
2024-02-28T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393069br/clinical-project-manager
2024-02-28T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393073br/territory-business-executive
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393079br/director-public-affairs
2024-02-28T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393081br/market-access-manager
2024-02-28T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392771br/maintenance-technician-i-mechanical
2024-02-28T15:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392978br/engineer-process-hvac
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393099br/associate-manager-mdm
2024-02-28T15:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393103br/associate-manager-erp-bpm
2024-02-28T15:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382307br/associate-director-data-architect-po-people-org
2024-03-06T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387156br/stage-chef-de-produit-dermatologie-psoriasis-hf
2024-02-28T17:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392985br/study-start-team-lead
2024-02-28T17:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393000br/omnichannel-engagement-manager-mwd
2024-03-07T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393139br/specialist-data-science-ai-ml
2024-02-28T23:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392954br/director-content-delivery
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393164br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-02-29T09:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392532br/business-coordinator
2024-02-29T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393047br/regionalnyy-kommercheskiy-menedzher-stavropol
2024-02-29T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393192br/head-inmarket-brands-biz-innovation
2024-02-29T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393193br/marketing-manager
2024-02-29T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393195br/senior-knowledge-management-strategist
2024-02-29T11:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391474br/senior-bpa-manager-rlt-cn
2024-02-29T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393208br/knowledge-management-expert
2024-02-29T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393202br/menedzher-po-klyuchevym-klientam-kardiologiya-gtula
2024-02-29T13:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393217br/manager-erp-bpm
2024-02-29T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387273br/head-search-and-evaluation-platform-enabling-technologies
2024-02-29T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392739br/clinical-research-associate-hungary-home-based
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393094br/country-quality-manager-qprp
2024-02-29T17:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390896br/patient-support-programs-manager
2024-02-29T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/375015br/cardiovascular-institutional-sales-specialist-springfield-remote
2024-02-29T23:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392714br/ad-access-reimbursement-cardiovascular-dakotas-remote
2024-03-01T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393015br/retirement-plans-specialist
2024-03-01T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392040br/operational-health-lead
2024-03-01T07:01:17+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392052br/so-ndp-governance-principal-analyst
2024-03-01T07:01:17+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386190br/territory-business-executive
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392966br/quality-control-manager-deputy-qualified-person
2024-03-01T11:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393276br/postdoc-discovery-sciences
2024-03-04T09:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393219br/production-technician
2024-03-01T13:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393312br/laborant-scheikunde
2024-03-01T15:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393314br/laborant
2024-03-01T15:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385222br/process-team-lead-mfd
2024-03-01T15:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391991br/senior-specialist-it-operations-manufacturing-site
2024-03-01T17:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393247br/business-data-migration-expert-procurement
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390898br/associate-director-product-growth-manager-x3-switzerland-or-us
2024-03-01T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392198br/associate-director-product-growth-manager-x3-us-or-switzerland
2024-03-01T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392792br/associate-director-data-strategy-solutions
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393339br/allergy-area-business-leader-new-york-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393340br/allergy-area-business-leader-philadelphia-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393341br/allergy-area-business-leader-charlotte-nc-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393343br/allergy-area-business-leader-baltimore-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393344br/allergy-area-business-leader-atlanta-ga-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393345br/allergy-area-business-leader-san-francisco-ca-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393347br/allergy-area-business-leader-cincinnati-oh-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393350br/allergy-area-business-leader-detroit-mi-remote
2024-03-06T21:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393351br/allergy-area-business-leader-memphis-tn-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393352br/allergy-area-business-leader-chicago-il-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393353br/allergy-area-business-leader-denver-co-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393354br/allergy-area-business-leader-dallas-tx-remote
2024-03-01T21:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393356br/associate-expert-science-technology-downstream-processing
2024-03-04T11:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393358br/principal-scientist-vitro-adme
2024-03-04T17:02:37+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392273br/vivo-senior-scientist-i-80-100
2024-03-02T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393376br/disease-area-partner-immunology-giza
2024-03-03T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393377br/administrative-assistant
2024-03-03T13:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393256br/country-head-people-organisation
2024-03-03T23:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393380br/lead-medical-science
2024-03-04T03:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393387br/senior-fin-analyst-imus-bpa
2024-03-04T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382887br/qc-analyst-i-visuelle-inspektion-2-schichten-schaftenau
2024-03-04T09:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393274br/senior-good-clinical-practices-pharmacovigilance-auditor
2024-03-04T09:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393389br/associate-director-drug-substance-early-phase
2024-03-04T09:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393398br/medical-lead
2024-03-04T09:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393395br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-04T09:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393397br/senior-brand-manager
2024-03-04T09:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393399br/manager-im-us-bpa
2024-03-04T09:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393091br/gl-platform-quality-head-sm-lmm
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393215br/people-partner-mfd
2024-03-04T11:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393235br/responsable-grands-comptes-urticaire-grand-est-bfc-hf
2024-03-08T09:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393357br/medical-engagement-lead
2024-03-04T11:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393392br/sr-principal-clin-data-stds-specialist
2024-03-06T07:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393405br/business-analysis-manager
2024-03-04T11:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393413br/responsable-grands-comptes-urticaire-idf-sud-hf
2024-03-08T09:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393418br/specialist
2024-03-04T11:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393419br/regional-business-manager
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393420br/specialist
2024-03-04T13:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393429br/responsable-grands-comptes-urticaire-bretagne-centre-hf
2024-03-08T09:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393432br/territory-business-executive
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389741br/hr-systems-and-integration-lead
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393402br/przedstawiciel-medyczny-linia-cardio-bialystok
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393421br/clinical-research-medical-advisor-haemato-oncology
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393440br/complaint-hub-associate
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393441br/people-organization-hr-business-partner-vienna-80-100-mfd
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382667br/infrastructure-enterprise-architect-mergers-acquisitions
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388343br/pca-center-excellence-lead
2024-03-05T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391976br/business-process-analyst-it-supply-chain-logistics-mfd
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392905br/tm-academy-clinical-sciences-innovation-fellow
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393213br/clinical-project-manager
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393216br/associate-director-it-advanced-therapy-business-analyst
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393316br/clinical-research-medical-advisor-oncology
2024-03-04T15:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393409br/senior-fra-specialist-inventory
2024-03-04T17:02:37+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393453br/sr-bus-analyst-ddit-usi-cpm
2024-03-04T17:02:37+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393455br/associate-director-architecture
2024-03-04T17:02:37+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386244br/qa-engineer
2024-03-04T17:02:37+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387600br/sales-representative-mwd-rheuma-heidelbergfreiburg
2024-03-04T17:02:37+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393204br/saperp-deployment-director
2024-03-14T19:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393459br/responsable-de-radiofarmacia
2024-03-04T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393462br/managersr-manager-partnering-and-access-innovation-global-health
2024-03-04T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393463br/buyer-rd-mandarin-speaker
2024-03-04T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393464br/discovery-postdoctoral-fellow-chronic-inflammation
2024-03-04T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383530br/sourcing-manager-it-digital
2024-03-04T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391966br/senior-process-expert-aseptic-processing
2024-03-04T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392675br/product-specialist-neurosciences-puglia
2024-03-04T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393003br/business-data-migration-lead-americas
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393240br/associate-director-pk-sciences
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392117br/director-congress-strategy-and-orchestration
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393466br/patient-access-lead
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393467br/customer-experience-content-partner
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393468br/therapy-area-lead
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393470br/new-products-strategic-pricing-partner
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393474br/business-data-migration-expert-material-management-procurement
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393476br/disease-area-partner-ascvd-alexandria
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393477br/senior-disease-area-partner-ascvd-cairo
2024-03-04T21:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385722br/director-business-development-licensing
2024-03-04T23:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393482br/delegue-hospitalier-dermatologie
2024-03-14T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393483br/radioligand-therapy-area-business-leader-southwest-remote
2024-03-04T23:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393484br/oncology-sales-specialist-hematology-columbus-remote
2024-03-04T23:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387071br/sales-value-manager-monterrey
2024-03-05T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390852br/customer-service-fmd
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393485br/benefits-expert
2024-03-05T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393486br/commercial-analyst
2024-03-06T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386836br/rlt-sasayamaassociate-qa-operation-compliance
2024-03-05T05:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393491br/gaojiyiyaodaibiao-zishenchanpinzhuguan
2024-03-05T05:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393493br/rlt-sasayamaassociate-rlt-lab-technician
2024-03-05T05:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392170br/specialiste-process-culture-cellulaire-hf
2024-03-05T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393495br/access-new-commercial-partnerships-manager
2024-03-05T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392223br/field-sales-leader-hematology
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393505br/gaojidaqujingli
2024-03-05T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393509br/scheduling-manager-mfd
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393514br/qc-site-manager-pharmacien-adjoint-marseille-hf
2024-03-05T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393522br/qa-officer
2024-03-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393532br/senior-legal-counsel-operations-china
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393545br/site-quality-lead-saint-genis-pouilly-01-hf
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392581br/senior-specialistsap-abap-btps4hana
2024-03-05T13:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393378br/internship-particle-characterization-masters-student
2024-03-05T13:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393423br/manager-inspection-audit-readiness
2024-03-05T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393544br/maintenance-coordinator-process
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393547br/engineer-process
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393552br/global-environmental-social-governance-controls-compliance-lead
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393561br/it-assistant-digital-workspace-et-projet-it
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393566br/expert-medico-economie-heor-health-economics-outcomes-research
2024-03-08T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393567br/pharmaziepraktikant-mwd-regulatory-affairs-ab-november-2024
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/375075br/ddit-im-ux-design-lead
2024-03-05T15:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393542br/global-category-head-fleet
2024-03-05T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393548br/clinical-development-medical-director-renal
2024-03-05T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393570br/medical-goverance-lead-scientific-affairs
2024-03-05T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393573br/business-data-migration-expert-commercial
2024-03-05T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393575br/business-data-migration-expert-manufacturing
2024-03-05T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393578br/business-data-migration-expert-procurement
2024-03-05T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393591br/delegue-hospitalier-paris-idf-et-normandie
2024-03-05T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393336br/administrative-professionalproject-coordinator
2024-03-05T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393564br/medical-director-clinical-pharmacology
2024-03-05T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393584br/qa-operations-specialist-mfd
2024-03-05T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393587br/itot-site-lead
2024-03-05T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393588br/itot-support-engineer
2024-03-05T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393601br/neuroscience-territory-account-specialist-atlanta-remote
2024-03-05T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392835br/l-t-central-services-specialist
2024-03-05T21:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393605br/rewards-process-specialist
2024-03-05T21:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393603br/learning-services-specialist
2024-03-15T09:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393606br/global-reg-sub-publishing-specialist
2024-03-05T21:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393331br/qc-analyst-ii-temporary-2-years-contract
2024-03-05T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387866br/head-record-report-us-operations-nocc-mexico
2024-03-05T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393613br/equipment-specialist-befristet-2-jahre
2024-03-05T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393614br/summer-student-marketing
2024-03-05T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393615br/cardiovascular-territory-account-specialist-salem-or-remote
2024-03-05T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393616br/summer-student-value-access
2024-03-05T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393619br/director-data-strategy-acquisition-and-contracting
2024-03-05T23:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393621br/gcp-bioanalysis-lab-operations-expert
2024-03-11T23:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393620br/summer-student-marketing
2024-03-06T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393622br/summer-student-psp-operations
2024-03-06T01:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393623br/summer-student-oncology
2024-03-06T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393625br/summer-student-value-access-npp
2024-03-06T01:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392913br/customer-engagement-lead
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393626br/summer-student-online-experience
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393627br/summer-student-capability-building
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393628br/summer-student-ce-channel-performance
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393629br/summer-student-business-planning-analysis
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393630br/summer-student-legal-services
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393631br/summer-student-supply-chain
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393632br/summer-student-marketing
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393633br/summer-student-data-strategy
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393634br/summer-student-data-strategy
2024-03-06T03:00:39+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393635br/xianyuzhurenxianyuzhuguan
2024-03-17T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393645br/sso-clinical-project-manager
2024-03-06T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393648br/lead-consultant-management-consulting-early-research-drug-developme
2024-03-06T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386046br/manager-digital-analytics
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391944br/global-product-manager
2024-03-08T11:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393624br/senior-international-trade-expert-mfd
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393654br/produktionsmitarbeiterin-keine-nachtschicht-mo-so-schaftenau
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393655br/people-engagement-expert
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393658br/clinical-operations-program-head
2024-03-06T11:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383218br/tehnik-v-biofarmacevtiki-mzd
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392482br/associate-director-isc-endpoint-data-protection
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392511br/senior-process-expert-cgt
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392707br/sr-spec-ddit-dev-ba-trd
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393565br/production-technician-1-year-temporary-contract
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393664br/netzwerkmanager-mwd-ta-prostate-cancer-region-sudbayern
2024-03-06T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393465br/authority-affairs-manager
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393677br/associate-director-data-management
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393679br/associate-director-aiml-products
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390708br/produktionsmitarbeiterin-3-schichten-schaftenau-tirol
2024-03-06T15:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393318br/senior-fra-specialist-gl
2024-03-06T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393681br/head-ip-immunology
2024-03-06T17:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393685br/junior-mass-spectrometry-expert-mfd-analytical-characterization
2024-03-07T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393652br/associate-clinical-trial-supply-manager
2024-03-06T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393689br/tehnolog-proizvodnih-procesov-pakiranja-i-mzd
2024-03-06T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393694br/oncology-sales-specialist-womens-breast-cancer-harriburg-remote
2024-03-06T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393686br/research-scientist-necropsyhistology-preclinical-safety
2024-03-06T21:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393699br/rheumatology-territory-account-specialist-central-nj-remote
2024-03-06T21:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393700br/associate-director-hcp-education-delivery
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389800br/sso-study-start-team-lead
2024-03-06T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393706br/formulation-scientist-focus-rlt-mfd
2024-03-06T23:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393338br/crm-incentives-expert
2024-03-07T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393723br/associate-director-thought-leader-liaison-dermatology-southeast
2024-03-15T05:01:09+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393727br/medical-science-liaison-neuroscience-coastal-southeast-remote
2024-03-09T03:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393725br/regulatory-affairs-specialist
2024-03-07T05:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393729br/regulatory-affairs-associate-director
2024-03-07T05:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393731br/medical-representative
2024-03-07T05:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392256br/acheteur-industriel-hf
2024-03-07T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393730br/oncology-product-manager
2024-03-07T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393734br/senior-medical-safety-lead
2024-03-07T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393738br/project-coordinator
2024-03-07T09:00:42+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385362br/program-change-manager-operations-workstream
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389591br/global-program-safety-lead-cardio-renal-metabolic
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392230br/laboratorijski-analitik-mzd
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392595br/senior-process-technologist
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393585br/qa-operations-expert
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393748br/legal-trainee-novartis-operations
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393753br/senior-safety-signal-expert
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393758br/qc-analyst-ii
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393762br/qc-specialist-ii
2024-03-07T11:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393543br/buyer-german
2024-03-07T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393546br/senior-country-procurement-manager-germany
2024-03-07T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393776br/senior-coordinator
2024-03-07T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393784br/senior-mass-spectrometry-expert-analytical-characterisation-mfd
2024-03-07T15:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393787br/qa-assistant-troyes-hf
2024-03-07T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393788br/qa-assistant-bethune-hf
2024-03-07T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393791br/discovery-postdoctoral-fellow-covalent-drug-discovery
2024-03-07T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393794br/director-systems-accounts-cardiovascular-mountain-west-remote
2024-03-07T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391404br/chef-de-produit-senior-ophta-hf
2024-03-07T17:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393798br/site-engineering-lead-toulouse-hf
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393801br/clinical-biospecimen-expert-scientist
2024-03-07T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393807br/associate-director-ma-it-isc
2024-03-07T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393568br/process-expert
2024-03-07T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393604br/business-data-migration-expert-finance-2-positions
2024-03-12T19:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393815br/general-accounting-senior-specialist
2024-03-07T23:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393816br/general-accounting-manager
2024-03-07T23:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393817br/oncology-field-lead
2024-03-07T23:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393823br/associate-director-global-program-management
2024-03-08T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393819br/global-program-head-neuroscience-phd-or-md
2024-03-08T23:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393820br/summer-student-people-organization
2024-03-08T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393822br/summer-student-communications-engagement
2024-03-08T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393826br/senior-legal-counsel
2024-03-08T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393403br/sales-representative-market-brands-oncology-and-hematology
2024-03-08T03:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393743br/marketing-manager
2024-03-08T03:00:43+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393818br/neuro-portfolio-lead
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393830br/xianyuzhurenxianyuzhuguan
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393831br/gaojiyiyaodaibiao-zishenchanpinzhuguan
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393832br/portfolio-account-specialist-wellington-waikato-region
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393833br/portfolio-account-specialist-christchurch-region
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393834br/senior-product-manager-auckland-based
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393835br/marketing-coe-lead
2024-03-08T05:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392987br/automation-engineer-mfd
2024-03-08T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393837br/specialist
2024-03-08T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393840br/specialist
2024-03-08T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393841br/japan-clinical-trial-lead
2024-03-08T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393842br/specialist
2024-03-08T09:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393844br/dir-ddit-apd-ai-platforms
2024-03-15T09:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393854br/lead-consultant-management-consulting-change-management
2024-03-08T09:00:44+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393381br/associate-or-manager-associate-engagement
2024-03-12T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393855br/specialist-za-analitiko-mzd
2024-03-08T11:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393857br/head-global-finance-master-datagfmd
2024-03-08T11:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393859br/lead-consultant-management-consulting-campaign-management
2024-03-08T11:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383281br/health-safety-environment-specialist
2024-03-08T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393057br/asset-life-cycle-lead
2024-03-08T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393220br/material-implementation-expert
2024-03-08T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393868br/senior-manager
2024-03-08T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393869br/sr-mgr-ddit-svcmgt-cn-data-platf
2024-03-08T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393875br/sr-mgr-ddit-soldel-china-data
2024-03-08T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393886br/laborant-scheikunde
2024-03-08T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393890br/senior-manager-commercial-analytics
2024-03-08T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386842br/associate-qa-compliance
2024-03-08T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391746br/associate-director-data-acquisition-contracting
2024-03-12T15:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393290br/elektrotechniker-mfd-kundl-tirol
2024-03-08T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393303br/technical-compliance-engineer-mfd
2024-03-14T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393456br/human-resources-specialist-german
2024-03-08T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393676br/change-manager-enterprise-data-management
2024-03-08T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393768br/patient-safety-specialist-fixed-term-contract
2024-03-08T15:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393882br/discovery-postdoctoral-fellow-diseases-aging-and-regenerative-medic
2024-03-08T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393897br/assoc-director-science-technology-molecular-analytical-development
2024-03-08T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387389br/assoc-director-scrum-master
2024-03-08T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392857br/product-specialist-hematology-calabria-e-sicilia-orientale
2024-03-08T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393708br/applied-computational-biologist-renal-i
2024-03-08T17:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393342br/associate-director-ms-pbpk
2024-03-08T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393821br/global-program-head-oncology-md-or-phd
2024-03-08T21:00:46+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393361br/executive-director-us-patient-advocacy
2024-03-11T23:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393363br/executive-director-us-corporate-communications
2024-03-11T23:00:47+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393360br/head-public-affairs-lacan
2024-03-15T23:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393824br/global-program-clinical-head-neuroscience-md-phd-or-pharmd
2024-03-09T03:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393919br/group-head-regulatory-writing-and-submissions
2024-03-09T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393920br/tco-physician
2024-03-09T11:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393922br/ad-thought-leader-liaison-dermatology-rocky-mountain-region
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393926br/gaojiyiyaodaibiao-zishenchanpinzhuguan
2024-03-11T03:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393927br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-11T03:00:41+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392385br/gcp-bioanalysis-principal-scientist-ii
2024-03-11T05:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393928br/xianyuzhurenxianyuzhuguan
2024-03-11T05:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393931br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-11T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393940br/medical-science-liaison-hematology-cluj
2024-03-11T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393941br/gaojiyiyaodaibiao-zishenchanpinzhuguan
2024-03-11T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392975br/business-data-migration-expert-finance
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393934br/information-governance-manager
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393944br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393946br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393948br/nadzornik-skladiscno-logisticnih-procesov
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393951br/technicien-de-maintenance-utilites-hf-cdd
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393952br/gaojiyiyaodaibiao-zishenchanpinzhuguan
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393954br/medical-scientific-liaison-pre-launch-hematology
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393955br/mgr-ddit-svcmgt-china
2024-03-11T11:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393880br/moderator-procesov-registracij-mzd
2024-03-11T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393961br/commercial-manager
2024-03-11T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393962br/procurement-analyst-ddit-procurement
2024-03-11T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393973br/equipment-specialist-i
2024-03-11T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393969br/specialist-data-scientist
2024-03-11T13:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393976br/senior-consultant
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393979br/customer-engagement-manager
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393987br/equipment-specialist-i
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/382599br/director-corporate-strategy
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393594br/qa-compliance-expert-reg-cmc-facilitator
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393671br/senior-business-planning-analyzes-manager-large-molecules
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393687br/head-protective-security-switzerland
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393782br/kierownik-ds-kluczowych-klientow-solid-tumors
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393870br/specialist-kontrole-kakovosti-za-laboratorijsko-opremo-mzd
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393990br/director-radioligand-therapy-access-lead-remote
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393980br/access-reimbursement-manager-renal-remote-charlotte-nc
2024-03-11T15:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393992br/qc-site-manager-pharmacien-adjoint-saint-genis-pouilly-hf
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393995br/postgraduate-external-analytics
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393997br/technicien-de-production-controle-qualite-cdd-01-hf
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393999br/clinical-research-associate-cra
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/385231br/therapeutic-data-strategy-director
2024-03-11T17:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393994br/associate-director-radioligand-therapy-access-lead-1-5-roles
2024-03-13T03:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394004br/clinical-research-medical-advisor
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394009br/global-program-safety-lead
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394012br/associate-director-channel-pricing-strategy-remote
2024-03-11T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393721br/head-finance-communications
2024-03-11T21:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393998br/director-channel-and-pricing-strategy-remote
2024-03-11T21:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394014br/order-cash-treasury-cash-management-team-lead
2024-03-11T21:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394015br/clinical-development-medical-director
2024-03-11T21:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394016br/associate-director-marketing-strategy
2024-03-12T19:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393716br/director-corporate-affairs-storytelling
2024-03-11T21:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393717br/manager-strategic-projects-chief-staff-office
2024-03-11T21:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393720br/head-finance-communications
2024-03-11T21:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394021br/head-refs-us-real-estate-and-facility-services-executive-director
2024-03-14T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393986br/vp-channel-strategy-and-account-management-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393988br/ed-channel-strategy-advanced-platforms-remote
2024-03-12T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394026br/oncology-area-business-leader-melanoma-west
2024-03-12T01:00:49+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394033br/gaojiyiyaodaibiaozishenchanpinzhuguan
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394034br/gaojiyiyaodaibiao-zishenchanpinzhuguan
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394036br/gaojiyiyaodaibiao-zishenchanpinzhuguan
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394038br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394039br/quyushichangjingliarea-marketing-manager
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394040br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394041br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394042br/quyushichangjingliarea-marketing-manager
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394043br/gaojidequjingli
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394045br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394048br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394049br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-12T05:01:04+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394050br/sr-spec-ddit-dev-soldel-ppm
2024-03-12T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394053br/principal-rwe-scientific-data-analyst
2024-03-12T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394056br/rwe-scientific-data-analyst-ii
2024-03-12T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394059br/elearning-technical-developer
2024-03-12T09:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394061br/information-specialist-literature-intelligence
2024-03-12T09:00:48+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384524br/manager
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391875br/process-support-unit-lead-mfd
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393852br/external-engagement-manager
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394073br/utilities-technieker-gebouwen
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394062br/xianyuzhurenxianyuzhuguan
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394067br/senior-analyst
2024-03-12T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/384519br/manager
2024-03-12T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393189br/chef-de-produit-rhumato-hf
2024-03-12T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394082br/therapeutic-area-partner-illaris-gulf-cluster
2024-03-12T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394084br/medical-advisor-hematology
2024-03-12T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394088br/qc-analyst-ii
2024-03-12T13:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393984br/external-analytical-operations-expert-fmd
2024-03-12T15:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394094br/qc-analyst-ii
2024-03-12T15:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394101br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-12T15:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393908br/technicien-laboratoire-prelevement-microbiologie-hf-cdd
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394103br/delegue-hospitalier-onco-val-de-loire
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394104br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394107br/oncology-sales-specialist-nm-hematology-indianapolis-remote
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394105br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394110br/chef-de-produit-hf
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394111br/chef-de-produit-hf-cdd
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389583br/sales-representative-dwm-ta-onkologie-hannover-wolfsburg-braunsc
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/389584br/sales-representative-dmw-ta-onkologie-bremen-hamburg-oldenburg
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393035br/qc-analyst
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393675br/responsable-grands-comptes-dermato-idf-nord-hf
2024-03-12T17:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394120br/talent-acquisition-lead-international-latin-america-and-canada-region
2024-03-12T19:00:52+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394123br/manager-patient-access
2024-03-12T21:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394126br/territory-account-specialist-cardiovascular-seattle-north-remote
2024-03-12T23:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394129br/clinical-project-manager-site-study-operationssso
2024-03-12T23:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394130br/clinical-project-manager-site-study-operationssso
2024-03-12T23:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394132br/associate-director-marketing-strategist-rheumatology
2024-03-13T17:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394133br/discovery-postdoctoral-fellow-neuroscience-multi-modal-genomics
2024-03-12T23:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/378694br/sap-basisaws-cloud-manager
2024-03-12T23:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391288br/head-health-data-insights-design
2024-03-12T23:00:51+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393639br/gerente-de-cuentas-clave
2024-03-13T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394139br/expert-science-technology-drug-product
2024-03-13T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394140br/trial-master-file-integration-oversight-manager
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394141br/head-pco-center-excellence
2024-03-13T01:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/387704br/lead-solution-design-region-accelerator
2024-03-13T03:00:45+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394153br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-14T05:01:23+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394154br/executive-director-martech-product-owner-salesforce
2024-03-13T05:01:07+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394155br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-13T05:01:07+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/388804br/shengchancaozuogong
2024-03-13T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393744br/data-insights-business-planning
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394160br/therapeutic-area-partner-qatar
2024-03-13T09:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394172br/rewards-process-specialist
2024-03-13T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394166br/associate-product-manager
2024-03-13T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394168br/assoc-dir-ddit-isc-ent-arch-digit-sec
2024-03-13T11:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393058br/engineer-automation
2024-03-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394184br/student-intern
2024-03-13T13:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394185br/supply-operations-manager
2024-03-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394189br/clinical-drug-development-postgraduate-training-program-mscphdmd
2024-03-13T13:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394193br/development-quality-assurance-manager-gcpgpvp
2024-03-13T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394187br/quality-specialist-managing-external-contractors-mfd
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394196br/process-team-lead
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394204br/analista-de-bi-efetividade-da-forca-de-vendas-sr-imi-sp
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394205br/assoc-dir-ddit-dev-ba-usdus
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393205br/re-lead-standards-process-governance
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393879br/senior-qa-operations-specialist-mwd
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393892br/solution-service-design-managers
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393959br/quality-assurance-specialist-laboratory-support-mfd
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394128br/pharmareferentin-onkologie-brustkrebs-westen
2024-03-13T15:00:56+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394217br/python-developer
2024-03-13T17:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/390766br/head-health-data-insights-design
2024-03-13T17:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394226br/engineering-maintenance-cmms-lead
2024-03-14T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394227br/sr-spec-ddit-isc-secops-cyber-tools
2024-03-13T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391114br/ast-specialist-ii-mfd
2024-03-13T19:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392368br/ldc-adopt-mgr-demand-and-supply-americas
2024-03-13T21:00:50+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394241br/gaojiyiyaodaibiaozishenchanpinzhuguan
2024-03-14T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394245br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-14T05:01:23+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394246br/director-product-strategy-lead-sma-intrathecal
2024-03-14T05:01:23+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392712br/senior-scientist-antigen-therapeutic-protein-production-80-100
2024-03-14T05:01:23+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393013br/research-scientist-immunogenicity-mechanistic-immunology-80-100
2024-03-14T05:01:23+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394247br/oncology-disease-area-lead-nm-hematology-columbus-remote
2024-03-14T07:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394249br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-14T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394254br/lead-capability-learning-solutions
2024-03-14T09:00:59+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/391682br/assoc-dir-ddit-dev-gco-tech-design
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394261br/lingshouteyaochanpinzhuanyuan
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394262br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394264br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394267br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-14T11:01:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393443br/customer-engagement-manager-hematology
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394280br/office-administrator
2024-03-14T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394285br/cxzhanerito-cx-strategy-lead
2024-03-14T13:01:07+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394289br/lead-cx-content-creation
2024-03-14T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/383961br/analista-de-eventos-sr-im-sao-paulo
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386212br/it-product-lead-europe-patient-services-salesforce
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393674br/delegue-hospitalier-idf-hf
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393805br/head-legal-secretary-pension-fund-board-trustees-80
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393911br/qa-operations-specialist-mfd
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394159br/clinical-operations-specialist
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394207br/hcm-engagement-manager
2024-03-14T15:00:55+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394302br/medical-representative
2024-03-14T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394306br/scm-analyst-mfd
2024-03-14T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394309br/senior-scientist-oncology-pathology-biomarkers
2024-03-14T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393877br/value-access-manager-senior-value-access-manager
2024-03-14T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394303br/ot-support-specialist-saint-genis-pouilly-01-hf
2024-03-14T17:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394006br/snr-key-account-manager-south-region-rare-diseases
2024-03-14T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394007br/snr-key-account-manager-north-region-rare-diseases
2024-03-14T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394311br/quality-projects-lead-cgmp
2024-03-14T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394313br/access-manager-marketing-population-health
2024-03-14T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394218br/bpa-fpa-core-consultant-global-functions-sao-paulo
2024-03-14T21:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394323br/disease-area-partner-immunology-giza
2024-03-14T21:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394030br/market-access-manager
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394046br/associate-pricing-manager
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394047br/associate-director-pricing
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394325br/associate-director-market-access
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/392367br/ldc-adopt-lead-supply-chain-americas
2024-03-14T23:00:53+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393223br/senior-regulatory-writer
2024-03-15T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394328br/associate-director-regulatory-writing
2024-03-15T01:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394331br/gaojiyiyaodaibiaozishenchanpinzhuguan
2024-03-15T03:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394332br/global-ops-manager
2024-03-15T03:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393229br/associate-director-biomarker-project-lead
2024-03-15T05:01:09+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393346br/principal-scientist-medicinal-chemist-80-100
2024-03-15T05:01:09+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394334br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-15T05:01:09+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394335br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-15T05:01:09+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394336br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-15T05:01:09+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394337br/gaojiyiyaodaibiaozishenchanpinzhuguan
2024-03-15T05:01:09+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394338br/associate-external-operations-manager
2024-03-15T05:01:09+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394339br/oncology-disease-area-lead-nm-hematology-seattle-remote
2024-03-15T05:01:09+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394028br/associate-market-access-manager
2024-03-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394341br/gaojidequjingli
2024-03-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394342br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394343br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394344br/xianyuzhurenxianyuzhuguan
2024-03-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394345br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394346br/gaojiyiyaodaibiao-zishenchanpinzhuanyuan
2024-03-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394340br/gaojidequjingli
2024-03-15T07:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/386303br/senior-expert-data-digital
2024-03-15T09:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393929br/customer-engagement-associate-12mth-contract
2024-03-15T09:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394032br/analytics-insights-manager
2024-03-15T09:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394347br/manager-advanced-analytics
2024-03-15T09:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394350br/manager-front-end-dev-python-java-angular-js-flask-quickly
2024-03-15T09:01:00+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394364br/field-product-specialist-cardiovascular
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394363br/field-product-specialist-cardiovascular
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394362br/field-product-specialist-cardiovascular
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394357br/medical-representative
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394360br/logistics-specialist
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394365br/senior-analyst
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394369br/snr-spec-ddit-apd-da-integration
2024-03-15T11:00:58+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393458br/human-resources-specialist-spanish
2024-03-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393760br/communication-manager-and-patient-relations
2024-03-15T13:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393895br/chemielabortechniker-qc-analyst-ii-mwd-schaftenau-osterreich
2024-03-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394393br/technology-product-associate-director
2024-03-15T13:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394315br/head-patient-centre-outcomes-center-excellence
2024-03-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394333br/senior-clinical-finance-manager
2024-03-15T13:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394372br/head-safety-case-processing
2024-03-15T13:00:02+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394392br/specialist-ddit-isc-qnova
2024-03-15T13:00:54+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394394br/asistant-manager-innovation-and-data-sc
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394396br/manager-erc-policies
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394397br/executive-ncq
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394400br/allergy-territory-account-specialist-fort-collins-co-remote
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394401br/allergy-territory-account-specialist-annapolis-md-remote
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394403br/laborant-omgevingscontrole
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394406br/allergy-territory-account-specialist-colorado-springsco-remote
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394407br/allergy-territory-account-specialist-charleston-wv-remote
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394409br/allergy-territory-account-specialist-denver-co-remote
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394411br/director-solution-delivery-one-psp-sf
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394412br/allergy-territory-account-specialist-lexington-remote
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394413br/allergy-territory-account-specialist-tucson-az-remote
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394414br/allergy-territory-account-specialist-louisville-south-remote
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394415br/allergy-territory-account-specialist-phoenix-north-az-remote
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393206br/associate-director-solution-delivery-quality-control
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/393949br/strategic-account-manager-cardio-mfd
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394144br/crm-incentives-expert
2024-03-15T15:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394417br/allergy-territory-account-specialist-phoenix-south-az-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394418br/allergy-territory-account-specialist-salt-lake-city-ut-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394420br/allergy-territory-account-specialist-spokane-wa-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394423br/allergy-territory-account-specialist-orange-county-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394425br/allergy-territory-account-specialist-san-diego-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394428br/allergy-territory-account-specialist-las-vegas-nv-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394429br/qc-analyst-omgevingscontrole
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394431br/allergy-territory-account-specialist-seattle-east-wa-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394432br/allergy-territory-account-specialist-seattle-west-wa-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394433br/head-ddit-isc-business-continuity-mgmt
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394434br/allergy-territory-account-specialist-portland-or-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394435br/allergy-territory-account-specialist-sacramento-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394436br/allergy-territory-account-specialist-fresno-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394437br/allergy-territory-account-specialist-san-francisco-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394438br/allergy-territory-account-specialist-bakersfield-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394440br/allergy-territory-account-specialist-los-angeles-west-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394441br/allergy-territory-account-specialist-los-angeles-east-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394442br/allergy-territory-account-specialist-san-jose-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394443br/allergy-territory-account-specialist-pasadena-ca-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394444br/allergy-territory-account-specialist-atlanta-north-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394446br/allergy-territory-account-specialist-bowling-green-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394447br/allergy-territory-account-specialist-atlanta-south-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394448br/allergy-territory-account-specialist-chattanooga-tn-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394449br/allergy-territory-account-specialist-cincinnati-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394450br/allergy-territory-account-specialist-macon-ga-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394453br/allergy-territory-account-specialist-indianapolis-south-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394454br/allergy-territory-account-specialist-jacksonville-fl-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394455br/allergy-territory-account-specialist-daytona-beach-fl-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394231br/coordinateur-prestataire-operations-locales-hf
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394297br/embrace-advisor-milano
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394456br/allergy-territory-account-specialist-peoria-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394457br/allergy-territory-account-specialist-tampa-fl-remote
2024-03-15T17:01:06+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394416br/allergy-territory-account-specialist-louisville-north-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394002br/access-value-manager-onco-hematologia-brasil
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394458br/allergy-territory-account-specialist-st-louis-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394459br/allergy-territory-account-specialist-palm-beach-fl-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394460br/allergy-territory-account-specialist-oklahoma-city-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394461br/allergy-territory-account-specialist-sarasota-fl-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394462br/allergy-territory-account-specialist-miami-fl-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394463br/allergy-territory-account-specialist-fort-worth-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394464br/allergy-territory-account-specialist-dallas-east-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394465br/allergy-territory-account-specialist-nashville-east-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394466br/allergy-territory-account-specialist-dallas-west-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394467br/allergy-territory-account-specialist-nashville-west-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394468br/allergy-territory-account-specialist-houston-east-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394469br/allergy-territory-account-specialist-houston-west-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394470br/allergy-territory-account-specialist-murfreesboro-tn-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394471br/allergy-territory-account-specialist-austin-north-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394472br/allergy-territory-account-specialist-birmingham-al-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394473br/allergy-territory-account-specialist-austin-south-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394474br/allergy-territory-account-specialist-pensacola-fl-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394475br/allergy-territory-account-specialist-san-antonio-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394478br/allergy-territory-account-specialist-corpus-christi-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394481br/allergy-territory-account-specialist-albuquerque-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394482br/allergy-territory-account-specialist-columbus-ms-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394483br/allergy-territory-account-specialist-jackson-ms-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394484br/allergy-territory-account-specialist-new-orleans-remote
2024-03-15T19:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394485br/allergy-territory-account-specialist-little-rock-ar-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394487br/allergy-territory-account-specialist-shreveport-la-remote
2024-03-15T19:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394488br/allergy-territory-account-specialist-knoxville-tn-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394489br/allergy-territory-account-specialist-detroit-mi-remote
2024-03-15T19:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394490br/allergy-territory-account-specialist-harrisburg-pa-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394492br/allergy-territory-account-specialist-flint-mi-remote
2024-03-15T19:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394493br/allergy-territory-account-specialist-baltimore-md-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394494br/allergy-territory-account-specialist-grand-rapids-mi-remote
2024-03-15T19:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394495br/allergy-territory-account-specialist-washington-dc-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394496br/allergy-territory-account-specialist-bethesda-md-remote
2024-03-15T19:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394497br/allergy-territory-account-specialist-fairfax-va-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394498br/allergy-territory-account-specialist-portland-me-remote
2024-03-15T19:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394500br/allergy-territory-account-specialist-pittsburgh-pa-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394501br/allergy-territory-account-specialist-newark-de-remote
2024-03-15T19:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394502br/allergy-territory-account-specialist-boston-north-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394503br/allergy-territory-account-specialist-boston-south-remote
2024-03-15T19:01:01+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394504br/allergy-territory-account-specialist-fredericksburg-va-remote
2024-03-15T19:00:03+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394549br/principal-scientist-cadd
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394206br/research-development-quality-risk-management-manager
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394511br/global-med-dir-autoimmune-disease
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394505br/allergy-territory-account-specialist-norfolk-va-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394506br/allergy-territory-account-specialist-hartford-ct-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394507br/allergy-territory-account-specialist-richmond-va-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394508br/allergy-territory-account-specialist-new-haven-ct-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394510br/allergy-territory-account-specialist-raleigh-nc-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394512br/allergy-territory-account-specialist-white-plains-ny-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394513br/allergy-territory-account-specialist-albany-ny-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394514br/allergy-territory-account-specialist-syracuse-ny-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394515br/allergy-territory-account-specialist-buffalo-ny-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394516br/allergy-territory-account-specialist-springfield-ma-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394517br/allergy-territory-account-specialist-ann-arbor-mi-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394518br/allergy-territory-account-specialist-morristown-nj-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394519br/allergy-territory-account-specialist-allentown-pa-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394520br/allergy-territory-account-specialist-toledo-oh-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394521br/allergy-territory-account-specialist-edison-nj-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394522br/allergy-territory-account-specialist-durham-nc-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394523br/allergy-territory-account-specialist-philadelphia-pa-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394524br/allergy-territory-account-specialist-winston-salem-nc-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394525br/allergy-territory-account-specialist-toms-river-nj-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394526br/allergy-territory-account-specialist-columbus-oh-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394527br/allergy-territory-account-specialist-charlotte-nc-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394528br/allergy-territory-account-specialist-columbia-sc-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394529br/allergy-territory-account-specialist-midtown-manhattan-ny-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394530br/allergy-territory-account-specialist-indianapolis-north-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394531br/allergy-territory-account-specialist-charleston-sc-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394532br/allergy-territory-account-specialist-brooklyn-ny-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394533br/allergy-territory-account-specialist-queens-ny-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394534br/allergy-territory-account-specialist-johnson-city-tn-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394535br/allergy-territory-account-specialist-bay-shore-ny-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394536br/allergy-territory-account-specialist-jersey-city-nj-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394537br/allergy-territory-account-specialist-greenville-sc-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394538br/allergy-territory-account-specialist-cleveland-oh-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394539br/allergy-territory-account-specialist-akron-oh-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394540br/allergy-territory-account-specialist-chicago-n-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394541br/allergy-territory-account-specialist-chicago-s-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394542br/allergy-territory-account-specialist-green-bay-wi-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394543br/allergy-territory-account-specialist-milwaukee-wi-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394544br/allergy-territory-account-specialist-naperville-il-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394545br/allergy-territory-account-specialist-minneapolis-mn-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394546br/allergy-territory-account-specialist-des-moines-ia-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394547br/allergy-territory-account-specialist-kansas-city-mo-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394548br/allergy-territory-account-specialist-lincoln-ne-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394550br/allergy-territory-account-specialist-sioux-falls-sd-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394551br/allergy-territory-account-specialist-wichita-ks-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394553br/medical-science-liaison-allergy-derm-tennessee-remote
2024-03-15T21:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394329br/associate-director-innovation-capability-clinical-trial-diversity
2024-03-15T23:01:10+01:00
daily
0.5
https://www.novartis.com/careers/career-search/job-details/394558br/therapy-area-medical-lead-heart-failure
2024-03-17T09:00:59+01:00
daily
0.5
https://www.novartis.com/investors
2024-03-11T10:59:01+01:00
daily
0.5
https://www.novartis.com/investors/share-data-analysis
2024-03-14T11:34:31+01:00
daily
0.5
https://www.novartis.com/about
2024-02-21T20:38:48+01:00
daily
0.5
https://www.novartis.com/patients-and-caregivers
2024-03-12T09:40:15+01:00
daily
0.5
https://www.novartis.com/clinicaltrials
2024-02-08T17:15:03+01:00
daily
0.5
https://www.novartis.com/healthcare-professionals
2024-02-08T17:19:04+01:00
daily
0.5
https://www.novartis.com/research-and-development
2024-02-08T17:14:22+01:00
daily
0.5
https://www.novartis.com/research-and-development/technology-platforms
2024-02-08T17:43:40+01:00
daily
0.5
https://www.novartis.com/diseases/coronavirus
2023-10-31T10:31:24+01:00
daily
0.5
https://www.novartis.com/esg
2024-02-09T12:13:16+01:00
daily
0.5
https://www.novartis.com/news
2024-03-15T17:20:20+01:00
daily
0.5
https://www.novartis.com/investors/company-overview
2024-03-14T11:45:21+01:00
daily
0.5
https://www.novartis.com/esg/environmental-sustainability
2024-02-02T08:43:04+01:00
daily
0.5
https://www.novartis.com/about/novartis-and-european-union
2024-02-15T09:44:46+01:00
daily
0.5
https://www.novartis.com/esg/global-health
2024-02-08T17:52:18+01:00
daily
0.5
https://www.novartis.com/partnering
2024-02-09T08:18:10+01:00
daily
0.5
https://www.novartis.com/esg/access
2023-12-04T07:28:54+01:00
daily
0.5
https://www.novartis.com/about/diversity-equity-and-inclusion
2024-02-08T17:03:24+01:00
daily
0.5
https://www.novartis.com/about/people-and-culture
2024-02-08T16:59:53+01:00
daily
0.5
https://www.novartis.com/about/novartis-gene-therapies
2023-11-17T17:46:11+01:00
daily
0.5
https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond
2023-11-17T17:03:13+01:00
daily
0.5
https://www.novartis.com/about/quality
2024-02-02T11:51:13+01:00
daily
0.5
https://www.novartis.com/esg/ethics-risk-and-compliance
2024-02-08T17:51:44+01:00
daily
0.5
https://www.novartis.com/diseases
2024-03-08T09:42:42+01:00
daily
0.5
https://www.novartis.com/research-development/technology-platforms/radioligand-therapy
2023-11-03T08:37:19+01:00
daily
0.5
https://www.novartis.com/research-development/technology-platforms/gene-therapy
2023-11-17T17:01:02+01:00
daily
0.5
https://www.novartis.com/supplier-portal
2024-02-08T17:16:28+01:00
daily
0.5
https://www.novartis.com/research-development/technology-platforms/cell-therapy
2023-11-17T17:03:43+01:00
daily
0.5
https://www.novartis.com/about/manufacturing/contract-manufacturing
2024-03-14T09:14:35+01:00
daily
0.5
https://www.novartis.com/about/manufacturing/global-biotech-cooperations/what-we-do/microbial-manufacturing
2023-10-31T11:36:39+01:00
daily
0.5
https://www.novartis.com/about/manufacturing/global-biotech-cooperations/what-we-do/quality-regulatory
2023-10-31T11:42:52+01:00
daily
0.5
https://www.novartis.com/about/manufacturing
2024-03-12T11:17:30+01:00
daily
0.5
https://www.novartis.com/clinicaltrials/healthcare-professionals-researchers
2023-11-02T09:07:46+01:00
daily
0.5
https://www.novartis.com/clinicaltrials/patients
2023-12-04T06:49:19+01:00
daily
0.5
https://www.novartis.com/clinicaltrials/novartis-trials
2023-11-17T17:27:42+01:00
daily
0.5
https://www.novartis.com/clinicaltrials/NCT05089656
2022-09-22T15:02:42+02:00
daily
0.5
https://www.novartis.com/about/therapeutic-areas
2024-02-01T10:19:37+01:00
daily
0.5
https://www.novartis.com/healthcare-professionals/medical-congresses-and-events/asco-annual-meeting
2024-02-08T17:28:03+01:00
daily
0.5
https://www.novartis.com/careers/why-novartis
2023-12-01T17:06:05+01:00
daily
0.5
https://www.novartis.com/careers/our-business-functions/careers-commercial-and-sales
2024-02-08T18:12:25+01:00
daily
0.5
https://www.novartis.com/careers/our-business-functions
2023-12-01T17:01:36+01:00
daily
0.5
https://www.novartis.com/careers/career-hub
2023-12-04T13:19:17+01:00
daily
0.5
https://www.novartis.com/about/therapeutic-areas/oncology/my-cancer-my-words
2024-01-31T10:06:36+01:00
daily
0.5
https://www.novartis.com/investors/reporting-and-transparency-hub
2024-02-16T12:39:40+01:00
daily
0.5
https://www.novartis.com/investors/reporting-and-transparency-hub/novartis-society-integrated-report
2024-01-31T07:36:57+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-afinitor-significantly-improves-progression-free-survival-advanced-nonfunctional-gastrointestinal-and-lung-net
2021-10-05T11:51:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-entrestotm-recommended-chmp-eu-approval
2021-10-05T11:51:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-appoints-james-e-bradner-md-president-novartis-institutes-biomedical-research-mark-fishman-retires
2022-04-08T11:39:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-nomme-le-dr-james-e-bradner-president-des-instituts-novartis-pour-la-recherche-biomedicale-suite-au-prochain-depart-la-retraite-de-mark-fishman
2021-10-05T11:51:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ernennt-dr-james-e-bradner-zum-prasidenten-der-novartis-institutes-biomedical-research-da-mark-fishman-den-ruhestand-tritt
2021-10-05T11:51:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-launches-novartis-access-portfolio-affordable-medicines-treat-chronic-diseases-lower-income-countries
2021-10-05T11:51:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-lance-novartis-access-une-gamme-de-medicaments-prix-abordables-pour-lutter-contre-les-maladies-chroniques-dans-les-pays-faible-revenu
2021-10-05T11:51:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-lanciert-novartis-access-ein-portfolio-von-erschwinglichen-medikamenten-zur-behandlung-von-chronischen-erkrankungen-landern-mit-niedrigen-einkommen
2021-10-05T11:51:27+02:00
daily
0.5
https://www.novartis.com/news/media-releases/swissmedic-approves-novartis-new-heart-failure-medicine-entrestotm
2021-10-05T11:51:27+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-foundation-healthcare-models-and-disease-elimination-programs-showcased-ectmih
2021-10-05T11:51:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-farydak-first-its-class-anticancer-agents-approved-patients-multiple-myeloma
2021-10-05T11:51:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-launches-zarxiotm-filgrastim-sndz-first-biosimilar-united-states
2021-10-05T11:51:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-new-revolade-use-first-class-therapy-patients-severe-aplastic-anemia
2021-10-05T11:51:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-global-partnership-amgen-develop-and-commercialize-pioneering-neuroscience-treatments
2021-10-05T11:51:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-setzt-sich-weiter-fur-die-endgultige-ausrottung-von-lepra-ein
2021-10-05T11:51:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-lapproche-de-la-derniere-ligne-droite-dans-la-lutte-visant-eradiquer-la-lepre
2021-10-05T11:51:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-tafinlar-and-mekinist-first-combination-approved-patients-aggressive-form-melanoma
2021-10-05T11:51:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-continues-commitment-go-last-mile-effort-eliminate-leprosy
2021-10-05T11:51:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/das-novartis-international-biocamp-zeigt-wie-zusammenarbeit-und-vielfalt-innovationen-fordern-und-inspiriert-kunftige-wissenschaftliche-fuhrungskrafte
2021-10-05T11:51:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/le-novartis-international-biocamp-souligne-le-role-de-la-collaboration-et-de-la-diversite-pour-stimuler-linnovation-et-inspirer-les-futurs-leaders-scientifiques
2021-10-05T11:51:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-international-biocamp-highlights-how-collaboration-and-diversity-drive-innovation-and-inspires-future-science-leaders
2021-10-05T11:51:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-expands-use-novartis-drug-promacta-include-treatment-children-ages-1-and-older-chronic-immune-thrombocytopenia
2021-10-05T11:51:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-acquires-all-remaining-rights-gsks-ofatumumab-develop-treatments-ms-and-other-autoimmune-indications
2021-10-05T11:51:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-odomzo-gains-eu-approval-locally-advanced-basal-cell-carcinoma-providing-new-non-invasive-therapy-patients
2021-10-05T11:51:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-completes-divestiture-influenza-vaccines-business-csl-limited-usd-275-million
2021-10-05T11:51:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-partners-phase-4-partners-and-institutional-investors-help-create-mereo-biopharma-group-ltd
2021-10-05T11:51:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-foundation-confirms-new-members-its-board-trustees-including-new-chairman-dr-joerg-reinhardt
2021-10-05T11:51:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-novartis-drug-odomzo-sonidegib-locally-advanced-basal-cell-carcinoma-labcc-form-skin-cancer
2021-10-05T11:51:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-and-mekinist-achieves-important-eu-and-us-regulatory-milestones
2021-10-05T11:51:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-revolade-recommended-chmp-eu-approval-treat-patients-severe-aplastic-anemia-serious-blood-disorder
2021-10-05T11:51:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-solid-performance-second-quarter-strong-innovation-and-progress-new-launches
2021-10-05T11:51:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-solide-performance-au-deuxieme-trimestre-grace-la-force-de-linnovation-et-aux-progres-des-nouveaux-lancements
2021-10-05T11:51:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-eine-solide-performance-mit-starken-innovationen-und-fortschritten-bei-neueinfuhrungen
2021-10-05T11:51:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-malaria-treatment-coartem-80480mg-receives-who-prequalification-enabling-greater-access-patients
2021-10-05T11:51:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda-reduce-risk-cardiovascular-death-and-heart-failure-hospitalization
2021-10-05T11:52:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-receives-european-approval-pre-loaded-intraocular-lens-delivery-system-treat-patients-undergoing-cataract-surgery
2021-10-05T11:52:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-launches-first-app-visually-impaired-people-use-apple-watch-and-other-smart-watches
2021-10-05T11:52:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-deepens-its-industry-leading-pipeline-acquisition-spinifex-pharmaceuticals-inc
2021-10-05T11:52:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-publication-lancet-showing-sustained-efficacy-secukinumab-over-one-year-psoriatic-arthritis-patients
2021-10-05T11:52:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-farydak-recommended-chmp-eu-approval-treat-multiple-myeloma-providing-patients-new-mechanism-action
2021-10-05T11:52:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-us-launch-glatopatm-first-generic-competitor-copaxone-20mg
2021-10-05T11:52:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-strong-innovation-momentum-its-second-meet-novartis-management-investor-day
2021-10-05T11:52:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-receives-european-approval-new-trifocal-presbyopia-correcting-intraocular-lens-patients-undergoing-cataract-surgery
2021-10-05T11:52:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-from-large-european-study-reinforcing-benefit-first-line-tasigna-newly-diagnosed-patients-cml
2021-10-05T11:52:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-data-show-majority-patients-polycythemia-vera-treated-jakavi-achieved-long-term-disease-control
2021-10-05T11:52:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-eha-show-increased-pfs-benefit-farydak-new-subgroup-patients-previously-treated-multiple-myeloma
2021-10-05T11:52:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-arzerra-improved-median-progression-free-survival-54-patients-relapsed-chronic-lymphocytic-leukemia
2021-10-05T11:52:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-new-analysis-showing-xolair-improving-quality-life-78-chronic-spontaneous-urticaria-patients
2021-10-05T11:52:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-gains-fda-approval-promacta-providing-new-option-children-ages-6-and-older-chronic-itp-rare-blood-disorder
2021-10-05T11:52:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-wcd-demonstrating-significant-efficacy-cosentyx-patients-psoriasis-nails-palms-and-soles
2021-10-05T11:52:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-one-year-results-demonstrating-sustained-secukinumab-efficacy-ankylosing-spondylitis-patients
2021-10-05T11:52:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-ctl019-data-showing-its-potential-treatment-specific-types-hard-treat-non-hodgkin-lymphoma
2021-10-05T11:52:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-asco-zykadia-and-combination-tafinlar-and-mekinist-certain-nsclc-patients-unmet-needs
2021-10-05T11:52:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/combination-novartis-drugs-tafinlar-and-mekinist-shows-significant-survival-benefit-patients-metastatic-melanoma
2021-10-05T11:52:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-21-medicines-and-11-investigational-compounds-asco-and-eha
2021-10-05T11:52:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-afinitor-extended-progression-free-survival-phase-iii-trial-advanced-gastrointestinal-or-lung-neuroendocrine-tumors
2021-10-05T11:52:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-two-positive-us-phase-iii-programs-copd-qva149-and-nva237
2021-10-05T11:52:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-lung-cancer-drug-zykadia-gains-eu-approval-providing-new-therapy-certain-patients-alk-nsclc
2021-10-05T11:52:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-study-arzerra-met-primary-endpoint-improved-progression-free-survival-patients-relapsed-cll
2021-10-05T11:52:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-cc-significant-margin-expansion-cc-and-strong-innovation-q11-now-more-focused-portfolio
2021-10-05T11:52:27+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-affiche-au-t11-une-forte-progression-de-ses-ventes-tcc-une-hausse-importante-de-sa-marge-tcc-et-une-innovation-tres-dynamique-avec-un-portefeuille-desormais-mieux-cible
2021-10-05T11:52:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal1-umsatzsteigerungen-kwk-deutlich-hohere-margen-kwk-und-beachtliche-innovationen-jetzt-mit-einem-starker-fokussierten-portfolio
2021-10-05T11:52:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-celebrates-19th-annual-community-partnership-day-more-27000-associates-volunteering-their-local-communities
2021-10-05T11:52:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/data-aan-showed-gilenya-high-efficacy-achieving-no-evidence-disease-activity-previously-treated-highly-active-ms-patients
2021-10-05T11:52:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-fda-approval-glatopatm-first-generic-competitor-ms-therapy-copaxone-20mg
2021-10-05T11:52:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-receives-fda-approval-new-multifocal-intraocular-lens-treat-cataract-patients-united-states
2021-10-05T11:52:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/data-lancet-show-novartis-drug-arzerra-plus-chlorambucil-improved-median-progression-free-survival-71-cll-patients
2021-10-05T11:52:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/gilenya-data-aan-highlight-novartis-leadership-innovation-new-ms-assessment-methods-benefit-patients-and-physicians
2021-10-05T11:52:36+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-jadenutm-simplify-treatment-administration-patients-chronic-iron-overload
2021-10-05T11:52:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-accelerates-cancer-immunotherapy-efforts-aduro-biotech-alliance-and-launch-new-immuno-oncology-research-group
2021-10-05T11:52:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyxtm-two-year-data-shows-sustained-effect-and-favorable-safety-profile-psoriasis-patients
2021-10-05T11:52:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-data-shows-cosentyxtm-significantly-superior-stelara-and-clears-skin-pasi-90-nearly-80-psoriasis-patients
2021-10-05T11:52:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-jakavi-polycythemia-vera-first-targeted-therapy-approved-patients-rare-blood-cancer
2021-10-05T11:52:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-present-new-late-breaking-cosentyxtm-data-aad-2015-showing-significant-patient-benefit-achieving-clear-skin
2021-10-05T11:52:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-first-biosimilar-zarxiotm-filgrastim-sndz-from-sandoz
2021-10-05T11:52:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-completion-transactions-gsk
2021-10-05T11:52:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-gibt-abschluss-von-transaktionen-mit-gsk-bekannt
2021-10-05T11:52:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-annonce-la-conclusion-des-transactions-avec-gsk
2021-10-05T11:52:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/positive-phase-ii-data-highlights-benefits-alcons-rth258-patients-neovascular-wet-age-related-macular-degeneration
2021-10-05T11:52:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-novartis-board-directors
2021-10-05T11:52:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration
2021-10-05T11:52:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/aktionare-genehmigen-alle-antrage-des-verwaltungsrats-von-novartis
2021-10-05T11:52:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-lung-cancer-drug-zykadia-recommended-eu-approval-patients-alk-nsclc-previously-treated-crizotinib
2021-10-05T11:52:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-farydak-first-hdac-inhibitor-patients-multiple-myeloma
2021-10-05T11:52:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-lcz696-granted-fda-priority-review
2021-10-05T11:52:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-receives-fda-approval-pazeotm-solution-ocular-allergy-itch-relief
2021-10-05T11:52:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-study-nejm-showing-jakavi-was-superior-standard-therapy-rare-blood-cancer-polycythemia-vera
2021-10-05T11:52:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-solid-sales-growth-margin-expansion-and-pipeline-progress-2014-portfolio-transformation-will-focus-company-leading-businesses
2021-10-05T11:52:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-enregistre-en-2014-une-forte-augmentation-de-ses-ventes-sa-marge-et-progres-de-son-pipeline-la-transformation-du-portefeuille-concentrera-lentreprise-sur-ses-principales-activites
2021-10-05T11:53:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-2014-solide-umsatzsteigerungen-hohere-margen-und-fortschritte-der-pipeline-mit-der-umgestaltung-des-portfolios-fokussiert-sich-das-unternehmen-auf-fuhrende-geschaftsbereiche
2021-10-05T11:53:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-bexsero-vaccine-approved-fda-prevention-meningitis-b-leading-cause-bacterial-meningitis-us
2021-10-05T11:53:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-jakavi-recommended-chmp-eu-approval-treat-adults-rare-blood-cancer-polycythemia-vera
2021-10-05T11:53:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab-moderate-severe-plaque-psoriasis-patients
2021-10-05T11:53:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyxtm-first-il-17-inhibitor-receive-eu-approval-first-line-treatment-moderate-severe-psoriasis-patients
2021-10-05T11:53:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-announces-joint-investment-company-qualcomm-leading-innovation-digital-medicines-physicians-and-patients
2021-10-05T11:53:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-robust-phase-iii-results-qva149-and-nva237-and-submits-regulatory-applications-us-fda
2021-10-05T11:53:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-biosimilar-filgrastim-recommended-approval-fda-oncologic-drugs-advisory-committee
2021-10-05T11:53:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-collaborates-intellia-therapeutics-and-caribou-biosciences-explore-making-medicines-and-drug-discovery-tools-crispr-genome-editing-technology
2021-10-05T11:53:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-sandoz-erelzitm-treat-multiple-inflammatory-diseases
2021-10-05T12:04:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-convenes-experts-discuss-new-technologies-healthcare-novartis-international-biocamp
2021-10-05T12:04:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/experten-diskutieren-am-novartis-international-biocamp-neue-technologien-im-gesundheitsbereich
2021-10-05T12:04:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-convie-plusieurs-experts-au-novartis-international-biocamp-afin-de-discuter-des-nouvelles-technologies-en-matiere-de-sante
2021-10-05T12:04:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients-secondary-progressive-ms
2021-10-05T12:04:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/six-leading-scientists-receive-prestigious-novartis-prizes-immunology-16th-international-congress-immunology
2021-10-05T12:04:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cdk46-inhibitor-lee011-ribociclib-receives-fda-breakthrough-therapy-designation-first-line-treatment-hrher2-advanced-breast-cancer
2021-10-05T12:04:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-achieves-us-approval-cypass-micro-stent-micro-invasive-surgical-device-treat-glaucoma
2021-10-05T12:04:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-solid-q2-despite-full-quarter-us-gleevec-generic-impact-significant-positive-innovation-news-strengthens-future-growth-prospects
2021-10-05T12:04:36+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-un-2eme-trimestre-solide-malgre-limpact-sur-le-trimestre-du-generique-de-gleevec-aux-us-nouvelles-positives-importantes-de-linnovation-renforcent-les-perspectives-de-croissance
2021-10-05T12:04:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-im-2-quartal-solide-ergebnisse-trotz-us-generikakonkurrenz-fur-gleevec-im-gesamten-quartal-wichtige-positive-neuigkeiten-zu-innovationen-starken-zukunftige-wachstumsperspektiven
2021-10-05T12:04:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-launches-dailies-total1-multifocal-contact-lenses-first-and-only-water-gradient-lenses-designed-people-presbyopia
2021-10-05T12:04:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-biosimilar-etanercept-recommended-fda-advisory-committee-approval-treat-multiple-inflammatory-diseases
2021-10-05T12:04:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-data-shows-sandoz-biosimilar-etanercept-candidate-has-equivalent-efficacy-originator-product
2021-10-05T12:04:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pkc412-midostaurin-pivotal-data-published-nejm-show-60-response-rate-advanced-systemic-mastocytosis-sm
2021-10-05T12:04:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/largest-global-psoriasis-survey-shows-84-people-face-discrimination-and-humiliation-because-their-skin
2021-10-05T12:04:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-adds-bispecific-antibodies-its-growing-immuno-oncology-portfolio-through-collaboration-and-licensing-agreement-xencor
2021-10-05T12:04:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/timely-use-novartis-entresto-could-prevent-or-postpone-over-28000-us-deaths-year-among-hfref-patients-according-expert-analysis-jama-cardiology
2021-10-05T12:04:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-partnership-medicines-malaria-venture-develop-next-generation-antimalarial-treatment
2021-10-05T12:04:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erweitert-partnerschaft-mit-medicines-malaria-venture-zur-entwicklung-von-malariamedikamenten-der-nachsten-generation
2021-10-05T12:04:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-etend-son-partenariat-avec-medicines-malaria-venture-pour-developper-la-prochaine-generation-de-traitement-antipaludeen
2021-10-05T12:04:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-long-term-safety-data-revolade-adults-chronic-immune-thrombocytopenia-rare-blood-disorder
2021-10-05T12:04:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-data-showing-jakavi-superior-best-available-therapy-patients-less-advanced-polycythemia-vera-pv
2021-10-05T12:04:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-data-demonstrates-sandoz-etanercept-and-rituximab-biosimilar-candidates-bioequivalent-originator-products
2021-10-05T12:04:50+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-amg-334-significantly-reduces-patients-monthly-migraine-days-phase-ii-study-chronic-migraine-prevention
2021-10-05T12:04:50+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-scientific-evidence-cosentyx-ankylosing-spondylitis-and-psoriatic-arthritis-patients-eular-2016
2021-10-05T12:04:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-mekinist-demonstrates-overall-survival-benefit-three-year-follow-patients-advanced-melanoma
2021-10-05T12:04:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pivotal-data-tafinlar-mekinist-demonstrated-63-percent-overall-response-rate-treating-rare-form-lung-cancer
2021-10-05T12:04:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-more-50-percent-eligible-ph-cml-patients-maintain-treatment-free-remission-tfr-after-stopping-tasigna
2021-10-05T12:04:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-afinitor-receives-eu-approval-treat-certain-types-advanced-gastrointestinal-gi-and-lung-neuroendocrine-tumors-net
2021-10-05T12:04:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-its-strong-foundation-long-term-sustainable-growth-third-meet-novartis-management-event
2021-10-05T12:04:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-biosimilar-rituximab-regulatory-submission-accepted-european-medicines-agency
2021-10-05T12:04:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-entresto-given-strong-class-i-recommendation-both-us-and-eu-heart-failure-guidelines-less-year-after-regulatory-approvals
2021-10-05T12:04:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-investment-fortihfy-clinical-program-entresto-and-heart-failure
2021-10-05T12:04:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-present-pivotal-data-hematologic-and-solid-tumor-cancers-2016-asco-annual-meeting
2021-10-05T12:04:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/monaleesa-2-trial-novartis-lee011-ribociclib-stopped-due-positive-efficacy-results-interim-analysis-hrher2-advanced-breast-cancer
2021-10-05T12:05:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-focuses-pharmaceuticals-division-creating-two-business-units-novartis-pharmaceuticals-and-novartis-oncology-appoints-leaders-executive-committee-novartis
2021-10-05T12:05:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-renforce-la-division-pharmaceuticals-par-la-creation-de-deux-unites-daffaires-novartis-pharmaceuticals-et-novartis-oncology-et-nomme-de-nouveaux-dirigeants-son-comite-de-direction
2021-10-05T12:05:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-fokussiert-ihre-division-pharmaceuticals-durch-schaffung-der-geschaftseinheiten-novartis-pharmaceuticals-und-novartis-oncology-und-beruft-deren-leiter-die-geschaftsleitung-von-novartis
2021-10-05T12:05:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-innovative-hypertension-program-vietnam
2021-10-05T12:05:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/major-study-published-nejm-confirms-novartis-ultibro-breezhaler-superiority-over-seretide-preventing-copd-exacerbations
2021-10-05T12:05:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-afinitor-recommended-chmp-european-union-approval-treat-select-gi-and-lung-neuroendocrine-tumors
2021-10-05T12:05:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-three-fda-breakthrough-therapy-designations-ilaris-treat-rare-types-periodic-fever-syndromes
2021-10-05T12:05:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-solid-q1-despite-gleevec-loss-exclusivity-investing-behind-new-launches-long-term-growth
2021-10-05T12:05:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal-trotz-verlust-der-exklusivrechte-gleevec-solide-ergebnisse-und-investiert-neueinfuhrungen-zugunsten-langfristigen-wachstums
2021-10-05T12:05:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-enregistre-un-premier-trimestre-solide-malgre-la-perte-dexclusivite-de-gleevec-et-investi-dans-de-nouveaux-lancements-pour-soutenir-la-croissance-long-terme
2021-10-05T12:05:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-afinitor-significantly-reduces-seizures-phase-iii-study-patients-tuberous-sclerosis-complex
2021-10-05T12:05:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-ec-approval-subcutaneous-route-administration-biosimilar-binocrits-nephrology-indication
2021-10-05T12:05:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-revolade-first-class-therapy-children-aged-1-year-and-above-chronic-itp
2021-10-05T12:05:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-analyses-show-novartis-entrestotm-reduced-cardiovascular-death-or-hospitalization-heart-failure-consistently-benefitting-patients-reduced-ejection-fraction-regardless
2021-10-05T12:05:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-publishes-updated-2015-segment-financials-reflecting-new-division-structure
2021-10-05T12:05:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-superior-stelara-delivering-long-lasting-skin-clearance-pasi-90-psoriasis-patients-52-weeks
2021-10-05T12:05:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-new-indication-novartis-drug-afinitor-progressive-nonfunctional-gi-and-lung-neuroendocrine-tumors-net
2021-10-05T12:05:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors
2021-10-05T12:05:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-0
2021-10-05T12:05:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-alle-antrage-des-verwaltungsrats
2021-10-05T12:05:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-receives-breakthrough-therapy-designation-from-fda-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml
2021-10-05T12:05:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-expands-leadership-position-treating-glaucoma-through-acquisition-transcend-medical-inc
2021-10-05T12:05:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-strengthens-its-biosimilars-portfolio-acquisition-pfizers-biosimilar-infliximab-eea
2021-10-05T12:05:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-advances-its-biosimilars-program-ema-acceptance-regulatory-submission-biosimilar-pegfilgrastim
2021-10-05T12:05:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-foundation-commemorates-world-leprosy-day-its-continued-efforts-go-last-mile-toward-elimination
2021-10-05T12:05:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-and-core-margin-expansion-cc1-2015-announces-plans-accelerate-growth-alcon-streamline-group-operations
2021-10-05T12:05:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-enregistre-en-2015-une-forte-croissance-des-ventes-et-une-hausse-de-sa-marge-core-tcc1-et-annonce-des-plans-pour-accelerer-la-croissance-dalcon-et-rationaliser-les-operations-du-groupe
2021-10-05T12:05:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-2015-eine-kraftige-steigerung-des-umsatzes-und-der-kern-gewinnmarge-kwk1-plane-zur-wachstumsbeschleunigung-bei-alcon-und-zur-straffung-der-konzernaktivitaten-bekannt-gegeben
2021-10-05T12:05:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-two-new-fda-approvals-cosentyx-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis-us
2021-10-05T12:05:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-continues-grow-immuno-oncology-pipeline-through-collaboration-and-licensing-agreement-surface-oncology
2021-10-05T12:05:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-collaborates-qualcomm-digital-innovation-breezhalertm-inhaler-device-treat-copd
2021-10-05T12:05:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-two-major-trials-showing-significant-efficacy-cosentyx-ankylosing-spondylitis-patients
2021-10-05T12:05:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/300-million-child-friendly-antimalarial-treatments-supplied-without-profit-novartis
2021-10-05T12:05:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-advances-its-biosimilars-program-european-medicines-agency-ema-acceptance-regulatory-submission-biosimilar-etanercept
2021-10-05T12:05:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-new-ctl019-phase-ii-data-demonstrating-93-complete-remission-pediatric-patients-rr-all
2021-10-05T12:05:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/phase-iii-data-shows-sandoz-proposed-biosimilar-pegfilgrastim-has-similar-safety-and-efficacy-reference-product
2021-10-05T12:05:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-improves-overall-survival-23-global-phase-iii-study-aml-patients-flt3-mutations
2021-10-05T12:05:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-ctl019-study-data-demonstrating-overall-response-adult-patients-certain-types-lymphoma
2021-10-05T12:05:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-studies-jakavi-show-disease-improvement-patients-myelofibrosis-and-polycythemia-vera
2021-10-05T12:05:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-targeted-combination-therapy-sabcs-reinforcing-commitment-breast-cancer-patients
2021-10-05T12:05:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-clinical-advances-ash-2015-underscoring-leadership-hematology-research
2021-10-05T12:05:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-entrestotm-receives-eu-approval
2021-10-05T12:05:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-two-landmark-european-approvals-cosentyx-treat-patients-ankylosing-spondylitis-and-psoriatic-arthritis
2021-10-05T12:05:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-corporation-finalizes-settlement-agreement-resolving-civil-suit-filed-us-attorneys-office-southern-district-new-york
2021-10-05T12:05:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/regulatory-submission-sandoz-proposed-biosimilar-pegfilgrastim-accepted-fda
2021-10-05T12:05:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/flame-study-shows-superiority-novartis-ultibro-breezhaler-over-seretide-reducing-copd-exacerbations
2021-10-05T12:05:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-introduces-contoura-vision-first-personalized-lasik-procedure-american-academy-ophthalmology-annual-meeting
2021-10-05T12:05:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-two-year-data-cosentyx-showing-no-progression-joint-damage-84-psoriatic-arthritis-patients
2021-10-05T12:05:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-two-year-data-novartis-cosentyx-show-sustained-response-and-no-progression-spinal-damage-shown-x-ray-80-patients-ankylosing-spondylitis
2021-10-05T12:05:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-nominating-elizabeth-doherty-and-ton-buechner-board-directors
2021-10-05T12:05:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-new-hypertension-program-ghana
2021-10-05T12:05:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-strong-core-margin-expansion-cc-and-continued-strengthen-pipeline-q3-track-full-year-guidance
2021-10-05T12:06:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-au-troisieme-trimestre-une-forte-hausse-de-sa-marge-core-tcc-et-continue-de-renforcer-son-pipeline-confirmant-ainsi-ses-previsions-pour-lexercice
2021-10-05T12:06:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-steigert-die-kerngewinnmarge-kwk-im-dritten-quartal-kraftig-starkt-erneut-die-pipeline-und-ist-auf-kurs-fur-die-jahresprognose
2021-10-05T12:06:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-first-il-17a-inhibitor-cosentyxtm-treat-ankylosing-spondylitis-and-psoriatic-arthritis
2021-10-05T12:06:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-broadens-immuno-oncology-pipeline-acquisition-admune-therapeutics-and-licensing-agreements-xoma-and-palobiofarma
2021-10-05T12:06:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment-options-against-chronic-diseases
2021-10-05T12:06:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-showing-majority-patients-are-able-maintain-clear-or-almost-clear-skin-cosentyx-across-3-years
2021-10-05T12:06:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/long-term-efficacy-gilenya-reinforced-new-no-evidence-disease-activity-neda-4-analysis-ms-patients-over-seven-years
2021-10-05T12:06:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-receives-fda-approval-pre-loaded-intraocular-lens-delivery-system-treat-patients-undergoing-cataract-surgery
2021-10-05T12:06:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-proposed-biosimilar-etanercept
2021-10-05T12:06:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-secukinumab-phase-iii-data-confirming-significant-efficacy-patients-psoriatic-arthritis
2021-10-05T12:06:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/patients-aggressive-form-melanoma-lived-more-two-years-average-when-taking-novartis-therapies-tafinlar-mekinist
2021-10-05T12:06:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-next-generation-car-t-cell-therapy-ctl119-combined-ibrutinib-shows-high-rate-responses-cll-patients
2021-10-05T12:08:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-expanded-use-zykadia-first-line-alk-positive-metastatic-non-small-cell-lung-cancer-nsclc
2021-10-05T12:08:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-new-analyses-reinforce-potential-ultibro-breezhaler-copd-patients-historically-treated-steroids
2021-10-05T12:08:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-first-line-use-zykadia-alk-positive-advanced-non-small-cell-lung-cancer-nsclc
2021-10-05T12:08:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-asco-icml-and-eha-meetings-demonstrate-meaningful-advancements-cancer-care
2021-10-05T12:08:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-initiative-tackle-hypertension-and-its-root-causes-low-income-urban-communities
2021-10-05T12:08:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-celebrates-21st-annual-community-partnership-day-over-24500-associates-volunteering-their-local-communities
2021-10-05T12:08:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-exercises-exclusive-option-agreement-conatus-treatment-nash
2021-10-05T12:08:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-rydapt-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml-and-three-types-systemic-mastocytosis-sm
2021-10-05T12:08:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-announces-eu-launch-cypass-micro-stent-micro-invasive-glaucoma-surgical-device-lower-intraocular-pressure-iop-patients-primary-open-angle-glaucoma
2021-10-05T12:08:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-across-all-divisions-cc1-growth-drivers-including-cosentyx-and-entresto-more-offset-generic-erosion-innovation-momentum-continued
2021-10-05T12:08:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ventes-en-progression-tcc1-dans-toutes-ses-divisions-les-moteurs-de-croissance-cosentyx-et-entresto-inclus-compensent-lerosion-due-aux-generiques-linnovation-toujours-en-plein-essor
2021-10-05T12:08:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-umsatzsteigerungen-allen-divisionen-kwk1-wobei-wachstumstreiber-wie-cosentyx-und-entresto-die-einbussen-durch-generika-mehr-als-wettmachen-innovationsdynamik-setzt-sich-fort
2021-10-05T12:08:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-global-collaboration-amgen-commercialize-first-class-amg-334-erenumab-program-migraine-prevention-us-and-canada
2021-10-05T12:08:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-real-world-data-aan-confirms-benefit-gilenya-four-key-measures-disease-activity-relapsing-ms
2021-10-05T12:08:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilars-rituximab-and-etanercept-recommended-approval-europe
2021-10-05T12:08:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/nih-study-nejm-shows-novartis-drug-eltrombopag-first-line-therapy-standard-treatment-improves-responses-severe-aplastic-anemia
2021-10-05T12:08:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-development-programs-nash-through-clinical-collaboration-allergan
2021-10-05T12:08:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation-treatment-adult-patients-rr-dlbcl
2021-10-05T12:08:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-strengthen-rd-pipeline-licensing-ecf843-ophthalmic-indications
2021-10-05T12:08:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-combination-tafinlar-mekinist-receives-eu-approval-braf-v600-positive-advanced-non-small-cell-lung-cancer-nsclc
2021-10-05T12:08:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-first-car-t-cell-therapy-bla-pediatric-and-young-adult-patients-rr-b-cell-all-granted-fda-priority-review
2021-10-05T12:08:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-receives-us-fda-approval-new-acrysof-iq-restor-25-multifocal-toric-iol-activefocustm-design-uncompromised-distance-vision-and-presbyopia-correction
2021-10-05T12:08:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-rlx030-serelaxin-patients-acute-heart-failure
2021-10-05T12:08:24+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-first-and-only-il-17a-inhibitor-potentially-modify-course-psoriasis
2021-10-05T12:08:24+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-analysis-shows-novartis-entresto-improves-glycemic-control-reduced-ejection-fraction-heart-failure-patients-diabetes
2021-10-05T12:08:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-ribociclib-lee011-receives-fda-approval-first-line-treatment-hrher2-metastatic-breast-cancer-combination-any-aromatase-inhibitor
2021-10-05T12:08:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-winners-inaugural-healthcare-access-challenge-sandoz-hack
2021-10-05T12:08:27+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-almost-all-psoriasis-patients-rapidly-regain-skin-clearance-following-treatment-pause
2021-10-05T12:08:27+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-data-demonstrate-sandoz-proposed-biosimilar-adalimumab-has-equivalent-efficacy-reference-medicine
2021-10-05T12:08:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats
2021-10-05T12:08:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting
2021-10-05T12:08:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle
2021-10-05T12:08:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-tafinlar-mekinist-braf-positive-non-small-cell-lung-cancer-nsclc-patients
2021-10-05T12:08:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-zykadia-receives-fda-priority-review-first-line-use-patients-alk-metastatic-nsclc
2021-10-05T12:08:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-recu-la-certification-top-employer-suisse-2017
2021-10-05T12:08:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-als-top-arbeitgeber-schweiz-2017-ausgezeichnet
2021-10-05T12:08:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-votubia-receives-eu-approval-treat-refractory-partial-onset-seizures-patients-tsc
2021-10-05T12:08:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-progress-towards-access-and-environmental-goals-2016-corporate-responsibility-performance-report
2021-10-05T12:08:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-launches-new-trifocal-toric-intraocular-lens-patients-astigmatism-undergoing-cataract-surgery
2021-10-05T12:08:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-solid-2016-performance-growth-products1-absorbing-gleevec-us-loe-innovation-momentum-continued-announces-share-buyback
2021-10-05T12:08:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-solide-performance-en-2016-les-produits-de-croissance1-absorbant-la-perte-dexclusivite-de-gleevec-aux-usa-dynamique-continue-dinnovation-rachat-dactions-annonce
2021-10-05T12:08:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-2016-solide-ergebnisse-wobei-die-wachstumsprodukte1-den-verlust-der-exklusivrechte-fur-gleevec-den-usa-wettmachen-innovationsdynamik-halt-aktienruckkauf-angekundigt
2021-10-05T12:08:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-invests-next-generation-therapies-reduce-cardiovascular-risk-patients-underlying-lipid-disorders
2021-10-05T12:08:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-bolsters-ophthalmology-pipeline-through-acquisition-encore-vision-inc
2021-10-05T12:08:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-exclusive-option-collaboration-and-license-agreement-conatus-develop-new-oral-treatments-chronic-liver-diseases
2021-10-05T12:08:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-recommendation-ilaris-treat-rare-diseases-adults-and-children-called-periodic-fever-syndromes
2021-10-05T12:08:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-votubia-recommended-chmp-eu-approval-treat-refractory-partial-onset-seizures-patients-tsc
2021-10-05T12:08:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-dermatology-portfolio-through-acquisition-ziarco-group-limited
2021-10-05T12:08:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-launches-sms-life-20-nigeria-help-improve-access-essential-medicines
2021-10-05T12:08:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-lance-sms-life-20-au-nigeria-pour-aider-ameliorer-lacces-aux-medicaments-essentiels
2021-10-05T12:08:50+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-fuhrt-sms-life-20-nigeria-ein-um-den-zugang-zu-unentbehrlichen-arzneimitteln-zu-verbessern
2021-10-05T12:08:50+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-pegpleranib-phase-iii-clinical-trial-program-patients-neovascular-age-related-macular-degeneration-namd-or-wet-amd
2021-10-05T12:08:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-lee011-ribociclib-plus-letrozole-analyses-show-superior-pfs-across-broad-spectrum-patients-first-line-hrher2-advanced-breast-cancer-versus-letrozole
2021-10-05T12:08:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ultibro-breezhaler-improved-lung-function-and-copd-symptoms-after-direct-switch-from-previous-treatment
2021-10-05T12:08:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-lucentis-received-eu-approval-new-indication-lucentis-only-treatment-available-wide-range-cnv-conditions
2021-10-05T12:08:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-zykadia-first-line-study-results-showing-166-month-progression-free-survival-patients-alk-advanced-nsclc
2021-10-05T12:08:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-shows-treatment-free-remission-rates-are-consistently-above-50-regardless-reason-switch-tasigna-from-glivec
2021-10-05T12:09:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-burden-myeloproliferative-neoplasms-rare-blood-cancers-daily-activity-and-ability-work
2021-10-05T12:09:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-interim-data-demonstrate-sandoz-proposed-biosimilar-rituximab-has-equivalent-efficacy-reference-product
2021-10-05T12:09:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-results-from-first-global-registration-trial-ctl019-pediatric-and-young-adult-patients-rr-b-all
2021-10-05T12:09:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-seg101-crizanlizumab-formerly-selg1-significantly-reduces-frequency-sickle-cell-pain-crises-phase-ii-study
2021-10-05T12:09:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-access-communique-son-bilan-un-et-annonce-la-signature-dun-protocole-daccord-avec-le-rwanda
2021-10-05T12:09:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-access-shares-one-year-learnings-and-announces-memorandum-understanding-rwanda
2021-10-05T12:09:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-access-informiert-uber-erfahrungen-im-ersten-jahr-und-gibt-memorandum-understanding-mit-ruanda-bekannt
2021-10-05T12:09:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-acquires-selexys-pharmaceuticals-corporation-and-selg1-antibody-reduction-pain-crises-sickle-cell-disease-scd
2021-10-05T12:09:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-commends-publication-major-report-which-recommends-broad-use-dual-bronchodilators-treat-copd
2021-10-05T12:09:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/innovative-study-three-treatment-switches-confirms-sandoz-biosimilar-etanercept-has-equivalent-efficacy-originator
2021-10-05T12:09:19+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-amg-334-significantly-reduces-monthly-migraine-days-second-pivotal-phase-iii-episodic-migraine-study
2021-10-05T12:09:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-ash-and-sabcs-showcase-latest-innovations-development-patients-blood-disorders-and-breast-cancer
2021-10-05T12:09:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-analysis-novartis-entresto-data-shows-long-term-benefits-heart-failure-readmissions-and-total-cardiovascular-deaths
2021-10-05T12:09:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-granted-fda-priority-review-newly-diagnosed-flt3-mutated-aml-and-advanced-systemic-mastocytosis
2021-10-05T12:09:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-cosentyx-data-showing-long-lasting-efficacy-psoriatic-arthritis-over-3-years-including-patient-reported-pain
2021-10-05T12:09:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-improves-ranking-2016-access-medicine-index
2021-10-05T12:09:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-lee011-ribociclib-granted-fda-priority-review-first-line-treatment-hrher2-advanced-breast-cancer
2021-10-05T12:09:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-wins-two-prestigious-prix-galien-foundation-awards-gleevec-recognized-discovery-decade-best-pharmaceutical-product-cosentyx-best-biotechnology-product
2021-10-05T12:09:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-solid-third-quarter-growth-products1-offsetting-gleevec-patent-expiration-several-positive-readouts-potential-blockbusters
2021-10-05T12:09:36+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-solide-ergebnisse-wobei-die-wachstumsprodukte1-den-verlust-des-patents-fur-gleevec-wettmachen-mehrere-positive-daten-fur-potenzielle-blockbuster
2021-10-05T12:09:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-un-troisieme-trimestre-solide-les-produits-de-croissance1-ayant-compense-lexpiration-du-brevet-de-glivec-plusieurs-resultats-positifs-concernant-des-blockbusters-potentiels
2021-10-05T12:09:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-launches-cypass-micro-stent-american-academy-ophthalmology-aao-2016-annual-meeting
2021-10-05T12:09:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-alk-metastatic-nsclc-therapy-zykadia-extends-progression-free-survival-beyond-18-months-phase-ii-study
2021-10-05T12:09:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-tafinlar-dabrafenib-mekinist-trametinib-demonstrate-superior-overall-survival-benefit-advanced-melanoma-patients-three-year-follow
2021-10-05T12:09:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-breakthrough-therapy-lee011-plus-letrozole-demonstrates-superior-progression-free-survival-first-line-treatment-hrher2-advanced-breast-cancer-compared-standard-care
2021-10-05T12:09:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-over-half-psoriasis-patients-do-not-reach-achievable-treatment-goal-clear-skin-largest-global-survey
2021-10-05T12:09:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-late-breaking-data-show-cosentyx-delivers-high-and-long-lasting-skin-clearance-over-4-years-psoriasis-patients
2021-10-05T12:09:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-study-shows-amg-334-significantly-reduces-monthly-migraine-days-people-episodic-migraine
2021-10-05T12:09:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-invites-young-entrepreneurs-enter-sandoz-hack-global-competition-help-solve-healthcare-access-challenges
2021-10-05T12:10:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-three-new-fda-approvals-expanded-use-ilaris-treating-rare-periodic-fever-syndrome-conditions
2021-10-05T12:10:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-top-line-results-from-ascend-4-phase-iii-trial-zykadia-untreated-adult-alk-nsclc-patients
2021-10-05T12:10:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novel-novartis-malaria-compound-shows-potential-be-effective-against-infections-resistant-all-currently-available-antimalarial-drugs
2021-10-05T12:10:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/important-new-analysis-shows-novartis-entresto-associated-higher-relative-health-related-quality-life-scores-among-hfref-patients
2021-10-05T12:10:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-baf312-reduces-risk-disability-progression-pivotal-phase-iii-study-secondary-progressive-ms-patients
2021-10-05T12:10:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-data-presented-ectrims-show-benefit-gilenya-patient-disability-progression-10-years
2021-10-05T12:10:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-positive-data-ehmtic-showing-amg-334-significantly-reduces-monthly-migraine-days-chronic-migraine
2021-10-05T12:10:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-foundation-showcases-progress-leprosy-elimination-programs-19th-international-leprosy-congress
2021-10-05T12:10:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-point-care-nijitm-system-may-provide-earlier-diagnosis-severe-allergic-asthma-and-faster-treatment-decisions
2021-10-05T12:10:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-launches-ngenuity-3d-visualization-system-designed-further-enhance-retinal-surgeon-experience
2021-10-05T12:10:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ultibro-breezhaler-consistently-more-effective-seretide-reducing-copd-flare-ups-across-different-patient-groups
2021-10-05T12:10:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/airflusal-forspiro-showed-superiority-12-months-over-seretide-diskus1-persistence-treatment
2021-10-05T12:10:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-new-data-reinforces-superiority-cosentyx-versus-stelara-achieving-skin-clearance-psoriasis-patients
2021-10-05T12:36:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-regulatory-submission-proposed-biosimilar-adalimumab-accepted-fda
2021-10-05T12:36:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-appoints-elizabeth-barrett-oncology-head
2021-10-05T12:36:19+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ernennt-elizabeth-barrett-zur-chefin-onkologie
2021-10-05T12:36:19+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-advances-head-head-superiority-trials-cosentyx-versus-humira-and-proposed-biosimilar-adalimumab
2021-10-05T12:36:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-promacta-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa
2021-10-05T12:36:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-received-fda-breakthrough-therapy-designation-initial-endocrine-based-treatment-premenopausal-women-hrher2-advanced-breast-cancer
2021-10-05T12:36:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-tasigna-approved-fda-first-and-only-cml-therapy-treatment-free-remission-data-its-label
2021-10-05T12:36:24+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-mekinist-granted-fda-priority-review-adjuvant-treatment-stage-iii-braf-v600-mutation-positive-melanoma
2021-10-05T12:36:24+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-oncology-head-retire
2021-10-05T12:36:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-gibt-rucktritt-des-onkologie-chefs-bekannt
2021-10-05T12:36:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-crizanlizumab-shown-prolong-time-patients-first-sickle-cell-pain-crisis-subgroup-analysis-sustain-study
2021-10-05T12:36:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult-treat-cancer
2021-10-05T12:36:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-new-phase-i-data-showing-proposed-biosimilar-pegfilgrastim-matches-reference-medicine
2021-10-05T12:36:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-tender-offer-advanced-accelerator-applications-commences
2021-10-05T12:36:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/kisqali-first-and-only-cdk46-inhibitor-show-superior-efficacy-vs-oral-endocrine-therapy-1l-treatment-randomized-phase-iii-trial-premenopausal-women-hrher2-advanced-breast-cancer
2021-10-05T12:36:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-first-biologic-show-long-term-efficacy-nail-and-palmoplantar-psoriasis-which-can-impact-90-psoriasis-patients
2021-10-05T12:36:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-strive-data-published-nejm-demonstrating-significant-and-sustained-efficacy-erenumab-amg334-migraine-prevention
2021-10-05T12:36:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ultibro-breezhaler-significantly-improved-copd-patients-lung-function-after-direct-switch-from-seretide
2021-10-05T12:36:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-tasigna-nilotinib-secures-eu-approval-first-and-second-line-treatment-ph-cml-cp-children
2021-10-05T12:36:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ascp-and-acs-join-forces-fight-cancer-ethiopia-uganda-and-tanzania
2021-10-05T12:36:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-sabcs-across-broad-range-breast-cancer-patient-populations-combination-treatments-and-lines-therapy
2021-10-05T12:36:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-data-reinforces-clinical-basis-switching-sandoz-biosimilar-medicines
2021-10-05T12:36:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-canakinumab-acz885-reduced-cardiovascular-risk-25-subgroup-cantos-phase-iii-trial-participants
2021-10-05T12:36:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-its-differentiated-late-stage-pipeline-rd-update-and-investor-event
2021-10-05T12:36:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-entresto-real-world-evidence-data-shows-beneficial-impact-quality-life-people-living-heart-failure
2021-10-05T12:36:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/punjab-province-pakistan-signs-agreement-novartis-access-against-chronic-diseases
2021-10-05T12:36:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key-secondary-endpoint-measures-disease-activity-namd-leading-cause-blindness
2021-10-05T12:36:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-positive-results-from-phase-iii-trial-kisqali-ribociclib-combination-therapy-premenopausal-women-hrher2-advanced-or-metastatic-breast-cancer
2021-10-05T12:36:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-study-data-demonstrating-cosentyx-reduced-signs-and-symptoms-psoriatic-arthritis-while-inhibiting-progression-joint-structural-damage
2021-10-05T12:36:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-seeks-leadership-cosentyx-showing-no-radiographic-progression-ankylosing-spondylitis-4-years
2021-10-05T12:36:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reaches-another-regulatory-milestone-ctl019-tisagenlecleucel-submission-its-maa-ema-children-young-adults-rr-b-cell-all-and-adult-patients-rr-dlbcl
2021-10-05T12:36:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-expanded-collaboration-banner-alzheimers-institute-pioneering-prevention-program
2021-10-05T12:36:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-data-ash-patients-serious-blood-disorders-lymphoma-leukemia-and-sickle-cell-disease
2021-10-05T12:37:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-submits-application-fda-kymriahtm-tisagenlecleucel-adult-patients-rr-dlbcl-seeking-second-indication-first-ever-fda-approved-car-t-therapy
2021-10-05T12:37:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-present-first-its-kind-evidence-cosentyx-potential-maintain-mobility-patients-and-psa
2021-10-05T12:37:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-advanced-accelerator-applications-strengthen-oncology-portfolio
2021-10-05T12:37:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-paradigms-data-show-children-and-adolescents-ms-had-82-lower-relapse-rate-gilenya-vs-interferon-beta-1a
2021-10-05T12:37:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-pegfilgrastim-accepted-ema-regulatory-review
2021-10-05T12:37:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-confirms-leadership-multiple-sclerosis-ms-scientific-advancements-and-new-data-presented-ectrims
2021-10-05T12:37:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-growth-top-and-bottom-line-all-divisions-q3
2021-10-05T12:37:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-au-troisieme-trimestre-croissance-du-chiffre-daffaires-et-du-resultat-dans-toutes-les-divisions
2021-10-05T12:37:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-steigert-im-dritten-quartal-umsatz-und-gewinn-allen-divisionen
2021-10-05T12:37:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-combination-adjuvant-therapy-tafinlar-mekinist-receives-fda-breakthrough-therapy-designation-stage-iii-braf-v600-mutation-positive-melanoma-patients
2021-10-05T12:37:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-revolade-shows-long-term-disease-control-chronicpersistent-immune-thrombocytopenia-itp
2021-10-05T12:37:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-receives-ce-mark-first-its-kind-autonometm-preloaded-intraocular-lens-iol-delivery-system-clareon-iol
2021-10-05T12:37:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-introduces-new-innovations-cataract-surgery-european-society-cataract-refractive-surgeons-2017-annual-congress
2021-10-05T12:37:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-uc-berkeley-collaborate-tackle-undruggable-disease-targets
2021-10-05T12:37:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-max-foundation-transform-pioneering-cancer-access-program-people-lower-income-countries
2021-10-05T12:37:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-rydapt-midostaurin-receives-eu-approval-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml-and-three-types-advanced-systemic-mastocytosis-sm
2021-10-05T12:37:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-xolair-confirms-re-treatment-efficacy-chronic-spontaneous-urticaria-patients-after-treatment-interruption
2021-10-05T12:37:27+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-adalimumab-matches-reference-biologic-terms-efficacy-and-safety-long-term-study
2021-10-05T12:37:27+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-sets-new-benchmark-psoriasis-robust-5-year-sustained-phase-iii-efficacy-and-safety-data
2021-10-05T12:37:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-rituximab-accepted-review-fda
2021-10-05T12:37:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iii-study-demonstrates-adjuvant-tafinlar-mekinist-reduced-risk-disease-recurrence-53-patients-resected-braf-v600-mutation-positive-melanoma
2021-10-05T12:37:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-analysis-demonstrating-amg-334-erenumab-significantly-reduced-monthly-migraine-days-patients-who-failed-previous-preventive-therapies
2021-10-05T12:37:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-landmark-phase-iii-trial-shows-fingolimod-significantly-reduces-relapses-children-and-adolescents-ms
2021-10-05T12:37:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-ceo-joseph-jimenez-retire-from-novartis-2018-vasant-narasimhan-appointed-ceo-effective-february-1-2018
2021-10-05T12:37:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice
2021-10-05T12:37:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-analysis-published-lancet-showing-acz885-reduced-lung-cancer-mortality-77-cantos-study-further-studies-planned
2021-10-05T12:37:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iii-cantos-study-demonstrates-targeting-inflammation-acz885-reduces-cardiovascular-risk
2021-10-05T12:37:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-appoints-bertrand-bodson-chief-digital-officer
2021-10-05T12:37:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-ribociclib-receives-eu-approval-first-line-treatment-hrher2-locally-advanced-or-metastatic-breast-cancer-combination-any-aromatase-inhibitor
2021-10-05T12:37:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-et-medicines-malaria-venture-lancent-une-etude-clinique-en-afrique-pour-kaf156-un-candidat-medicament-novateur-contre-le-paludisme-multiresistant
2021-10-05T12:37:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-launch-patient-trial-africa-kaf156-novel-compound-against-multidrug-resistant-malaria
2021-10-05T12:37:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-und-medicines-malaria-venture-starten-afrika-eine-patientenstudie-mit-kaf156-einem-neuartigen-wirkstoff-gegen-multiresistente-malaria
2021-10-05T12:37:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-expands-partnership-world-child-cancer-help-children-access-treatment-four-developing-countries
2021-10-05T12:37:50+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-rydapt-midostaurin-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml-and-three-types-advanced-systemic-mastocytosis-sm
2021-10-05T12:37:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/die-ergebnisse-im-zweiten-quartal-bestatigen-die-jahresprognosen-starke-forschungs-und-entwicklungsresultate-untermauern-das-potenzial-einiger-hoch-innovativer-produkte
2021-10-05T12:37:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-resultats-du-t2-confirment-les-previsions-de-lexercice-2017-les-tres-bons-resultats-du-pipeline-etayent-le-potentiel-de-plusieurs-produits-hautement-novateurs
2021-10-05T12:37:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/q2-results-confirm-full-year-guidance-strong-pipeline-results-underpin-potential-several-highly-innovative-products
2021-10-05T12:37:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-confirms-5-year-data-first-and-only-fully-human-il-17a-inhibitor-cosentyx-reinforcing-sustained-efficacy-and-safety-profile-psoriasis
2021-10-05T12:37:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-unanimously-10-0-recommended-approval-fda-advisory-committee-treat-pediatric-young-adult-rr-b-cell-all
2021-10-05T12:38:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-approval-eu-cosentyx-label-update-includes-long-term-superiority-data-versus-stelara-psoriasis
2021-10-05T12:38:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-first-line-use-zykadia-alk-positive-advanced-non-small-cell-lung-cancer-nsclc
2021-10-05T12:38:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-erelzi-biosimilar-etanercept-treat-multiple-inflammatory-diseases
2021-10-05T12:38:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/nejm-publishes-full-analysis-rydapt-midostaurin-phase-iii-ratify-trial-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-aml
2021-10-05T12:38:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-ribociclib-receives-positive-chmp-opinion-first-line-treatment-hrher2-locally-advanced-or-metastatic-breast-cancer-combination-any-aromatase-inhibitor
2021-10-05T12:38:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-shows-half-eligible-ph-cml-cp-patients-remain-treatment-free-remission-nearly-two-years-after-stopping-tasigna
2021-10-05T12:38:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pivotal-ctl019-6-month-follow-data-show-durable-remission-rates-children-young-adults-rr-b-cell-all
2021-10-05T12:38:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-combination-targeted-therapy-tafinlar-mekinist-receives-fda-approval-braf-v600e-mutant-metastatic-non-small-cell-lung-cancer-nsclc
2021-10-05T12:38:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iii-study-shows-acz885-canakinumab-reduces-cardiovascular-risk-people-who-survived-heart-attack
2021-10-05T12:38:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-achieves-important-regulatory-milestone-amg-334-erenumab-migraine-prevention-ema-filing-acceptance
2021-10-05T12:38:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients-majority-12-week-injection-interval
2021-10-05T12:38:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-real-world-study-shows-almost-half-chronic-urticaria-patients-are-not-receiving-any-treatment-despite-significant-disease-burden
2021-10-05T12:38:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-rixathon-biosimilar-rituximab-treat-blood-cancers-and-immunological-diseases
2021-10-05T12:38:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-international-ag-new-patient-survey-highlights-need-more-action-help-severe-asthma-patients-gain-control-their-disease
2021-10-05T12:38:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-generic-version-advair-diskus
2021-10-05T12:38:19+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-sustained-improvements-signs-and-symptoms-both-and-psa-80-patients-3-years
2021-10-05T12:38:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-data-demonstrating-efficacy-amg-334-erenumab-migraine-prevention-american-headache-society-annual-meeting
2021-10-05T12:38:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-interim-results-from-global-pivotal-ctl019-trial-show-durable-complete-responses-adults-rr-dlbcl
2021-10-05T12:38:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-tasigna-receives-eu-approval-inclusion-treatment-free-remission-tfr-data-product-label
2021-10-05T12:38:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-clinical-collaboration-bristol-myers-squibb-evaluate-potential-treatments-metastatic-colorectal-cancer
2021-10-05T12:38:27+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-ground-breaking-collaboration-ibm-watson-health-outcomes-based-care-advanced-breast-cancer
2021-10-05T12:38:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-landmark-study-tafinlar-mekinist-demonstrates-durable-survival-benefit-five-years-patients-braf-mutation-positive-metastatic-melanoma
2021-10-05T12:38:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-updated-data-reinforce-efficacy-and-safety-kisqali-ribociclib-plus-letrozole-first-line-option-hrher2-advanced-or-metastatic-breast-cancer
2021-10-05T12:38:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/progress-reported-global-fight-against-diarrheal-disease-cryptosporidiosis
2021-10-05T12:38:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilars-adalimumab-and-infliximab-accepted-regulatory-review-european-medicines-agency
2021-10-05T12:38:36+02:00
daily
0.5
https://www.novartis.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-focus-innovation-and-productivity-expects-next-growth-phase-begin-2018
2021-10-05T12:38:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ernennt-dr-klaus-moosmayer-zum-chief-ethics-risk-and-compliance-officer
2021-10-05T12:39:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-marks-new-era-migraine-patients-eu-approval-aimovig-first-its-kind-treatment-specifically-designed-migraine-prevention
2021-10-05T12:39:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-biosimilar-hyrimoz-adalimumab
2021-10-05T12:39:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-combination-tafinlar-mekinist-receives-positive-chmp-opinion-adjuvant-treatment-braf-v600-mutation-positive-melanoma
2021-10-05T12:39:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-renews-drug-donation-egaten-triclabendazole-until-2022-reaffirming-its-commitment-fight-against-liver-fluke
2021-10-05T12:39:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-demonstrates-commitment-lead-immuno-dermatology-licensing-il-17c-compound-atopic-dermatitis
2021-10-05T12:39:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-now-first-and-only-cdk46-inhibitor-indicated-us-first-line-therapy-specifically-premenopausal-women-and-initial-therapy-fulvestrant-postmenopausal-women
2021-10-05T12:39:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-solid-growth-second-quarter-and-continues-transformation-focused-medicines-company
2021-10-05T12:39:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-une-solide-croissance-au-deuxieme-trimestre-et-poursuit-sa-transformation-en-une-entreprise-axee-sur-les-medicaments
2021-10-05T12:39:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-ein-solides-wachstum-und-setzt-die-transformation-zu-einem-fokussierten-arzneimittelunternehmen-fort
2021-10-05T12:39:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kymriah-treating-two-aggressive-blood-cancers-marking-important-medical-advance-patients-europe
2021-10-05T12:39:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erhalt-positive-chmp-stellungnahme-fur-kymriah-zur-behandlung-zweier-aggressiver-blutkrebsarten-ein-wichtiger-medizinischer-fortschritt-fur-patientinnen-und-patienten-europa
2021-10-05T12:39:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-intention-seek-shareholder-approval-100-spinoff-alcon-eye-care-devices-business-initiates-share-buyback-usd-5-bn
2021-10-05T12:39:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-gibt-absicht-bekannt-die-genehmigung-der-aktionare-fur-einen-100igen-spin-des-geschafts-mit-ophthalmologischen-produkten-von-alcon-einzuholen-und-leitet-gleichzeitig-einen-aktienruck
2021-10-05T12:39:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-annonce-son-intention-de-solliciter-lapprobation-des-actionnaires-pour-la-scission-100-dalcon-sa-division-de-produits-ophtalmologiques-et-initie-un-rachat-dactions-hauteur-dusd
2021-10-05T12:39:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-demonstrating-long-term-efficacy-safety-and-tolerability-aimovig-erenumab-patients-chronic-and-episodic-migraine
2021-10-05T12:39:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-international-ag-global-study-novartis-and-european-migraine-and-headache-alliance-reveals-60-employed-people-severe-migraine-miss-average-week-work-month
2021-10-05T12:39:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-clear-about-psoriasis-survey-data-highlights-challenges-psoriasis-patients-face-achieve-goal-clear-skin
2021-10-05T12:39:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-international-ag-alcon-acrysof-iq-panoptix-trifocal-intraocular-lens-shows-superior-visual-performance-head-head-trial-post-cataract-surgery
2021-10-05T12:39:50+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-juliet-trial-kymriah-demonstrates-more-one-year-durability-responses-adults-relapsed-or-refractory-dlbcl
2021-10-05T12:39:50+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-impact-immune-thrombocytopenia-or-itp-rare-blood-disease-patients-quality-life
2021-10-05T12:39:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-study-real-world-data-concludes-jakavi-associated-reduction-risk-death-and-dangerous-blood-clots-patients-rare-blood-cancer
2021-10-05T12:39:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-presents-new-long-term-and-switching-data-biosimilars-zessly-infliximab-and-erelzi-etanercept-rheumatoid-arthritis
2021-10-05T12:39:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-data-advance-understanding-role-il-17a-and-reinforce-cosentyx-leadership-spondyloarthritis
2021-10-05T12:39:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-jco-publication-lutathera-netter-1-data-showing-significantly-longer-time-deterioration-key-quality-life-measures-patients-progressive-midgut-nets
2021-10-05T12:39:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-schullabor-empfangt-hunderttausendsten-besucher
2021-10-05T12:39:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/third-novartis-phase-iii-trial-shows-kisqali-combination-therapy-significantly-improves-pfs-hrher2-advanced-breast-cancer
2021-10-05T12:39:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-data-presented-asco-find-nearly-half-cml-patients-treated-tasigna-remain-remission-almost-three-years-after-stopping-therapy
2021-10-05T12:39:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-completes-sale-stake-consumer-healthcare-joint-venture-gsk-usd130-billion
2021-10-05T12:40:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-adalimumab
2021-10-05T12:40:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovig-erenumab-prevention-migraine
2021-10-05T12:40:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-expedites-review-novartis-drug-promacta-first-line-severe-aplastic-anemia-saa
2021-10-05T12:40:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-international-ag-patient-reported-outcomes-tool-revealed-significant-improvement-symptom-frequency-and-quality-life-domains-entresto
2021-10-05T12:40:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-zessly-infliximab-gastroenterological-rheumatological-and-dermatological-diseases
2021-10-05T12:40:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-prevention
2021-10-05T12:40:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-reinforce-companys-commitment-reimagining-cancer
2021-10-05T12:40:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitung
2021-10-05T12:40:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-strategy-focus-company-and-drive-sustainable-growth
2021-10-05T12:40:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-changes-executive-committee
2021-10-05T12:40:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avexis-inc
2021-10-05T12:40:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-arrow-trial-assess-mechanistic-superiority-direct-il-17a-inhibition-cosentyx-over-il-23-inhibition-tremfya
2021-10-05T12:40:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-all-outstanding-shares-avexis-inc
2021-10-05T12:40:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-gilenya-first-disease-modifying-therapy-pediatric-relapsing-multiple-sclerosis
2021-10-05T12:40:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-cares-project-100-commits-reducing-cataract-blindness-globally
2021-10-05T12:40:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-complete-response-letter-from-us-fda-proposed-biosimilar-rituximab
2021-10-05T12:40:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma
2021-10-05T12:40:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-proposed-acquisition-avexis
2021-10-05T12:40:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-tafinlar-mekinist-adjuvant-treatment-braf-v600-mutant-melanoma
2021-10-05T12:40:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-phase-iii-data-brolucizumab-demonstrate-reliability-12-week-treatment-interval
2021-10-05T12:40:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-launches-focalview-app-providing-opportunity-patients-participate-ophthalmology-clinical-trials-from-home
2021-10-05T12:40:24+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-analyses-aan-show-siponimods-efficacy-disability-and-cognition-secondary-progressive-ms-patients
2021-10-05T12:40:24+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-appoints-john-tsai-head-global-drug-development-and-chief-medical-officer
2021-10-05T12:40:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-strong-first-quarter-and-acted-become-more-focused-medicines-company
2021-10-05T12:40:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-une-bonne-performance-au-premier-trimestre-et-agi-pour-devenir-une-entreprise-plus-centree-sur-les-medicaments
2021-10-05T12:40:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-verzeichnet-ein-starkes-erstes-quartal-und-ergreift-schritte-um-ein-starker-fokussiertes-arzneimittelunternehmen-zu-werden
2021-10-05T12:40:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-signs-agreement-pear-therapeutics-develop-and-commercialize-prescription-digital-therapeutics-patients-substance-use-disorder-and-opioid-use-disorders
2021-10-05T12:40:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-first-its-kind-evidence-aan-reinforcing-robust-and-consistent-efficacy-aimovigtm-erenumab-migraine-patients-multiple-treatment-failures
2021-10-05T12:40:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-renews-commitment-malaria-elimination-investing-usd-100-million-research-and-develop-next-generation-antimalarials
2021-10-05T12:40:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-bekraftigt-engagement-zur-eliminierung-von-malaria-und-investiert-usd-100-millionen-die-erforschung-und-entwicklung-der-nachsten-generation-von-malariamedikamenten
2021-10-05T12:40:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-afin-deliminer-le-paludisme-en-investissant-100-millions-de-dollars-dans-la-recherche-et-le-developpement-dantipaludiques-de-nouvelle-generation
2021-10-05T12:40:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-tender-offer-avexis-commences
2021-10-05T12:40:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-analysis-demonstrating-entresto-helped-preserve-kidney-function-patients-chronic-heart-failure-especially-those-diabetes
2021-10-05T12:40:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-avexis-inc-usd-87-bn-transform-care-sma-and-expand-position-gene-therapy-and-neuroscience-leader
2021-10-05T12:40:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-schliesst-vereinbarung-zum-erwerb-von-avexis-inc-fur-usd-87-mrd-ab-um-therapie-der-sma-zu-transformieren-und-position-als-fuhrendes-gentherapie-und-neuroscience-unternehmen-auszubauen
2021-10-05T12:40:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-outlines-plans-next-healthcare-access-challenge-hack-support-local-digital-innovation
2021-10-05T12:40:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-jama-cardiology-publication-data-showing-entresto-improves-physical-and-social-activity-hfref-patients-versus-enalapril
2021-10-05T12:40:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-present-predictability-data-brolucizumab-namd-from-pivotal-hawk-and-harrier-trials-arvo
2021-10-05T12:40:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-sell-stake-consumer-healthcare-joint-venture-gsk-usd130-billion-focus-strategic-priorities
2021-10-05T12:40:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-verkauft-beteiligung-consumer-healthcare-joint-venture-fur-usd-13-milliarden-gsk-um-sich-auf-strategische-prioritaten-zu-konzentrieren
2021-10-05T12:40:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-infliximab
2021-10-05T12:40:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improves-outcomes-patients-secondary-progressive-ms
2021-10-05T12:40:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-drug-tasigna-approved-fda-treat-children-rare-form-leukemia
2021-10-05T12:40:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-teams-harvard-develop-next-generation-biomaterial-systems-deliver-immunotherapies
2021-10-05T12:40:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-changes-executive-committee-support-strategic-priorities
2021-10-05T12:40:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitung-zur-unterstutzung-strategischer-prioritaten
2021-10-05T12:40:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-annonce-des-changements-au-sein-de-son-comite-de-direction-afin-de-soutenir-ses-priorites-strategiques
2021-10-05T12:41:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-alliance-science-37-advance-virtual-clinical-trials-program
2021-10-05T12:41:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-xolair-recommended-new-global-chronic-urticaria-guideline
2021-10-05T12:41:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-0
2021-10-05T12:41:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale
2021-10-05T12:41:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-0
2021-10-05T12:41:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-pear-therapeutics-develop-digital-therapeutics-patients-schizophrenia-and-multiple-sclerosis
2021-10-05T12:41:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/treatment-novartis-ultibro-breezhaler-improved-cardiac-function-copd-patients-lung-hyperinflation
2021-10-05T12:41:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-new-data-show-cosentyx-improved-quality-life-over-5-years-two-thirds-patients-moderate-severe-plaque-psoriasis
2021-10-05T12:41:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-new-cosentyx-data-confirms-robust-efficacy-and-quality-life-improvements-scalp-psoriasis
2021-10-05T12:41:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-forms-alliance-develop-medicines-treating-infectious-diarrheal-disease
2021-10-05T12:41:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopa-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosis
2021-10-05T12:41:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-cosentyx-label-update-include-moderate-severe-scalp-psoriasis
2021-10-05T12:41:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-completes-subsequent-offering-period-tender-offer-advanced-accelerator-applications-sa
2021-10-05T12:41:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-updated-analysis-from-eliana-trial-showing-longer-term-durable-remissions-kymriahtm-children-young-adults-rr-all
2021-10-05T12:41:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutathera-treatment-gastroenteropancreatic-neuroendocrine-tumors
2021-10-05T12:41:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-exclusively-licenses-first-ophthalmology-gene-therapy-all-markets-outside-us-milestone-patients-rare-inherited-vision-loss
2021-10-05T12:41:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-good-operational-performance-and-landmark-innovation-2017-entering-our-next-growth-phase
2021-10-05T12:41:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-enregistre-en-2017-une-belle-performance-operationnelle-et-des-innovations-majeures-entrant-ainsi-dans-une-nouvelle-phase-de-croissance
2021-10-05T12:41:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-2017-eine-gute-operative-performance-sowie-wegweisende-innovationen-und-ist-gut-gerustet-fur-die-nachste-wachstumsphase
2021-10-05T12:41:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-erenumab-met-all-primary-and-secondary-endpoints-unique-phase-iiib-study-episodic-migraine-patients-who-have-failed-multiple-prior-preventive-treatments
2021-10-05T12:41:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-advanced-accelerator-applications-sa-and-announces-commencement-subsequent-offering-period
2021-10-05T12:41:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-global-collaboration-biocon-next-generation-biosimilars
2021-10-05T12:41:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-granted-us-fda-priority-review-kymriahtm-tisagenlecleucel-formerly-ctl019-adults-rr-dlbcl
2021-10-05T12:41:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/europe-africa-partnership-spearheads-development-next-generation-antimalarial-drug
2023-07-03T16:44:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-drives-differentiated-portfolio-deal-commercialize-new-treatment-opioid-induced-constipation-key-european-countries
2021-10-05T12:42:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-continues-transformation-leading-medicines-company-completion-alcon-spin
2021-10-05T12:42:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-updates-migraine-collaboration-amgen
2021-10-05T12:42:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-resubmits-biosimilar-pegfilgrastim-application-us-fda
2021-10-05T12:42:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-first-class-cosentyx-approved-china-psoriasis-patients
2021-10-05T12:42:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-expands-world-leading-gene-therapy-manufacturing-capacity-purchase-advanced-biologics-therapy-manufacturing-campus-longmont-colorado
2021-10-05T12:42:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-adds-clinical-and-preclinical-anti-inflammatory-programs-portfolio-acquisition-ifm-tre
2021-10-05T12:42:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease
2021-10-05T12:42:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-plans-alcon-spin-april-9-2019
2021-10-05T12:43:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-announces-acquisition-powervision-inc
2021-10-05T12:43:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-joins-global-chagas-disease-coalition-and-also-announces-first-multinational-prospective-randomized-study-people-chronic-chagas-cardiomyopathy
2021-10-05T12:43:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-change-sandoz-leadership
2021-10-05T12:43:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/three-winners-2019-sandoz-healthcare-access-challenge-hack-are-announced-sxsw
2021-10-05T12:43:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-superior-improvements-psoriasis-patients-quality-life-versus-janssens-il-23-stelara
2021-10-05T12:43:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-confirm-rapid-response-and-high-efficacy-cosentyx-psoriasis-patients-first-time-china
2021-10-05T12:43:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-1
2021-10-05T12:43:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/die-aktionare-von-novartis-heissen-der-generalversammlung-alle-antrage-des-verwaltungsrates-gut
2021-10-05T12:43:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-0
2021-10-05T12:43:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-issues-summary-financial-information-alcon-eye-care-business-ahead-shareholder-vote-proposed-spin
2021-10-05T12:43:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pursue-transformational-therapy-reduce-risk-cardiovascular-disease-people-living-elevated-levels-inherited-lipoproteina
2021-10-05T12:43:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-egaten-treatment-fascioliasis-neglected-tropical-disease
2021-10-05T12:43:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-core-margin-expansion-built-leading-advanced-therapy-platforms-and-focused-company-2018
2021-10-05T12:43:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/en-2018-novartis-enregistre-une-forte-croissance-de-ses-ventes-avec-une-expansion-de-sa-marge-core-developpe-des-plates-formes-leaders-de-traitements-de-pointe-et-recentre-lentreprise
2021-10-05T12:43:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-2018-ein-kraftiges-umsatzwachstum-bei-gleichzeitiger-steigerung-der-kerngewinnmarge-baut-wegweisende-therapieplattformen-auf-und-fokussiert-das-unternehmen
2021-10-05T12:43:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-prevention-vaso-occlusive-crises-sickle-cell-disease
2021-10-05T12:43:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-us-launch-reset-otm-help-treat-opioid-use-disorder
2021-10-05T12:43:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-endocyte
2021-10-05T12:43:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-european-commission-ec-approval-expanded-indication-kisqali-ribociclib
2021-10-05T12:43:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-offer-acquire-cellforcure-expand-manufacturing-capacity-innovative-cell-and-gene-therapies
2021-10-05T12:43:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-ceo-oncology-business-unit
2021-10-05T12:43:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-enters-commercialization-and-supply-agreement-insulin-biosimilars-anticipating-growing-demand-diabetes-burden-rises
2021-10-05T12:43:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-announces-acquisition-tear-film-innovations-inc
2021-10-05T12:43:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-self-administration-xolair-across-all-indications
2021-10-05T12:43:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-inc-and-pear-therapeutics-obtain-fda-clearance-reset-otm-treat-opioid-use-disorder
2021-10-05T12:43:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-demonstrates-consistent-efficacy-and-tolerability-kisqali-combination-therapy-hrher2-advanced-breast-cancer-patients-difficult-treat-visceral-disease
2021-10-05T12:43:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-byl719-alpelisib-plus-fulvestrant-consistently-improved-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-new-solar-1-analyses
2021-10-05T12:43:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-advances-ligelizumab-qge031-urticaria-phase-iii-basis-strong-phase-ii-head-head-data
2021-10-05T12:43:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-avxs-101-one-time-treatment-designed-address-genetic-root-cause-sma-type-1
2021-10-05T12:44:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/real-world-data-show-novartis-drug-revolade-improves-outcomes-itp-patients-compared-other-second-line-therapies
2021-10-05T12:44:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-longer-term-analyses-from-pivotal-kymriah-trials-showed-durable-responses-are-maintained-patients-advanced-blood-cancers
2021-10-05T12:44:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-crizanlizumab-seg101-data-analysis-sickle-cell-disease-and-investment-sentry-clinical-program
2021-10-05T12:44:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-eu-approval-gilenya-children-and-adolescents-ms-making-it-first-and-only-oral-disease-modifying-treatment-these-patients-europe
2021-10-05T12:44:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-eighth-european-commission-approval-biosimilar-ziextenzo-pegfilgrastim
2021-10-05T12:44:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-highlight-its-vision-strategy-and-benefits-standalone-company-investors-and-analysts-new-york-and-london
2021-10-05T12:44:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-landmark-eu-approval-one-time-gene-therapy-luxturna-restore-vision-people-rare-inherited-retinal-disease
2021-10-05T12:44:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-rises-second-place-2018-access-medicine-index
2021-10-05T12:44:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-launch-reset-treatment-patients-substance-use-disorder
2021-10-05T12:44:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-novartis-drug-promacta-first-line-saa-and-grants-breakthrough-therapy-designation-additional-new-indication
2021-10-05T12:44:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-expand-kisqali-combination-therapy-all-women-hrher2-locally-advanced-or-metastatic-breast-cancer
2021-10-05T12:44:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-files-initial-form-20-f-registration-statement-sec-proposed-spinoff-plans-investor-days-new-york-and-london
2021-10-05T12:44:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-study-supports-entresto-foundational-hfref-therapy-and-hospital-initiation-appropriate-stabilized-heart-failure-patients
2021-10-05T12:44:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-rd-update-highlights-industry-leading-development-pipeline-including-potential-blockbusters-and-advanced-therapy-platforms
2021-10-05T12:44:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-decides-not-pursue-us-biosimilar-rituximab-will-focus-robust-biosimilar-portfolio-unmet-access-and-sustainability-needs
2021-10-05T12:44:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-ash-and-sabcs-show-strength-pipeline-and-portfolio-hematology-and-oncology
2021-10-05T12:44:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoztm-adalimumab-adaz
2021-10-05T12:44:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-clinical-collaboration-pfizer-advance-treatment-nash
2021-10-05T12:44:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/two-year-data-novartis-brolucizumab-reaffirm-superiority-versus-aflibercept-reducing-retinal-fluid-patients-namd
2021-10-05T12:44:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-approval-cosentyx-label-update-europe-include-dosing-flexibility-psoriatic-arthritis
2021-10-05T12:44:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-develop-smart-suite-digital-health-platform-cataract-surgery
2021-10-05T12:44:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-lancet-publication-pioneering-study-migraine-prevention-showing-efficacy-aimovig-where-other-treatments-have-failed
2021-10-05T12:44:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-combi-ad-study-tafinlar-mekinist-continues-demonstrate-relapse-free-survival-benefit-patients-braf-v600-mutant-stage-iii-melanoma
2021-10-05T12:44:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-byl719-alpelisib-plus-fulvestrant-nearly-doubles-median-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-compared-fulvestrant-alone
2021-10-05T12:44:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-ii-geometry-mono-1-trial-investigational-medicine-capmatinib-inc280-shows-positive-results-patients-met-mutated-advanced-nsclc
2021-10-05T12:44:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-presentation-new-lutathera-netter-1-data-esmo-demonstrating-significant-improvement-pfs-regardless-baseline-liver-tumor-burden
2021-10-05T12:44:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms
2021-10-05T12:44:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-strong-growth-and-innovation-during-third-quarter-including-progressing-advanced-therapy-platforms-drive-future-growth
2021-10-05T12:44:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-enregistre-au-troisieme-trimestre-une-forte-croissance-et-fait-preuve-dune-innovation-dynamique-incluant-des-plateformes-therapeutiques-avancees-pour-soutenir-la-croissance-future
2021-10-05T12:44:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-starkes-wachstum-und-treibt-innovationen-wie-fortschrittliche-therapieplattformen-voran-um-das-zukunftige-wachstum-zu-beschleunigen
2021-10-05T12:44:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-5-year-data-psoriatic-arthritis-and-ankylosing-spondylitis-reinforces-cosentyx-leadership-spondyloarthritis
2021-10-05T12:44:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-global-resolution-biosimilar-adalimumab-patent-disputes-securing-patient-access
2021-10-05T12:44:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-data-from-first-direct-head-head-trial-demonstrate-superior-efficacy-gilenya-over-copaxone-patients-relapsing-remitting-multiple-sclerosis
2021-10-05T12:44:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/breadth-data-ectrims-underpins-novartis-relentless-commitment-decoding-science-multiple-sclerosis-ms-and-decreasing-patient-burden
2021-10-05T12:44:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-analysis-shows-crizanlizumab-seg101-increased-number-patients-free-sickle-cell-pain-crises-vs-placebo-during-sustain-study
2021-10-05T12:44:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-siponimod-first-and-only-drug-shown-meaningfully-delay-disability-progression-typical-spms-patients
2021-10-05T12:44:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-healthcare-access-challenge-hack-returns-seeking-digital-solutions-local-healthcare-access-challenges
2021-10-05T12:44:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-licenses-three-novel-anti-infective-programs-boston-pharmaceuticals
2021-10-05T12:44:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-five-grant-recipients-excellence-ophthalmology-vision-award-xova-nonprofit-sustainable-eye-health-initiatives
2021-10-05T12:45:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-file-new-lucentis-ranibizumab-indication-retinopathy-prematurity-rop-rare-disease-premature-infants-often-leads-blindness
2021-10-05T12:45:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-analysis-novartis-phase-iii-brolucizumab-rth258-data-reinforces-superior-reduction-retinal-fluid-key-marker-disease-activity-namd
2021-10-05T12:45:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-pegfilgrastim
2021-10-05T12:45:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-gilenya-treatment-children-and-adolescents-ms-marking-major-medical-advance-young-ms-patients-europe
2021-10-05T12:45:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-chmp-opinion-one-time-gene-therapy-luxturna-treat-children-and-adults-rare-inherited-retinal-disease
2021-10-05T12:45:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/worlds-largest-alzheimers-survey-reveals-most-adults-believe-cure-will-be-developed-their-lifetime
2021-10-05T12:45:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/launch-alcon-experience-academy-reinforces-commitment-training-and-education-eye-care-professionals
2021-10-05T12:45:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-real-world-evidence-confirms-efficacy-and-safety-benefits-cosentyx-daily-life-psoriasis-patients
2021-10-05T12:45:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-landmark-paradigms-study-demonstrating-significant-benefit-gilenya-children-and-adolescents-ms
2021-10-05T12:45:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-survey-shows-psoriasis-patients-want-treatment-effect-beyond-clear-skin
2021-10-05T12:45:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-confirms-commitment-switzerland-ahead-proposed-spinoff-from-novartis
2021-10-05T12:45:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-bestatigt-vor-dem-vorgeschlagenen-spin-von-novartis-das-engagement-der-schweiz
2021-10-05T12:45:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-confirme-son-engagement-envers-la-suisse-en-perspective-de-la-scission-proposee-avec-novartis
2021-10-05T12:45:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-divest-sandoz-us-dermatology-business-and-generic-us-oral-solids-portfolio-aurobindo
2021-10-05T12:45:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/european-commission-approves-novartis-combination-therapy-tafinlar-mekinist-adjuvant-treatment-braf-v600-mutation-positive-melanoma
2021-10-05T12:45:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/alcon-announces-voluntary-global-market-withdrawal-cypass-micro-stent-surgical-glaucoma
2021-10-05T12:45:24+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel
2021-10-05T12:45:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erhalt-die-zulassung-fur-seine-car-t-zell-therapie-kymriah-tisagenlecleucel-von-der-europaischen-kommission
2021-10-05T12:45:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-data-show-entresto-sacubitrilvalsartan-can-be-initiated-early-safely-hospitalized-patients-after-acute-heart-failure-episode
2021-10-05T12:45:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/solar-1-trial-novartis-investigational-alpha-specific-pi3k-inhibitor-byl719-alpelisib-meets-primary-endpoint-hrher2-advanced-breast-cancer-pik3ca-mutation
2021-10-05T12:45:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-appoints-dr-klaus-moosmayer-chief-ethics-risk-and-compliance-officer
2021-10-05T12:45:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-breadth-data-2019-ash-demonstrates-commitment-reimagining-medicine-hematology-through-innovative-therapeutic-platforms
2021-10-05T12:50:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global-cause-death
2021-10-05T12:50:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-launches-innovation-prize-assistive-tech-encourage-new-technologies-address-unmet-needs-multiple-sclerosis-community
2021-10-05T12:50:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-paragon-hf-analyses-suggest-entresto-benefit-beyond-hfref
2021-10-05T12:50:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-medicine-adakveo-crizanlizumab-approved-fda-reduce-frequency-pain-crises-individuals-living-sickle-cell-disease
2021-10-05T12:50:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-mayzent-siponimod-treatment-adult-patients-active-secondary-progressive-multiple-sclerosis-spms
2021-10-05T12:50:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-strategy-provide-innovative-medicines-more-patients-sub-saharan-africa
2021-10-05T12:50:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-presents-real-world-data-showing-effectiveness-erelzi-etanercept-szzs-rheumatic-disease-treatment
2021-10-05T12:50:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-prevent-data-show-cosentyx-delivers-early-relief-axial-spondyloarthritis
2021-10-05T12:50:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-tropifexor-ljn452-significantly-improves-several-key-biomarkers-nash-patients-moderate-severe-fibrosis
2021-10-05T12:50:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-agreement-acquire-aspens-japanese-operations-and-associated-assets-strengthening-position-worlds-third-largest-generics-market
2021-10-05T12:50:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-long-acting-oncology-supportive-care-biosimilar-ziextenzotm-pegfilgrastim-bmez
2021-10-05T12:50:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-encouraging-results-versus-humira-from-first-its-kind-head-head-trial-psoriatic-arthritis
2021-10-05T12:50:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-avxs-101-intrathecal-study-update
2021-10-05T12:50:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-approval-cosentyx-label-update-europe-include-dosing-flexibility-ankylosing-spondylitis
2021-10-05T12:50:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-another-strong-quarter-double-digit-sales-growth-and-core1-margin-expansion-2019-sales-and-profit-guidance-raised-beovu-launched-us
2021-10-05T12:50:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-verzeichnet-ein-weiteres-starkes-quartal-mit-zweistelligem-umsatz-wachstum-und-hoherer-kerngewinnmarge1-umsatz-und-gewinnerwartung-fur-2019-angehoben-us-einfuhrung-von-beovu
2021-10-05T12:50:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-encore-un-fort-trimestre-croissance-deux-chiffres-des-ventes-et-expansion-de-la-marge-core1-hausse-des-previsions-de-chiffre-daffaires-et-de-resultat-en-2019-beovu-lance-aux-usa
2021-10-05T12:50:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-jakavi-ruxolitinib-meets-primary-endpoint-phase-iii-study-acute-graft-versus-host-disease
2021-10-05T12:50:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-cosentyx-treatment-results-rapid-and-sustained-resolution-signs-and-symptoms-psoriatic-arthritis-patients-and-without-enthesitis
2021-10-05T12:50:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-real-world-evidence-confirms-high-efficacy-long-term-response-and-favorable-safety-profile-cosentyx-clinical-practice
2021-10-05T12:50:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-more-patients-are-completely-symptom-free-from-chronic-spontaneous-urticaria-ligelizumab-qge031-xolair-300-mg
2021-10-05T12:50:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept
2021-10-05T12:50:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-presents-updated-strong-data-wms
2021-10-05T12:50:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-positive-52-week-prevent-data-confirm-cosentyx-efficacy-addressing-entire-axspa-spectrum
2021-10-05T12:50:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-microsoft-announce-collaboration-transform-medicine-artificial-intelligence
2021-10-05T12:50:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-palladium-study-inhaled-combination-qmf149-patients-uncontrolled-asthma
2021-10-05T12:50:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-iridium-study-inhaled-combination-qvm149-patients-uncontrolled-asthma
2021-10-05T12:50:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-delivers-consistently-superior-overall-survival-monaleesa-3-trial-demonstrates-more-life-postmenopausal-hrher2-advanced-breast-cancer-patients
2021-10-05T12:50:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-presents-new-data-epns-continuing-show-significant-therapeutic-benefit-zolgensma-prolonging-event-free-survival-now-5-years-age-patients-spinal-muscular-atrophy-sma-type-1
2021-10-05T12:50:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/positive-results-from-novartis-five-year-verify-study-type-2-diabetes-demonstrate-long-term-clinical-benefits-early-combination-treatment-galvus-and-metformin
2021-10-05T12:50:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-positive-16-week-prevent-results-advance-potential-new-indication-patients-axial-spondyloarthritis
2021-10-05T12:50:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iii-asclepios-trials-demonstrate-robust-efficacy-ofatumumab-patients-relapsing-multiple-sclerosis
2021-10-05T12:50:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-data-show-neuronal-and-glial-filaments-biomarkers-disease-activity-have-potential-support-decision-making-management-multiple-sclerosis-ms-patient
2021-10-05T12:50:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-data-show-mayzent-can-help-preserve-mobility-longer-patients-secondary-progressive-multiple-sclerosis-spms
2021-10-05T12:50:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-ectrims-highlight-innovative-approach-reimagining-care-people-living-multiple-sclerosis-ms
2021-10-05T12:50:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-confirm-long-term-efficacy-and-safety-aimovig-majority-patients-episodic-migraine
2021-10-05T12:50:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-lung-cancer-therapy-capmatinib-inc280-granted-fda-breakthrough-therapy-designation-patients-met-mutated-advanced-non-small-cell-lung-cancer
2021-10-05T12:50:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-study-shows-migraine-support-workplace-can-improve-employee-quality-life
2021-10-05T12:50:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-global-deal-commercialize-proposed-biosimilar-natalizumab-key-multiple-sclerosis-medicine
2021-10-05T12:51:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/entresto-improved-measures-heart-structure-and-function-hfref-patients-new-novartis-study-additional-data-complement-findings
2021-10-05T12:51:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-paragon-hf-trial-suggests-entresto-benefit-hfpef-patients-narrowly-misses-primary-endpoint
2021-10-05T12:51:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ofatumumab-demonstrates-superiority-versus-aubagio-two-head-head-phase-iii-multiple-sclerosis-studies
2021-10-05T12:51:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-present-new-entresto-hfpef-and-hfref-data-esc-congress-2019
2021-10-05T12:51:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-will-appeal-district-court-new-jersey-ruling-biosimilar-erelzi-etanercept-szzs-us-patent-case
2021-10-05T12:51:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-stands-behind-zolgensma-onasemnogene-abeparvovec-xioi-treatment-children-less-2-years-age-spinal-muscular-atrophy
2021-10-05T12:51:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-significantly-prolongs-life-women-hrher2-advanced-breast-cancer-now-two-distinct-phase-iii-trials
2021-10-05T12:51:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-paragon-hf-trial-heart-failure-patients-preserved-ejection-fraction-hfpef
2021-10-05T12:51:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-lucentis-treatment-preterm-infants-retinopathy-prematurity-rop-disease-causing-visual-impairment-and-blindness
2021-10-05T12:51:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-first-patient-enrolled-clinical-study-proposed-biosimilar-denosumab-osteoporosis
2021-10-05T12:51:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-key-multiple-sclerosis-product-gilenya-approved-china
2021-10-05T12:51:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-strong-sales-double-digit-core-operating-income-growth-and-launches-zolgensma-and-piqray-second-quarter-sales-and-profit-guidance-increased
2021-10-05T12:51:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-au-2e-trimestre-fortes-ventes-croissance-deux-chiffres-du-resultat-operationnel-core-et-lancements-de-zolgensma-et-de-piqray-prevision-des-ventes-et-du-resultat-revue-la-hausse
2021-10-05T12:51:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-starke-umsatze-eine-zweistellige-steigerung-des-operativen-kernergebnisses-und-lanciert-zolgensma-und-piqray-anhebung-der-umsatz-und-gewinnerwartung
2021-10-05T12:51:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-accepts-file-and-accelerates-review-novartis-sickle-cell-disease-medicine-crizanlizumab-seg101
2021-10-05T12:51:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-amgen-and-banner-alzheimers-institute-discontinue-clinical-program-bace-inhibitor-cnp520-alzheimers-prevention
2021-10-05T12:51:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-launches-oncology-generic-gefitinib-13-eu-countries-loss-market-exclusivity-expanding-access-essential-medicine
2021-10-05T12:51:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-cognition-data-secondary-progressive-multiple-sclerosis-spms
2021-10-05T12:51:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-xiidra-bolstering-ophthalmic-portfolio
2021-10-05T12:51:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-aimovig-cuts-acute-migraine-medication-days-half-patients-who-failed-prior-preventive-therapies
2021-10-05T12:51:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-underpin-long-term-efficacy-aimovig-where-other-treatments-have-failed
2021-10-05T12:51:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-new-publication-showing-il-17a-antibody-cosentyx-improves-inflammation-and-rapidly-suppresses-il-23-plaque-psoriasis
2021-10-05T12:51:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-phase-2b-encore-lf-trial-nash-cirrhosis
2021-10-05T12:51:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-analysis-novartis-data-confirms-cosentyx-demonstrates-durable-comprehensive-treatment-across-psoriatic-disease
2021-10-05T12:51:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-sandoz-biosimilar-adalimumab-data-confirms-switching-from-reference-biologic-has-no-impact-safety-or-efficacy
2021-10-05T12:51:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-continues-innovate-cml-long-term-treatment-free-remission-results-following-tasigna-use-and-promising-combination-data-investigational-compound-asciminib-abl001
2021-10-05T12:51:31+02:00
daily
0.5
https://www.novartis.com/news/media-releases/three-quarters-people-living-axial-spondyloarthritis-struggle-find-job-imas-survey-shows
2021-10-05T12:51:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/cosentyx-provides-long-lasting-inhibition-radiographic-progression-psoriatic-arthritis-new-novartis-data-show
2021-10-05T12:51:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-first-show-efficacy-all-key-manifestations-psoriatic-arthritis
2021-10-05T12:51:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-leader-pharmaceuticals-business-unit
2021-10-05T12:51:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-stellt-neue-leiterin-der-pharmaceuticals-business-unit-vor
2021-10-05T12:51:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-positive-chmp-opinion-lysakare
2021-10-05T12:51:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-first-its-kind-histology-data-iscalimab-cfz533-suggesting-extended-survival-transplanted-organs-may-be-possible
2021-10-05T12:51:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/long-term-survival-benefit-shown-metastatic-melanoma-patients-treated-novartis-tafinlar-mekinist
2021-10-05T12:51:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shows-growing-strength-lung-cancer-innovation-new-capmatinib-investigational-data-and-novel-canakinumab-clinical-trials
2021-10-05T12:51:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/xolair-omalizumab-significantly-reduced-nasal-polyps-and-congestion-symptoms-adults-chronic-rhinosinusitis-nasal-polyps-two-phase-iii-studies
2021-10-05T12:51:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-significantly-extends-life-women-hrher2-advanced-breast-cancer-monaleesa-7-trial
2021-10-05T12:51:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iii-quartz-study-new-investigational-inhaled-combination-treatment-qmf149-meets-primary-and-key-secondary-endpoints-patients-inadequately-controlled-asthma
2021-10-05T12:51:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-novartis-piqray-first-and-only-treatment-specifically-patients-pik3ca-mutation-hrher2-advanced-breast-cancer
2021-10-05T12:51:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families
2021-10-05T12:51:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma
2021-10-05T12:51:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-company-transformation-catalyst-rich-pipeline-and-strong-progress-strategy-meet-novartis-management-investor-event
2021-10-05T12:51:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-ii-data-new-inhaled-combination-treatment-qvm149-demonstrates-significant-improvements-over-current-standard-care-inhaled-treatment
2021-10-05T12:51:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-demonstrate-novel-approaches-reimagining-medicine-cancer-and-serious-blood-disorders
2021-10-05T12:51:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-aan-show-gilenya-first-and-only-disease-modifying-therapy-proven-superiority-versus-glatiramer-acetate-relapsing-remitting-ms
2021-10-05T12:51:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-demonstrates-strategic-focus-china-first-kind-generic-approval-under-quality-consistency-evaluation-system
2021-10-05T12:51:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-acquire-xiidra-expanding-front-eye-portfolio-and-strengthening-leadership-eye-care
2021-10-05T12:51:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-aan-show-mayzents-positive-impact-cognitive-processing-speed-core-element-cognitive-function-people-living-secondary-progressive-ms
2021-10-05T12:52:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-avexis-data-aan-showed-long-term-durability-zolgensma-patients-spinal-muscular-atrophy-sma-type-1
2021-10-05T12:52:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-first-its-kind-algorithm-based-tool-help-ms-patients-and-physicians-evaluate-and-discuss-early-signs-progression-secondary-progressive-ms
2021-10-05T12:52:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-presented-robust-data-aan-demonstrating-efficacy-zolgensma-broad-spectrum-spinal-muscular-atrophy-sma-patients
2021-10-05T12:52:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlight-extensive-long-term-safety-and-efficacy-data-aimovig-across-spectrum-migraine-aan
2021-10-05T12:52:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-data-aan-reinforce-novartis-commitment-transforming-lives-people-all-ages-who-live-neurological-conditions
2021-10-05T12:52:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-enters-agreement-proposed-trastuzumab-biosimilar-currently-phase-iii-development-treat-selected-her2-positive-cancer-tumors
2021-10-05T12:52:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-starts-2019-strong-sales-and-double-digit-core1-operating-income-growth-mayzent-launch-and-alcon-spin-profit-guidance-upgraded
2021-10-05T12:52:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-entame-2019-avec-une-forte-croissance-des-ventes-et-une-hausse-deux-chiffres-du-resultat-operationnel-core1-le-lancement-de-mayzent-et-le-spin-dalcon-profit-annuel-revu-la-hausse
2021-10-05T12:52:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-startet-2019-mit-starken-umsatzen-und-einer-zweistelligen-steigerung-des-operativen-kernergebnisses1-einfuhrung-von-mayzent-sowie-abspaltung-von-alcon-gewinnprognose-angehoben
2021-10-05T12:52:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-data-reinforce-effectiveness-zolgensma-treating-spinal-muscular-atrophy-sma-type-1
2021-10-05T12:52:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-brolucizumab-rth258-patients-wet-amd
2021-10-05T12:52:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-post-hoc-analysis-shows-high-dose-enerzair-breezhaler-reduces-asthma-exacerbations-versus-medium-dose-complementing-key-pivotal-iridium-study-findings
2021-10-05T14:27:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-pivotal-study-tabrectatm-patients-metex14-metastatic-non-small-cell-lung-cancer
2021-10-05T14:27:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-collaboration-between-novartis-and-africa-medical-supplies-platform-facilitate-supply-covid-19-related-medicines
2021-10-05T14:27:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-ambitious-esg-targets-increase-access-medicines-and-achieve-full-carbon-neutrality
2021-10-05T14:27:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-new-analysis-shows-high-consistency-lowering-ldl-c-individual-response-investigational-inclisiran
2021-10-05T14:27:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-ii-study-lnp023-patients-paroxysmal-nocturnal-hemoglobinuria-pnh
2021-10-05T14:27:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-novel-stamp-inhibitor-asciminib-abl001-meets-primary-endpoint-phase-iii-chronic-myeloid-leukemia-study
2021-10-05T14:27:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma
2021-10-05T14:27:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-novartis-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis
2021-10-05T14:27:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-us-district-court-district-delaware-upholds-validity-gilenya-fingolimod-dosage-regimen-patent
2021-10-05T14:27:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-new-xolair-indication-treat-severe-chronic-rhinosinusitis-nasal-polyps
2021-10-05T14:27:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-phase-iii-asclepios-trials-demonstrating-superior-efficacy-ofatumumab-patients-relapsing-multiple-sclerosis
2021-10-05T14:27:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-kymriah-meets-primary-endpoint-interim-analysis-pivotal-study-follicular-lymphoma
2021-10-05T14:27:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-eu-approval-first-line-systemic-treatment-pediatric-psoriasis
2021-10-05T14:27:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-piqray-approval-europe-first-and-only-targeted-medicine-hrher2-advanced-breast-cancer-pik3ca-mutation
2021-10-05T14:27:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-plans-joint-investment-help-strengthen-future-antibiotics-manufacturing-europe
2021-10-05T14:27:36+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-analysis-shows-wet-amd-patients-achieved-sustained-fluid-control-faster-beovu-versus-aflibercept
2021-10-05T14:27:36+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-adakveo-receives-positive-chmp-opinion-prevention-recurrent-vaso-occlusive-crises-patients-sickle-cell-disease
2021-10-05T14:27:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-study-jakavi-chronic-graft-versus-host-disease-met-primary-and-key-secondary-endpoints
2021-10-05T14:27:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-strong-h1-performance-fy-2020-guidance-confirmed-higher-end-core-operating-income-and-lower-end-sales
2021-10-05T14:27:43+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielte-im-ersten-halbjahr-eine-starke-performance-die-jahresprognose-2020-fur-das-operative-kernergebnis-bzw-den-umsatz-wurde-am-oberen-bzw-unteren-ende-fruherer-voraussagen-bestatigt
2021-10-05T14:27:45+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-une-excellente-performance-au-s1-previsions-pour-2020-confirmees-dans-le-haut-de-la-fourchette-pour-le-resultat-operationnel-core-et-dans-le-bas-pour-le-chiffre-daffaires
2021-10-05T14:27:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-launches-first-its-kind-not-profit-portfolio-medicines-symptomatic-treatment-covid-19
2021-10-05T14:27:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iii-iridium-data-lancet-respiratory-medicine-show-benefit-enerzair-breezhaler-qvm149-first-class-inhaled-labalamaics-combination-uncontrolled-asthma
2021-10-05T14:27:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-enerzair-breezhaler-including-first-digital-companion-sensor-and-app-can-be-prescribed-alongside-treatment-uncontrolled-asthma-eu
2021-10-05T14:27:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-resolves-legacy-litigation-matters-finalizing-settlement-speaker-program-litigation-government-us-and-positioning-company-future-fully-scaling-its-next-generation-digital-engagement-technologies
2021-10-05T14:27:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-reviewing-options-after-federal-circuit-upholds-lower-court-ruling-biosimilar-erelzi-case
2021-10-05T14:27:54+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-met-inhibitor-tabrectatm-approved-japan-advanced-non-small-cell-lung-cancer-metex14
2021-10-05T14:27:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-simultaneous-approval-five-new-products-from-japanese-ministry-health-labour-and-welfare-offering-japanese-patients-broad-range-novel-treatment-options
2021-10-05T14:27:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-pediatric-psoriasis-reinforcing-established-efficacy-and-safety-profile
2021-10-05T14:27:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-new-xolair-indication-treat-severe-chronic-rhinosinusitis-nasal-polyps
2021-10-05T14:27:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-resolves-legacy-fcpa-investigations
2021-10-05T14:28:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-winners-innovation-prize-assistive-tech-rewarding-new-technologies-could-improve-mobility-and-independence-people-living-multiple-sclerosis
2021-10-05T14:28:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-research-shows-technology-talent-increasingly-drawn-pharma-industry-covid-19-solve-healthcare-challenges
2021-10-05T14:28:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-discontinues-hydroxychloroquine-clinical-trial-based-slow-enrollment-remains-committed-pandemic-research-efforts
2021-10-05T14:28:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-africa-sickle-cell-disease-program-uganda-and-tanzania
2021-10-05T14:28:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-new-indication-treat-active-non-radiographic-axial-spondyloarthritis
2021-10-05T14:28:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information
2021-10-05T14:28:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iiib-argon-study-meets-primary-endpoint-comparison-enerzair-breezhaler-qvm149-versus-free-combination-two-existing-inhaled-treatments-uncontrolled-asthma
2021-10-05T14:28:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-prevent-data-show-cosentyx-helps-patients-realize-early-and-lasting-relief-axial-spondyloarthritis
2021-10-05T14:28:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-fda-review-ofatumumab-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis
2021-10-05T14:28:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-treated-tafinlar-mekinist-following-surgery
2021-10-05T14:28:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-piqray-receives-positive-chmp-opinion-treat-hrher2-advanced-breast-cancer-pik3ca-mutation
2021-10-05T14:28:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-highlight-benefit-early-treatment-initiation-patients-secondary-progressive-multiple-sclerosis-spms
2021-10-05T14:28:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-shows-overall-survival-benefit-hrher2-advanced-breast-cancer-consistent-findings-patients-more-aggressive-disease
2021-10-05T14:28:19+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-late-breaking-ofatumumab-data-ean-demonstrating-robust-efficacy-and-safety-treatment-relapsing-forms-multiple-sclerosis-rms
2021-10-05T14:28:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-study-reveals-migraine-support-workspace-can-significantly-decrease-impact-disease-affected-employees
2021-10-05T14:28:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-receives-ec-approval-and-activates-day-one-access-program-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma
2021-10-05T14:28:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-showcase-bold-approaches-reimagine-cancer-and-blood-disorders-through-multiple-therapeutic-platforms
2021-10-05T14:28:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-met-inhibitor-tabrectatm-metastatic-non-small-cell-lung-cancer-metex14
2021-10-05T14:28:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-chmp-positive-opinion-enerzair-breezhaler-qvm149-potential-first-class-inhaled-labalamaics-combination-uncontrolled-asthma
2021-10-05T14:28:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-fourth-indication-eu-first-class-approval-axial-spondyloarthritis-spectrum
2021-10-05T14:28:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-maintains-strong-operational-performance-q1-confirms-fy-2020-guidance-time-and-advances-broad-range-efforts-support-global-response-covid-19
2021-10-05T14:28:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-setzt-im-1-quartal-die-starke-operative-performance-fort-bestatigt-derzeit-die-prognose-2020-und-fordert-verschiedenste-aktivitaten-um-globale-massnahmen-gegen-covid-19-zu-unterstutzen
2021-10-05T14:28:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-conserve-une-forte-performance-operationnelle-au-1er-trimestre-confirme-ce-stade-les-previsions-pour-2020-et-fournit-de-grands-efforts-pour-contribuer-la-reponse-mondiale-au-covid-19
2021-10-05T14:28:36+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-data-showing-jakavi-ruxolitinib-more-effective-best-available-therapy-acute-graft-versus-host-disease
2021-10-05T14:28:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kymriah-receives-fda-regenerative-medicine-advanced-therapy-designation-follicular-lymphoma
2021-10-05T14:28:40+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-mayzent-siponimod-data-show-sustained-effect-delaying-disability-five-years-patients-secondary-progressive-multiple-sclerosis-spms
2021-10-05T14:28:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-sponsor-large-clinical-trial-hydroxychloroquine-hospitalized-covid-19-patients
2021-10-05T14:28:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-acquires-amblyotech-pursuing-novel-digital-therapy-children-and-adult-patients-lazy-eye
2021-10-05T14:28:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-data-neurology-reinforcing-real-world-and-long-term-effectiveness-and-safety-aimovig-preventive-treatment-across-full-spectrum-migraine
2021-10-05T14:28:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-plan-initiate-clinical-study-jakavi-severe-covid-19-patients-and-establish-international-compassionate-use-program
2021-10-05T14:28:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-mutual-agreement-terminate-sale-sandoz-us-generic-oral-solids-dermatology-portfolio-aurobindo
2021-10-05T14:28:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-new-analysis-further-shows-durable-and-potent-ldl-c-reduction-inclisiran-investigational-first-class-sirna-cholesterol-lowering-treatment
2021-10-05T14:28:48+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-new-indication-axial-spondyloarthritis-spectrum
2021-10-05T14:28:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-receives-positive-chmp-opinion-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma
2021-10-05T14:28:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-life-sciences-companies-commit-expertise-and-assets-fight-against-covid-19-pandemic-alongside-bill-melinda-gates-foundation
2021-10-05T14:28:53+02:00
daily
0.5
https://www.novartis.com/news/media-releases/zolgensma-data-shows-rapid-significant-clinically-meaningful-benefit-sma-including-prolonged-event-free-survival-motor-milestone-achievement-and-durability-now-5-years-post-dosing
2021-10-05T14:28:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-presents-avxs-101-it-data-demonstrating-remarkable-increases-hfmse-scores-and-consistent-clinically-meaningful-response-older-patients-sma-type-2
2021-10-05T14:28:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-commits-donate-130-million-doses-hydroxychloroquine-support-global-covid-19-pandemic-response
2021-10-05T14:29:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-approval-from-japanese-ministry-health-labour-and-welfare-zolgensma-only-gene-therapy-patients-spinal-muscular-atrophy-sma
2021-10-05T14:29:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-three-pivotal-trials-showing-durable-and-potent-efficacy-inclisiran-investigational-first-class-sirna-cholesterol-lowering-therapy
2021-10-05T14:29:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic-creates-usd-20-million-global-fund-support-impacted-communities
2021-10-05T14:29:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/international-research-partnership-and-edctp-invest-eu44m-next-generation-antimalarials-combat-drug-resistant-malaria-africa
2021-10-05T14:29:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-resolves-generic-drug-antitrust-investigation-us
2021-10-05T14:29:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-2
2021-10-05T14:29:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lassemblee-generale-annuelle
2021-10-05T14:29:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-dndi-collaborate-development-new-oral-drug-treat-visceral-leishmaniasis
2021-10-05T14:29:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-ofatumumab-novel-b-cell-therapy-patients-relapsing-forms-multiple-sclerosis-rms
2021-10-05T14:29:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-beovu-next-generation-anti-vegf-treatment-wet-amd-leading-cause-blindness-worldwide
2021-10-05T14:29:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-met-inhibitor-capmatinib-inc280-first-potential-treatment-metex14-mutated-advanced-non-small-cell-lung-cancer-granted-priority-fda-review
2021-10-05T14:29:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-completes-acquisition-aspens-japanese-operations-strengthening-its-position-worlds-third-largest-market-generics-and-patent-medicines
2021-10-05T14:29:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-builds-its-axspa-leadership-us-label-update-dosing-flexibility-ankylosing-spondylitis
2021-10-05T14:29:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-margin-expansion-and-breakthrough-innovation-launching-five-nmes-2019
2021-10-05T14:29:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-2019-ein-starkes-umsatzwachstum-margen-steigerungen-und-bahnbrechende-innovationen-mit-der-markteinfuhrung-funf-neuer-wirkstoffe
2021-10-05T14:29:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-en-2019-une-forte-croissance-de-son-chiffre-daffaires-une-augmentation-de-sa-marge-et-une-percee-dans-linnovation-en-lancant-cinq-nouvelles-entites-moleculaires
2021-10-05T14:29:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-eu-approval-mayzent-siponimod-adult-patients-secondary-progressive-multiple-sclerosis-spms-active-disease
2021-10-05T14:29:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ligelizumab-qge031-more-effective-xolair-inhibiting-immunoglobulin-e-pathway-responsible-chronic-spontaneous-urticaria
2021-10-05T14:29:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-medicines-company-adding-potentially-first-class-investigational-cholesterol-lowering-therapy-inclisiran
2021-10-05T14:29:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-all-outstanding-shares-medicines-company
2021-10-05T14:29:27+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-luster-phase-iii-studies-patients-uncontrolled-gina-45-asthma
2021-10-05T14:29:29+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-beovu-brolucizumab-treatment-wet-amd
2021-10-05T14:29:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-data-show-superior-overall-survival-compared-fulvestrant-and-consistent-efficacy-across-advanced-breast-cancer-patient-subgroups-monaleesa-3
2021-10-05T14:29:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kymriah-demonstrates-consistent-efficacy-and-safety-outcomes-us-patients-when-used-real-world-setting
2021-10-05T14:29:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-global-survey-uncovers-profound-and-often-under-reported-effects-sickle-cell-disease-patients
2021-10-05T14:29:33+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iii-data-new-inhaled-dual-combination-qmf149-show-significant-improvement-across-key-asthma-outcomes-versus-monotherapy
2021-10-05T14:29:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-tender-offer-medicines-company-commences
2021-10-05T14:29:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-oral-therapy-iptacopan-lnp023-shows-benefit-monotherapy-treatment-naive-patients-rare-and-life-threatening-blood-disorder-paroxysmal-nocturnal-hemoglobinuria
2021-10-05T14:32:11+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-interim-analysis-phase-ii-data-iptacopan-rare-kidney-disease-c3-glomerulopathy-c3g
2021-10-05T14:32:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-iptacopan-met-phase-ii-study-primary-endpoint-rare-kidney-disease-iga-nephropathy-igan
2021-10-05T14:32:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-tabrecta-first-published-overall-survival-and-updated-overall-response-data-patients-metex14-metastatic-nsclc
2021-10-05T14:32:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-checkpoint-inhibitor-tislelizumab-met-primary-endpoint-overall-survival-pivotal-phase-iii-trial-esophageal-cancer-after-systemic-therapy
2021-10-05T14:32:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-clinically-relevant-improvement-median-overall-survival-data-final-analysis-pivotal-netter-1-study-targeted-radioligand-therapy-lutathera
2021-10-05T14:32:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-177lu-psma-617-significantly-improves-overall-survival-and-radiographic-progression-free-survival-men-metastatic-castration-resistant-prostate-cancer-phase-iii-vision-study
2021-10-05T14:32:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kymriah-pivotal-trial-demonstrates-strong-response-rates-and-remarkable-safety-profile-relapsed-or-refractory-follicular-lymphoma
2021-10-05T14:32:18+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-reports-longest-median-overall-survival-postmenopausal-hrher2-metastatic-breast-cancer-patients
2021-10-05T14:32:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-positive-phase-iii-results-from-junipera-study-supporting-cosentyx-potential-treatment-jia-population-eular-2021
2021-10-05T14:32:20+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis
2021-10-05T14:32:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program
2021-10-05T14:32:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-molecular-partners-announce-start-empathy-clinical-trial-ensovibep-treatment-covid-19
2021-10-05T14:32:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-unveil-new-data-asco-and-eha-from-its-robust-portfolio-including-overall-survival-prostate-and-breast-cancer
2021-10-05T14:32:23+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-plans-further-strengthen-its-antibiotics-manufacturing-setup-europe
2021-10-05T14:32:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reaches-milestone-delivery-1-billion-courses-antimalarial-treatment
2021-10-05T14:32:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/us-supreme-court-denies-sandoz-petition-review-biosimilar-erelzi-etanercept-szzs-case
2021-10-05T14:32:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-confirms-late-stage-clinical-development-plans-proposed-biosimilar-aflibercept-key-ophthalmology-medicine
2021-10-05T14:32:26+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iii-beovu-data-show-potential-fluid-resolution-more-diabetic-macular-edema-patients-fewer-injections-versus-aflibercept
2021-10-05T14:32:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-key-growth-drivers-and-launches-continue-momentum-q1-maintaining-confidence-growth-group-guidance-fy-2021-confirmed
2021-10-05T14:32:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-moteurs-cles-de-la-croissance-et-lancements-poursuivent-leur-essor-au-1er-trimestre-maintenant-la-confiance-dans-la-croissance-confirmation-des-previsions-pour-le-groupe-pour-2021
2021-10-05T14:32:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/wichtige-wachstumstreiber-und-neueinfuhrungen-von-novartis-setzen-ihre-dynamik-im-ersten-quartal-fort-und-erhalten-das-vertrauen-das-wachstum-konzernprognose-fur-2021-bestatigt
2021-10-05T14:32:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-initiate-smart-phase-3b-global-study-zolgensma-children-21-kg-building-real-world-experience
2021-10-05T14:32:34+02:00
daily
0.5
https://www.novartis.com/news/media-releases/kesimpta-ofatumumab-data-aan-showed-reduction-disability-progression-independent-relapse-activity-newly-diagnosed-patients-rms
2021-10-05T14:32:36+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-reserve-capacity-and-implement-technology-transfer-production-active-pharmaceutical-ingredient-roches-actemraroactemra
2021-10-05T14:32:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-adult-patients-relapsing-multiple-sclerosis
2021-10-05T14:32:37+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-targeted-radioligand-therapy-pipeline-license-compounds-targeting-fibroblast-activation-protein-fap
2021-10-05T14:32:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer
2021-10-05T14:32:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-appoints-karen-hale-chief-legal-officer
2021-10-05T14:32:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-zolgensma-data-demonstrate-age-appropriate-development-when-used-early-real-world-benefit-older-children-and-durability-5-years-post-treatment
2021-10-05T14:32:41+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-canakinumab-acz885-second-or-third-line-treatment-combination-chemotherapy-non-small-cell-lung-cancer
2021-10-05T14:32:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-change-executive-committee
2021-10-05T14:32:42+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-curevac-manufacture-covid-19-vaccine-candidate
2021-10-05T14:32:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-3
2021-10-05T14:32:44+02:00
daily
0.5
https://www.novartis.com/news/media-releases/die-aktionare-von-novartis-heissen-der-generalversammlung-alle-antrage-des-verwaltungsrats-gut
2021-10-05T14:32:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle-0
2021-10-05T14:32:46+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-strengthens-oncology-pipeline-successful-closing-tislelizumab-licensing
2021-10-05T14:32:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-eu-label-update-first-its-kind-maximise-data-axial-manifestations-psoriatic-arthritis
2021-10-05T14:32:47+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-bill-melinda-gates-foundation-collaborate-discover-and-develop-accessible-vivo-gene-therapy-sickle-cell-disease
2021-10-05T14:32:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda
2021-10-05T14:32:49+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-multiple-sclerosis-patients-and-nurses-prefer-kesimpta-ofatumumab-sensoready-autoinjector-pen
2021-10-05T14:32:50+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-agreement-acquire-gsks-cephalosporin-antibiotics-business-reinforcing-its-leading-global-position-antibiotics
2021-10-05T14:32:50+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-breakthrough-therapy-designations-investigational-stamp-inhibitor-asciminib-abl001-chronic-myeloid-leukemia
2021-10-05T14:32:52+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kesimpta-ofatumumab-self-administered-treatment-adult-patients-relapsing-multiple-sclerosis
2021-10-05T14:32:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-provide-manufacturing-capacity-pfizer-biontech-covid-19-vaccine
2021-10-05T14:32:55+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-renews-who-medicine-donation-pledge-aim-ending-leprosy
2021-10-05T14:32:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-and-margin-expansion-continued-progress-its-next-wave-medicines-2020
2021-10-05T14:32:56+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-hat-2020-umsatz-und-margen-gesteigert-und-die-nachste-welle-von-medikamenten-weiter-vorangetrieben
2021-10-05T14:32:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/en-2020-novartis-enregistre-une-croissance-de-son-chiffre-daffaires-et-de-sa-marge-il-continue-de-faire-progresser-sa-prochaine-vague-de-medicaments
2021-10-05T14:33:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-gsk-announce-collaboration-support-scientific-research-genetic-diversity-africa
2021-10-05T14:33:01+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ligelizumab-qge031-receives-fda-breakthrough-therapy-designation-patients-chronic-spontaneous-urticaria-csu
2021-10-05T14:33:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-oncology-pipeline-licensing-tislelizumab-from-beigene
2021-10-05T14:33:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-complete-response-letter-from-us-fda-inclisiran
2021-10-05T14:33:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-builds-commitment-addressing-need-neuropsychiatric-disorders-cadent-therapeutics-acquisition
2021-10-05T14:33:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-oral-therapy-iptacopan-lnp023-receives-fda-breakthrough-therapy-designation-pnh-and-rare-pediatric-disease-designation-c3g
2021-10-05T14:33:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-fda-advisory-committee-recommendation-use-entresto-treat-patients-hfpef
2021-10-05T14:33:09+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-positive-topline-results-from-second-phase-iii-trial-beovu-patients-diabetic-macular-edema
2021-10-05T14:33:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-ruxcovid-study-ruxolitinib-hospitalized-patients-covid-19
2021-10-05T14:33:12+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-leqvio-inclisiran-first-class-sirna-lower-cholesterol-two-doses-year
2021-10-05T14:33:14+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-data-demonstrate-superior-benefit-across-main-intrinsic-subtypes-metastatic-breast-cancer
2021-10-05T14:33:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-demonstrates-nearly-five-years-median-overall-survival-metastatic-breast-cancer
2021-10-05T14:33:15+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-bosulif-chronic-myeloid-leukemia-trial
2021-10-05T14:33:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-analyses-confirm-benefit-kymriah-clinically-meaningful-rates-complete-response-seen-patients-certain-advanced-lymphomas
2021-10-05T14:33:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-first-data-from-reach3-trial-showing-jakavi-ruxolitinib-significantly-improved-outcomes-patients-steroid-resistantdependent-chronic-gvhd
2021-10-05T14:33:19+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-confidence-growing-sales-margin-expansion-fueled-market-brands-and-rich-pipeline-annual-meet-management-investor-event
2021-10-05T14:33:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-secures-exclusive-rights-potential-acute-respiratory-distress-syndrome-cell-therapy
2021-10-05T14:33:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-data-ash-reinforce-breadth-novartis-hematology-portfolio-across-multiple-blood-cancers-and-serious-hematologic-diseases
2021-10-05T14:33:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-set-achieve-100-renewable-electricity-its-european-operations
2021-10-05T14:33:24+02:00
daily
0.5
https://www.novartis.com/news/media-releases/results-from-real-world-data-and-post-hoc-analysis-novartis-beovu-pivotal-trials-presented-aao-2020
2021-10-05T14:33:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-analyses-investigational-inclisiran-demonstrate-consistently-effective-and-sustained-ldl-c-reduction-month-17-regardless-age-and-gender
2021-10-05T14:33:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-can-covid-trial-hospitalized-patients-covid-19-pneumonia-and-cytokine-release-syndrome-crs
2021-10-05T14:33:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-early-synovitis-reduction-patients-psoriatic-arthritis-first-its-kind-study
2021-10-05T14:33:28+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iv-study-showing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-prevention
2021-10-05T14:33:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-sickle-cell-medicine-adakveo-approved-europe-prevent-recurrent-vaso-occlusive-crises
2021-10-05T14:33:30+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-kymriah-manufacturing-footprint-first-ever-approved-site-commercial-car-t-cell-therapy-manufacturing-asia
2021-10-05T14:33:32+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-latest-phase-iii-data-reinforcing-cosentyx-first-line-systemic-treatment-pediatric-psoriasis
2021-10-05T14:33:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-treating-blindness
2021-10-05T14:33:35+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-collaboration-molecular-partners-develop-two-darpin-therapies-designed-potential-use-against-covid-19
2021-10-05T14:33:36+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-solid-q3-performance-11-core-operating-income-growth-net-sales-line-prior-year-strong-pipeline-progression-upgrades-full-year-core-operating-income-guidance
2021-10-05T14:33:38+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-im-3-qu-mit-solider-performance-operatives-kernergebnis-steigt-um-11-nettoumsatz-auf-vorjahresniveau-starke-pipeline-fortschritte-jahresprognose-fur-operatives-kernergebnis-angehoben
2021-10-05T14:33:39+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-au-t3-performance-solide-croissance-de-11-du-resultat-operationnel-core-chiffre-daffaires-net-proche-de-lan-dernier-pipeline-en-fort-progres-hausse-du-resultat-operationnel-core-prevu
2021-10-05T14:33:51+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-promising-interim-phase-ii-data-potential-first-class-oral-therapy-iptacopan-lnp023-rare-renal-disease-c3-glomerulopathy-c3g
2021-10-05T14:33:59+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-european-medicines-agency-ema-has-granted-orphan-drug-designation-iptacopan-lnp023-iga-nephropathy-igan
2021-10-05T14:34:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-us-food-and-drug-administration-fda-orphan-drug-designation-branaplam-lmi070-huntingtons-disease-hd
2021-10-05T14:34:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-leqvio-inclisiran-potential-first-class-sirna-treatment-high-cholesterol
2021-10-05T14:34:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-received-european-medicines-agency-ema-prime-designation-iptacopan-lnp-c3-glomerulopathy-c3g
2021-10-05T14:34:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-phase-iii-analysis-demonstrates-novartis-beovu-showed-improvement-best-corrected-visual-acuity-wet-amd-patients-early-persistent-fluid
2021-10-05T14:34:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/zolgensma-data-including-patients-more-severe-sma-baseline-further-demonstrate-therapeutic-benefit-including-prolonged-event-free-survival-increased-motor-function-and-milestone-achievement
2021-10-05T14:34:06+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-avxs-101-intrathecal-clinical-development-program
2021-10-05T14:34:08+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-receives-highest-rating-any-cdk46-inhibitor-esmo-magnitude-clinical-benefit-scale
2021-10-05T14:34:10+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-piqray-data-show-survival-benefit-patients-hrher2-advanced-breast-cancer-pik3ca-mutation
2021-10-05T14:34:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-late-breaking-data-from-phase-iii-combi-i-trial-spartalizumab-pdr001-tafinlar-and-mekinist-advanced-melanoma
2021-10-05T14:34:13+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-tafinlar-mekinist-demonstrates-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-study-published-nejm
2021-10-05T14:34:16+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reinforces-commitment-patient-access-pricing-eur-185-billion-sustainability-linked-bond
2021-10-05T14:34:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/european-medicines-agency-ema-approves-safety-label-update-novartis-beovu
2021-10-05T14:34:17+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-positive-topline-results-from-first-phase-iii-trial-beovu-versus-aflibercept-patients-diabetic-macular-edema-dme
2021-10-05T14:34:19+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-early-treatment-mayzent-siponimod-delays-disability-progression-and-show-benefits-cognitive-performance-patients-secondary-progressive-multiple-sclerosis-spms
2021-10-05T14:34:21+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-data-actrims-ectrims-kesimpta-ofatumumab-newly-diagnosed-treatment-naive-adults-relapsing-multiple-sclerosis
2021-10-05T14:34:22+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-actrims-ectrims-highlight-strength-leading-multiple-sclerosis-ms-portfolio-life-changing-therapies-people-across-ms-spectrum
2021-10-05T14:34:24+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-community-statement-global-managed-access-program-avxs-101
2021-10-06T12:17:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-community-statement-coronavirus-disease-covid-19
2021-10-06T12:17:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-community-statement-global-managed-access-program-avxs-101-0
2021-10-06T12:17:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-statement-changes-senior-leadership-team
2021-10-06T12:17:57+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-statement-access-zolgensma-onasemnogene-abeparvovec-xioi
2021-10-06T12:17:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-reports-first-quarter-2018-financial-and-operating-results
2021-10-06T12:17:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-announces-first-patient-dosed-phase-3-trial-avxs-101-pre-symptomatic-sma-types-1-2-and-3
2021-10-06T12:17:58+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-presents-initial-data-from-pivotal-us-trial-sma-type-1-and-24-month-follow-data-from-phase-1-trial-avxs-101-sma-type-1-annual-meeting-american-academy-neurology
2021-10-06T12:18:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-present-avxs-101-data-annual-meeting-american-academy-neurology
2021-10-06T12:18:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-gene-therapy-awarded-sakigake-designation-spinal-muscular-atrophy-type-1
2021-10-06T12:18:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-enters-licensing-agreement-genethon
2021-10-06T12:18:00+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-reports-fourth-quarter-and-full-year-2017-financial-and-operating-results
2021-10-06T12:18:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-report-fourth-quarter-and-full-year-2017-financial-and-operating-results
2021-10-06T12:18:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-initiate-screening-remaining-patients-pivotal-trial-avxs-101-sma-type-1-following-review-preliminary-data-from-first-three-patients
2021-10-06T12:18:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-announces-closing-public-offering-common-stock-and-full-exercise-underwriters-option-purchase-additional-shares
2021-10-06T12:18:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-announces-pricing-public-offering-common-stock
2021-10-06T12:18:04+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-announces-proposed-public-offering-common-stock
2021-10-06T12:18:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-announces-expanded-clinical-development-program-avxs-101-spinal-muscular-atrophy
2021-10-06T12:18:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/regenxbio-and-avexis-announce-expansion-relationship-through-amended-license-agreement-development-and-commercialization-treatments-spinal-muscular-atrophy
2021-10-06T12:18:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/avexis-announces-alignment-fda-next-steps-toward-bla-submission-avxs-101-sma-type-1
2021-10-06T12:18:07+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expects-sustain-long-term-growth-robust-pipeline-25-potential-blockbusters-highlighted-rd-day
2021-10-06T17:07:25+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-present-broad-range-portfolio-data-ectrims-reinforcing-long-standing-commitment-people-living-multiple-sclerosis
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-resolves-legacy-federal-government-civil-investigation-us-regarding-generic-drugs
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-rapid-and-effective-disease-activity-control-remibrutinib-lou064-patients-chronic-spontaneous-urticaria
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-accelerates-efforts-toward-esg-targets-increase-access-medicines-improve-health-equity-and-achieve-net-zero-carbon-emissions
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-report-positive-results-phase-2b-study-novel-ganaplacidelumefantrine-combination-children-malaria
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/new-data-reinforce-efficacy-and-convenience-novartis-cosentyx-secukinumab-300-mg-autoinjector-adults-psoriasis
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-achieving-complete-control-chronic-spontaneous-urticaria-csu-improves-overall-quality-life-reported-patients
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-bring-gene-therapies-patients-severe-vision-loss
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-acquiert-arctos-medical-elargissant-ainsi-son-portefeuille-doptogenetique-afin-de-proposer-des-therapies-geniques-aux-patients-souffrant-dune-severe-perte-de-la-vision
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ubernimmt-arctos-medical-und-erweitert-damit-ihr-optogenetik-portfolio-um-patientinnen-und-patienten-mit-einem-schwerem-verlust-des-sehvermogens-gentherapien-anbieten-zu-konnen
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-collaboration-harmonia-phase-iii-head-head-trial-evaluating-kisqali-vs-ibrance-patients-hrher2-advanced-breast-cancer
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-kisqali-data-showing-longest-median-overall-survival-ever-reported-hrher2-advanced-breast-cancer
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-findings-from-real-world-study-alpelisib-demonstrating-clinical-benefit-people-pik3ca-related-overgrowth-spectrum-pros
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-reports-positive-health-related-quality-life-data-177lu-psma-617-radioligand-therapy-patients-advanced-prostate-cancer-esmo-2021
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-first-fda-filing-acceptance-anti-pd-1-antibody-tislelizumab-people-esophageal-cancer
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-strengthens-pipeline-entering-agreement-biosimilar-bevacizumab-key-oncology-medicine
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-findings-ers-reinforcing-efficacy-enerzair-breezhaler-highlighting-its-digital-companion-well-showcasing-commitment-low-carbon-footprint-asthma-solutions
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/world-first-agreement-between-novartis-and-nhs-enables-broad-and-rapid-access-first-class-cholesterol-lowering-medicine-leqvio-vinclisiran
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-leqvio-inclisiran-analyses-show-effective-and-sustained-ldl-c-reduction-two-sub-populations-patients-ascvd
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-important-overall-survival-and-quality-life-results-across-solid-tumor-portfolio-among-other-key-data-esmo
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-belinda-study-investigating-kymriah-second-line-treatment-aggressive-b-cell-non-hodgkin-lymphoma
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-secures-new-approval-china-cosentyx-secukinumab-pediatric-psoriasis
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-iii-trials-beovu-diabetic-macular-edema-including-dosing-intervals-16-weeks
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-lift-partial-clinical-trial-hold-and-plans-initiate-new-pivotal-phase-3-study-intrathecal-oav-101-older-patients-sma
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivered-strong-q2-performance-driven-momentum-key-growth-brands-fy-2021-guidance-unchanged
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-forte-performance-au-deuxieme-trimestre-soutenue-par-la-dynamique-des-marques-cles-de-croissance-previsions-pour-lexercice-2021-inchangees
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-hat-im-zweiten-quartal-dank-der-dynamik-wichtiger-wachstums-marken-eine-starke-performance-erzielt-prognose-fur-2021-unverandert
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pledges-10-year-commitment-morehouse-school-medicine-26-historically-black-colleges-universities-medical-schools-and-other-leading-organizations-co-create-effective-measurable-solutions-health-equity
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-positive-phase-iii-reach3-data-jakavi-chronic-gvhd
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-appoints-rob-kowalski-chief-people-organization-officer
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-eu-launch-ready-dilute-generic-pemetrexed-treat-most-prevalent-form-lung-cancer
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/positive-survival-data-novartis-investigational-radioligand-therapy-177lu-psma-617-published-new-england-journal-medicine
2021-12-02T12:33:04+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-hewlett-packard-enterprise-join-forces-advance-novartis-global-health-efforts
2021-12-02T18:33:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/kesimpta-ofatumumab-data-show-long-term-preservation-iggigm-levels-and-no-increased-risk-serious-infections-people-living-multiple-sclerosis
2021-12-03T22:33:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/new-zolgensma-data-demonstrate-age-appropriate-development-when-used-presymptomatically-and-rapid-clinically-meaningful-efficacy-symptomatic-children-even-those-severe-sma-baseline
2021-12-04T11:03:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-completes-acquisition-gsks-cephalosporin-business-reinforcing-leading-global-position-antibiotics
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptances-beovu-patients-diabetic-macular-edema
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/kesimpta-ofatumumab-data-ectrims-highlights-preservation-igg-levels-and-safety-experience-over-extended-exposure-35-years-people-living-relapsing-multiple-sclerosis
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/global-heart-hub-and-novartis-partner-tackle-ascvd-global-health-crisis-and-worlds-1-killer
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-signs-new-initial-agreement-biontech-support-fill-and-finish-mrna-pfizer-biontech-covid-19-vaccine
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-top-line-results-canopy-1-phase-iii-study-support-further-evaluation-canakinumab-lung-cancer
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-solid-q3-results-strong-growth-innovative-medicines-announces-strategic-review-sandoz
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-de-solides-resultats-au-3e-trimestre-avec-une-forte-croissance-dinnovative-medicines-et-annonce-un-examen-strategique-de-sandoz
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-solide-ergebnisse-mit-starkem-wachstum-bei-innovative-medicines-das-unternehmen-kundigt-eine-strategische-uberprufung-von-sandoz
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-priority-review-us-fda-and-filing-acceptance-ema-kymriah-treat-patients-relapsed-or-refractory-follicular-lymphoma
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-novartis-scemblix-asciminib-novel-mechanism-action-treatment-chronic-myeloid-leukemia
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-sell-its-roche-stake-bilateral-transaction-roche
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-verkauft-ihre-roche-beteiligung-einer-bilateralen-transaktion-roche
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/new-data-ash-spotlight-novartis-recently-approved-scemblix-next-generation-car-t-platform-and-expanding-hematology-portfolio
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-iptacopan-meets-primary-endpoints-phase-ii-study-rare-kidney-disease-c3-glomerulopathy-c3g
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/leqvio-inclisiran-reduced-ldl-c-people-who-are-overweight-or-obese
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-publication-cephalalgia-data-showcasing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-prevention
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-positive-phase-iii-results-cosentyx-children-active-enthesitis-related-arthritis-era-and-juvenile-psoriatic-arthritis-jpsa-acr-2021
2021-12-02T12:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-rd-day-spotlights-attractive-growth-profile-underpinned-strong-market-brands-20-potential-high-value-pipeline-assets-and-technology-platforms
2021-12-06T17:48:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/bilateral-transaction-between-novartis-and-roche-successfully-closed
2021-12-06T17:48:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/new-kisqali-data-shows-consistent-overall-survival-benefit-across-genomic-and-clinical-subtypes-interest-hrher2-metastatic-breast-cancer
2021-12-08T15:33:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-year-two-phase-iii-trial-beovu-diabetic-macular-edema
2021-12-09T16:48:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-highlight-efficacy-piqray-hrher2-metastatic-breast-cancer-pik3ca-driver-mutation-immediately-post-cdk46i
2021-12-10T14:03:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kymriah-demonstrates-strong-responses-high-risk-patients-relapsed-or-refractory-follicular-lymphoma-extended-study-follow
2021-12-11T18:03:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-scemblix-demonstrates-sustained-response-rate-48-week-follow-patients-chronic-myeloid-leukemia
2021-12-11T22:03:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-t-chargetm-next-generation-car-t-platform-first-human-data-ash-2021
2021-12-13T20:48:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-initiates-new-usd-15-billion-share-buyback-highlighting-confidence-growth-and-pipeline
2021-12-16T07:03:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-ligelizumab-qge031-studies-chronic-spontaneous-urticaria-csu
2021-12-20T07:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-strengthens-immunotherapy-pipeline-option-collaboration-and-license-agreement-beigene-tigit-inhibitor-ociperlimab
2021-12-20T12:18:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-submits-biologics-license-application-proposed-biosimilar-trastuzumab-us-fda
2021-12-20T22:18:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-submits-marketing-authorization-application-proposed-biosimilar-trastuzumab-ema
2021-12-22T07:18:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-acquire-gyroscope-therapeutics-adding-one-time-gene-therapy-could-transform-care-geographic-atrophy-leading-cause-blindness
2021-12-22T08:03:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-novartis-leqvio-inclisiran-first-class-sirna-lower-cholesterol-and-keep-it-low-two-doses-year
2021-12-22T22:18:04+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis
2021-12-23T00:03:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-4
2022-03-03T13:19:05+01:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle-1
2022-03-03T13:19:05+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda-0
2022-03-03T13:19:05+01:00
daily
0.5
https://www.novartis.com/news/media-releases/new-peer-reviewed-research-shows-no-increased-risk-serious-covid-19-infections-kesimpta-ofatumumab-treated-adults-multiple-sclerosis
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-targets-growth-opportunities-respiratory-and-complex-generics-through-acquisition-respiratory-device-company-coalesce
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-again-demonstrate-age-appropriate-development-when-zolgensma-used-presymptomatically-and-post-hoc-data-reveal-sma-type-1-patients-could-speak-swallow-and-maintain-airway-protection
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-carisma-therapeutics-manufacturing-her-2-targeted-car-m-cell-therapy
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/nejm-publication-novartis-kisqali-data-shows-longest-median-overall-survival-ever-reported-hrher2-advanced-breast-cancer
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-voyager-therapeutics-reach-license-option-agreement-next-generation-gene-therapy-vectors-neurological-diseases
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-5
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaire
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gut
2022-06-29T02:04:03+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-peer-reviewed-safety-and-tolerability-data-further-strengthens-kesimptas-ofatumumab-favorable-benefit-risk-profile-patients-relapsing-multiple-sclerosis
2022-06-30T00:19:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-launches-generic-lenalidomide-19-countries-across-europe-expanding-access-essential-oncology-medicine
2022-06-30T00:19:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-mid-single-digit-sales-growth-margin-expansion-and-advancement-robust-pipeline-2021
2022-06-30T00:19:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-enregistre-en-2021-une-croissance-du-chiffre-daffaires-net-un-chiffre-dans-le-milieu-de-la-fourchette-une-expansion-de-la-marge-et-une-avancee-du-robuste-pipeline
2022-06-30T00:19:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-2021-ein-umsatzwachstum-im-mittleren-einstelligen-bereich-verbessert-die-margen-und-treibt-die-solide-pipeline-voran
2022-06-30T00:19:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-molecular-partners-report-positive-topline-data-from-phase-2-study-ensovibep-mp0420-darpin-antiviral-therapeutic-covid-19
2022-06-30T00:19:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-collaboration-alnylam-explore-targeted-therapy-restore-liver-function
2022-06-30T00:19:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-us-court-appeals-federal-circuit-cafc-upholds-validity-gilenya-fingolimod-dosage-regimen-patent
2022-06-30T00:19:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-jakavi-treat-acute-and-chronic-graft-versus-host-disease
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kymriah-car-t-cell-therapy-adult-patients-relapsed-or-refractory-follicular-lymphoma-europe
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-european-commission-approval-beovu-people-living-diabetic-macular-edema
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-new-organizational-structure-accelerate-growth-strengthen-pipeline-and-increase-productivity
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-gibt-neue-organisationsstruktur-bekannt-fur-schnelleres-wachstum-eine-starkere-pipeline-und-hohere-produktivitat
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-four-year-data-efficacy-and-safety-kesimpta-ofatumumab-people-living-relapsing-multiple-sclerosis
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-zolgensma-manufacturing-capacity-approval-multi-product-north-carolina-facility
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-novartis-vijoice-alpelisib-first-and-only-treatment-select-patients-pik3ca-related-overgrowth-spectrum-pros
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-extends-collaboration-agreement-drive-cutting-edge-digital-solutions-global-fight-against-antimicrobial-resistance-amr
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-anti-pd-1-tislelizumab-accepted-ema-regulatory-review-esophageal-and-lung-cancers
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-early-clinical-data-unique-krasg12c-inhibitor-american-association-cancer-research-annual-meeting
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-launches-generic-brimonidine-tartratetimolol-maleate-eyedrop-us-patients-ocular-hypertension-expanding-leading-ophthalmic-portfolio
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-tabrecta-patients-metex14-advanced-non-small-cell-lung-cancer
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-solid-sales-and-profit-growth-strong-performance-market-brands-supports-confidence-mid-term-growth-outlook
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-solide-croissance-du-chiffre-daffaires-et-du-benefice-la-forte-performance-des-marques-existantes-soutient-la-confiance-dans-les-previsions-de-croissance-moyen-terme
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-ein-solides-umsatz-und-gewinnwachstum-die-starke-performance-auf-dem-markt-befindlicher-marken-stutzt-das-vertrauen-die-mittelfristigen-wachstumsaussichten
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-tislelizumab-plus-chemotherapy-significantly-improved-overall-survival-first-line-treatment-advanced-esophageal-cancer-phase-iii-study
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approval-first-car-t-cell-therapy-adults-relapsed-or-refractory-follicular-lymphoma
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-data-demonstrate-only-kisqali-offers-more-life-first-line-setting-postmenopausal-hrher2-advanced-breast-cancer-patients
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-jakavi-be-first-post-steroid-treatment-acute-and-chronic-graft-versus-host-disease
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-production-radioligand-therapy-medicines
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-showcase-latest-oncology-research-and-innovation-including-breast-and-prostate-cancer
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-appoints-new-board-representative-global-amr-industry-alliance
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-novartis-kymriah-car-t-cell-therapy-adult-patients-relapsed-or-refractory-follicular-lymphoma
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-new-global-act4biosimilars-initiative-improve-patient-access-and-increase-adoption-least-30-30-countries-2030
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-partnership-american-society-hematology-fight-sickle-cell-disease-sub-saharan-africa
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-cdk46i-data-asco-reinforce-novartis-kisqali-only-drug-class-consistently-proven-overall-survival-benefit-hrher2-metastatic-breast-cancer
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-data-show-piqray-effectiveness-across-key-biomarkers-patients-hrher2-metastatic-breast-cancer
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-tafinlar-dabrafenib-mekinist-trametinib-demonstrates-unprecedented-efficacy-pediatric-patients-braf-v600-low-grade-gliomas-phase-iiiii-study
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-scemblix-novel-mechanism-action-shows-superior-long-term-efficacy-and-consistent-tolerability-96-week-follow-chronic-myeloid-leukemia-trial
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-five-year-kymriah-data-show-durable-remission-and-long-term-survival-maintained-children-and-young-adults-advanced-b-cell-all
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-research-reveals-critical-actions-needed-ensure-covid-19-driven-surge-virtual-health-and-care-drives-health-access-and-equity
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-application-proposed-biosimilar-adalimumabs-high-concentration-formulation-accepted-ema
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-nature-medicine-publication-zolgensma-data-demonstrating-age-appropriate-milestones-when-treating-children-sma-presymptomatically
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-plans-petition-us-court-appeals-federal-circuit-further-review-uphold-validity-gilenya-fingolimod-dosing-regimen-patent
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-tabrecta-treatment-metex14-skipping-advanced-non-small-cell-lung-cancer
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-tafinlar-mekinist-receives-fda-approval-first-tumor-agnostic-indication-braf-v600e-solid-tumors
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-renews-commitment-neglected-tropical-disease-and-malaria-elimination-investing-usd-250-million-over-five-years-research-and-develop-new-treatments
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-scemblix-novel-treatment-adult-patients-chronic-myeloid-leukemia
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-novartis-extension-phase-data-show-nearly-80-rms-patients-treated-kesimpta-ofatumumab-had-no-evidence-disease-activity-neda-3
2022-06-30T07:19:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/cosentyx-secukinumab-receives-expanded-approvals-eu-use-childhood-arthritic-conditions
2022-06-28T21:49:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-maintains-growth-momentum-and-confirms-fy22-group-guidance
2022-12-05T17:19:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-oral-monotherapy-iptacopan-demonstrates-clinically-meaningful-superiority-over-anti-c5-treatment-phase-iii-apply-pnh-study
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-pluvicto-patients-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-unveils-new-focused-strategy-underpinned-eight-potential-multi-billion-dollar-peak-sales-brands-deep-pipeline-meet-management-event
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-plans-petition-us-supreme-court-uphold-validity-gilenya-fingolimod-dosing-regimen-patent
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-further-progress-its-biosimilar-pipeline-release-positive-results-denosumab-integrated-phase-iiii-clinical-trial
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-statement-regarding-competition-authority-investigation-assertion-patent
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-invests-early-technical-development-capabilities-next-generation-biotherapeutics
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-tislelizumab-demonstrated-efficacy-and-tolerability-first-line-advanced-liver-cancer-phase-iii-trial
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-adds-one-more-year-survival-benefit-broadest-set-patients-including-those-aggressive-hrher2-advanced-breast-cancer
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-depth-immunology-pipeline-novel-data-key-upcoming-international-congresses
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-appoints-fiona-marshall-phd-president-novartis-institutes-biomedical-research-jay-bradner-md-steps-down-from-executive-committee-novartis
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-breast-and-prostate-cancer-esmo
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-scemblix-novel-mechanism-action-approved-european-commission-adult-patients-chronic-myeloid-leukemia
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-intention-separate-sandoz-business-create-standalone-company-way-100-spin
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-canopy-study-evaluating-canakinumab-adjuvant-treatment-non-small-cell-lung-cancer
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/applications-proposed-first-kind-multiple-sclerosis-biosimilar-natalizumab-accepted-us-fda-and-ema
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-supplemental-biologics-license-application-accepted-us-fda-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation-hcf
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-continued-strong-momentum-key-growth-brands-progress-strategic-initiatives-and-confirms-fy22-group-guidance
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/new-phase-iii-data-show-novartis-tislelizumab-significantly-extended-median-overall-survival-more-6-months-first-line-advanced-esophageal-cancer-combination-chemotherapy
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-resumes-production-and-delivery-radioligand-therapy-medicines-ahead-schedule
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-further-investment-key-manufacturing-facility-austria-support-increased-global-demand-essential-antibiotics
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/new-long-term-leqvio-inclisiran-data-from-novartis-show-sustained-efficacy-and-safety-over-four-years
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-highlights-scientific-advances-kisqali-iptacopan-scemblix-and-ytb323-data-sabcs-and-ash
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-decision-move-phase-3-study-novel-ganaplacidelumefantrine-sdf-combination-adults-and-children-malaria
2022-12-05T17:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-setzt-die-wachstumsdynamik-fort-und-bestatigt-die-konzernprognose-fur-das-geschaftsjahr-2022
2023-01-18T11:07:06+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-will-das-sandoz-geschaft-durch-eine-hundertprozentige-ausgliederung-als-eigenstandiges-unternehmen-abspalten
2023-01-18T11:07:09+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-eine-anhaltend-starke-dynamik-der-wichtigsten-wachstumsmarken-sowie-fortschritte-bei-strategischen-initiativen-und-bestatigt-die-konzernprognose-fur-das-geschaftsjahr-2022
2023-01-18T11:07:11+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-maintient-sa-dynamique-de-croissance-et-confirme-les-previsions-de-lexercice-2022-pour-le-groupe
2023-01-18T11:07:14+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-continue-le-fort-elan-des-principales-marques-de-croissance-progresse-dans-ses-initiatives-strategiques-et-confirme-les-previsions-de-lexercice-2022-pour-le-groupe
2023-01-18T11:07:16+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-announces-appointment-chairman-designate-sandoz-board-directors
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-biologics-license-application-proposed-biosimilar-denosumab-accepted-us-fda
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/patients-hidradenitis-suppurativa-experienced-sustained-efficacy-and-symptom-improvement-one-year-when-treated-novartis-cosentyx
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-continues-grow-further-core-margin-expansion-and-achieves-important-innovation-milestones
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-poursuit-sa-croissance-avec-une-nouvelle-expansion-de-sa-marge-core-et-franchit-des-etapes-importantes-dans-linnovation
2023-06-02T01:34:02+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-setzt-wachstumskurs-mit-weiterer-steigerung-der-kerngewinnmarge-fort-und-erreicht-wichtige-innovations-meilensteine
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-citrate-free-high-concentration-formulation-adalimumab-biosimilar
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-agreement-acquire-leading-antifungal-agent-mycamine-from-astellas-reinforcing-hospital-offering-and-leading-anti-infectives-portfolio
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-pivotal-phase-iii-apply-pnh-data-ash-demonstrating-investigational-oral-monotherapy-iptacopan-superiority-over-anti-c5
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-pluvicto-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-hemoglobin-levels-complement-inhibitor-naive-patients-pnh
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-prolonged-pfs-benefit-pre-and-perimenopausal-patients-aggressive-hrher2-metastatic-breast-cancer-compared-chemotherapy
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pluvictotm-shows-statistically-significant-and-clinically-meaningful-radiographic-progression-free-survival-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-6
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaire-0
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gut-0
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-signs-memorandum-understanding-build-new-biologics-production-plant-slovenia-support-increasing-global-demand-biosimilar-medicines
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-tafinlar-mekinist-approved-fda-pediatric-patients-braf-v600e-low-grade-glioma-most-common-pediatric-brain-cancer
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shares-zolgensma-long-term-data-demonstrating-sustained-durability-75-years-post-dosing-100-achievement-all-assessed-milestones-children-treated-prior-sma-symptom-onset
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-phase-iii-natalee-trial-meets-primary-endpoint-interim-analysis-demonstrating-clinically-meaningful-benefit-broad-population-patients-early-breast-cancer
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-entresto-receives-positive-chmp-opinion-pediatric-heart-failure
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-approval-european-commission-hyrimoz-adalimumab-high-concentration-formulation
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-five-year-data-disability-outcomes-and-safety-kesimpta-ofatumumab-people-living-relapsing-multiple-sclerosis
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-major-innovation-milestones-raises-fy-guidance
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-une-croissance-forte-de-son-chiffre-daffaires-une-expansion-robuste-de-sa-marge-des-etapes-majeures-de-linnovation-et-rehausse-ses-previsions-pour-lexercice-2023
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-kraftige-umsatzsteigerungen-eine-robuste-margenerhohung-und-wichtige-innovationsmeilensteine-erhohung-der-jahresprognose
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-phase-iii-appoint-pnh-trial-shows-investigational-oral-monotherapy-iptacopan-improves-hemoglobin-near-normal-levels-leading-transfusion-independence-all-treatment-naive-pnh-patients
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-present-new-data-across-oncology-portfolio-including-kisqali-phase-iii-natalee-trial-early-breast-cancer-asco
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-positive-chmp-opinion-hidradenitis-suppurativa
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-exclusively-commercialize-six-products-us-reinforcing-global-leadership-position-patent-medicines
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-strengthens-pipeline-expansion-through-partnership-develop-and-manufacture-multiple-biosimilars
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-feature-new-pnh-and-cml-scientific-data-from-broad-hematology-portfolio-european-hematology-association-annual-meeting
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/new-sandoz-board-directors-appointed
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-marketing-authorization-applications-proposed-biosimilar-denosumab-accepted-ema
2023-06-01T07:49:05+02:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-european-approval-cosentyx-first-and-only-il-17a-inhibitor-hidradenitis-suppurativa
2023-12-03T09:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-plans-move-new-central-basel-headquarters-mid-2024-following-proposed-spin-standalone-company
2023-12-12T09:19:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-significantly-reduced-risk-recurrence-25-across-broad-population-patients-early-breast-cancer-clinically-meaningful-benefit-was-consistent-across-subgroups
2023-12-03T09:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-presents-compelling-investment-proposition-standalone-company-capital-markets-day
2023-12-03T09:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-unveils-results-from-global-patient-and-physician-survey-disrupting-notion-cml-solved-disease
2023-12-03T09:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-medicines-strategy-and-renal-pipeline-agreement-acquire-chinook-therapeutics-usd-32bn-upfront-usd-40-share
2023-12-03T09:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-introduces-act4biosimilars-action-plan-accelerate-patient-access-biosimilar-medicines
2023-12-03T09:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-signs-agreement-divest-front-eye-ophthalmology-assets-line-focused-strategy
2023-12-03T09:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-publishes-new-five-year-efficacy-data-kesimpta-ofatumumab-treatment-relapsing-multiple-sclerosis
2023-12-13T14:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-launch-hyrimoz-adalimumab-adaz-high-concentration-formulation-marking-sandoz-entrance-us-immunology-space
2023-12-02T22:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-will-appeal-us-court-appeals-uphold-validity-entresto-combination-patent-maintains-2023-guidance-and-mid-term-outlook
2023-12-02T22:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-builds-neuroscience-pipeline-and-xrna-platform-capabilities-acquisition-dtx-pharma
2023-12-02T18:49:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-raises-guidance-announces-usd-15-billion-share-buyback-and-board-endorses-sandoz-spin-off12
2023-12-02T17:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-realise-une-forte-croissance-de-son-chiffre-daffaires-et-de-sa-marge-releve-ses-previsions-et-annonce-un-rachat-dactions-dusd-15-milliards1-le-conseil-dadministration-approuve-le-spin-de-sandoz2
2023-12-02T18:49:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-erzielt-kraftige-umsatz-und-margensteigerungen-und-erhoht-die-prognose-aktienruckkaufprogramm-von-usd-15-milliarden-angekundigt-der-verwaltungsrat-unterstutzt-den-spin-von-sandoz12
2023-12-02T18:49:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-plans-build-biosimilar-technical-development-center-slovenia-support-future-growth-biosimilar-pipeline
2023-12-02T17:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-multiple-sclerosis-biosimilar-natalizumab
2023-12-02T17:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-remibrutinib-phase-iii-trials-met-their-primary-endpoints-and-showed-rapid-symptom-control-chronic-spontaneous-urticaria
2023-12-02T17:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-completes-acquisition-chinook-therapeutics
2023-12-02T17:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-positive-results-from-mylight-phase-lll-study-biosimilar-aflibercept
2023-12-02T14:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-issues-egm-invitation-and-shareholder-information-brochure-sandoz-publishes-listing-prospectus-ahead-proposed-spin-vote
2023-12-02T14:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-publiziert-einladung-und-aktionarsbroschure-zur-ausserordentlichen-generalversammlung-sandoz-veroffentlicht-den-kotierungsprospekt-im-vorfeld-der-abstimmung-zum-vorgeschlagenen-spin
2023-12-02T14:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-publie-linvitation-lage-et-la-brochure-dinformation-aux-actionnaires-sandoz-publie-le-prospectus-de-cotation-avant-le-vote-sur-la-proposition-de-scission
2023-12-02T14:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-fda-approval-tyruko-natalizumab-sztn-first-and-only-fda-approved-biosimilar-relapsing-forms-multiple-sclerosis
2023-12-02T14:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-completes-acquisition-leading-antifungal-agent-mycamine-from-astellas-reinforcing-leading-global-anti-infectives-portfolio
2023-12-02T14:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-long-term-leqvio-inclisiran-data-demonstrating-consistent-efficacy-and-safety-beyond-six-years
2023-12-02T07:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-publishes-supplement-listing-prospectus-including-sandoz-h1-2023-financial-statements
2023-12-02T06:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-publie-un-supplement-au-prospectus-de-cotation-comprenant-les-etats-financiers-de-sandoz-au-premier-semestre-2023
2023-12-02T07:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-veroffentlicht-nachtrag-zum-kotierungsprospekt-einschliesslich-finanzabschluss-von-sandoz-fur-das-1-halbjahr-2023
2023-12-02T07:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-appoints-patrick-horber-md-president-international-marie-france-tschudin-president-innovative-medicines-international-and-chief-commercial-officer-steps-down-from-executive-committee-novartis
2023-12-01T23:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-ernennt-dr-patrick-horber-zum-president-international-da-marie-france-tschudin-president-innovative-medicines-international-und-chief-commercial-officer-aus-der-geschaftsleitung-von-novartis-ausscheidet
2023-12-02T06:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-nomme-patrick-horber-docteur-en-medecine-au-poste-de-president-international-alors-que-marie-france-tschudin-president-innovative-medicines-international-et-chief-commercial-officer-quitte-le-comite-executif-de-novartis
2023-12-02T06:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-deal-commercialize-biosimilar-ustekinumab-further-reinforcing-growing-pipeline-and-immunology-patient-offering
2023-12-01T23:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-reduced-risk-cancer-recurrence-while-maintaining-quality-life-patients-diagnosed-early-breast-cancer
2023-12-01T23:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-proposed-100-spin-sandoz
2023-12-01T05:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-le-projet-de-scission-100-de-sandoz
2023-12-01T08:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-stimmen-dem-geplanten-100-igen-spin-von-sandoz-zu
2023-12-01T23:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-breast-and-gastric-cancer-biosimilar-trastuzumab
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-radioligand-therapy-lutathera-demonstrated-statistically-significant-and-clinically-meaningful-progression-free-survival-first-line-advanced-gastroenteropancreatic-neuroendocrine-tumors-gep-nets
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-confirms-sandoz-spin-october-4-2023
2023-12-01T10:19:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-tyruko-natalizumab-first-and-only-biosimilar-multiple-sclerosis-europe
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-completes-divestment-front-eye-ophthalmology-assets
2023-12-01T10:19:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-executes-sandoz-spin-completing-strategic-transformation-leading-focused-innovative-medicines-company
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-present-new-oncology-data-esmo-2023-demonstrating-practice-changing-innovation-advanced-prostate-and-early-breast-cancer
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-kisqali-natalee-analysis-reinforces-consistent-reduction-risk-recurrence-across-key-subgroups-patients-early-breast-cancer
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-pluvictotm-shows-clinically-meaningful-and-highly-statistically-significant-rpfs-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer-pre-taxane-setting
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-12-sales-and-21-core-operating-income-growth-from-continuing-operations-cc1-executes-sandoz-spin-achieves-important-innovation-milestones-and-raises-fy-2023-guidance
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-hausse-de-12-du-chiffre-daffaires-et-de-21-du-resultat-operationnel-core-tcc1-spin-de-sandoz-etapes-importantes-de-linnovation-hausse-des-previsions-pour-2023
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-steigert-umsatz-um-12-und-operatives-kernergebnis-um-21-fortzufuhrende-geschaftsbereiche-kwk1-sandoz-abgespalten-wichtige-innovationsmeilensteine-erreicht-und-prognose-2023-erhoht
2023-12-01T07:04:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-confirms-unconstrained-supply-pluvicto-and-continues-significantly-expand-number-treatment-centers
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-atrasentan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan
2023-12-01T10:19:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-data-show-potential-remibrutinib-oral-treatment-chronic-spontaneous-urticaria-providing-significant-symptom-improvement-early-week-2
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-showcases-significant-data-updates-from-kisqali-iptacopan-and-scemblix-sabcs-and-ash
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-upgrades-mid-term-sales-growth-guidance-showcases-its-differentiated-innovative-medicines-strategy-and-robust-pipeline-rd-day
2023-12-01T18:34:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-statistically-significant-proteinuria-reduction-patients-c3-glomerulopathy-c3g
2023-12-13T14:41:32+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-48-week-results-from-phase-iii-apply-pnh-trial-showing-sustained-efficacy-and-long-term-safety-fabhalta-iptacopan-adults-paroxysmal-nocturnal-hemoglobinuria-pnh
2023-12-13T14:41:32+01:00
daily
0.5
https://www.novartis.com/news/media-releases/latest-novartis-kisqali-natalee-analysis-reinforces-25-reduction-risk-recurrence-across-broad-population-patients-early-breast-cancer-supports-regulatory-submissions
2023-12-13T14:41:32+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-absence-transfusions-first-oral-monotherapy-adults-pnh
2023-12-13T14:41:33+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-expands-production-pluvictotm-addition-its-largest-and-most-advanced-radioligand-therapy-manufacturing-facility-indianapolis
2024-01-05T15:32:45+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-scemblix-shows-superior-major-molecular-response-mmr-rates-vs-standard-care-tkis-phase-iii-trial-newly-diagnosed-patients-chronic-myeloid-leukemia
2024-01-08T07:19:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors
2024-01-19T16:04:01+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-delivers-strong-full-year-performance-10-net-sales-and-18-core-operating-income-growth-cc1-margin-expansion-continuing-innovation-momentum-multiple-positive-ph3-readouts
2024-01-31T09:29:04+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-forte-performance-en-2023-hausse-de-10-du-chiffre-daffaires-net-et-de-18-du-resultat-operationnel-core-tcc1-expansion-de-la-marge-innovation-nombreux-resultats-positifs-de-phase-iii
2024-01-31T09:27:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/starkes-jahresergebnis-novartis-steigert-den-nettoumsatz-um-10-das-operative-kernergebnis-um-18-kwk1-sowie-die-margen-weitere-innovationsdynamik-mit-mehreren-positiven-phase-3-ergebnissen
2024-02-05T22:48:49+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash
2024-02-05T22:48:45+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-presents-new-data-safety-and-efficacy-zolgensma-including-maintained-and-improved-motor-milestones-older-and-heavier-children-sma
2024-03-04T07:19:03+01:00
daily
0.5
https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-7
2024-03-05T15:34:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaire-1
2024-03-05T15:34:02+01:00
daily
0.5
https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gut-1
2024-03-05T15:34:02+01:00
daily
0.5
https://www.novartis.com/news/novartis-financial-results-q1-2021
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-inaugurates-innovative-watershed-project-india-increase-water-availability
2023-04-11T16:15:33+02:00
daily
1.0
https://www.novartis.com/news/world-cancer-day-2021
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/global-health-corporate-responsibility
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/achieving-100-renewable-electricity
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-appoints-marc-boutin-global-head-patient-engagement-advocacy
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-provides-update-use-and-safety-beovu-patients-wet-amd
2021-09-14T13:02:04+02:00
daily
1.0
https://www.novartis.com/news/avexis-data-integrity-updates
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/epis-explores-how-covid-19-shaping-future-digital-engagement-within-healthcare
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-ranks-second-2021-access-medicine-index
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/highlights-from-co-creating-impact-summit-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-chagas-disease-day-2021
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/bold-advocates-blood-cancers-and-blood-disorders
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/blood-cancer-awareness-month-cutting-edge-innovation-hematology
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/solar-1-nejm-publication
2021-10-07T09:00:16+02:00
daily
1.0
https://www.novartis.com/news/mission-transform-planetary-health
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-announces-flexible-return-office-and-site-field-activities-starting-may-11-2020
2021-10-13T09:18:27+02:00
daily
1.0
https://www.novartis.com/news/novartis-completes-safety-review-and-initiates-update-beovu-prescribing-information-worldwide
2021-09-09T09:50:29+02:00
daily
1.0
https://www.novartis.com/news/novartis-announces-first-european-donation-hydroxychloroquine-switzerland
2021-09-09T09:51:21+02:00
daily
1.0
https://www.novartis.com/news/novartis-coronavirus-update-supply-chain-response-measures-efpia-rd-call
2021-10-14T08:01:51+02:00
daily
1.0
https://www.novartis.com/news/expanding-car-t-manufacturing-australia
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-ash
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/why-healthcares-digital-moment-now
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/avexis-renamed-novartis-gene-therapies-signifying-growing-importance-gene-therapy-novartis-corporate-strategy
2021-10-07T09:12:50+02:00
daily
1.0
https://www.novartis.com/news/ruxcovid-clinical-trial
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/study-suggests-there-may-be-two-stages-fatal-lung-disease-covid-19
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/choice-responsibility-reimagining-how-we-work
2022-12-05T08:13:49+01:00
daily
1.0
https://www.novartis.com/news/international-womens-day-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-sight-day-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/standing-racial-equity-and-justice-one-novartis
2021-09-09T09:49:34+02:00
daily
1.0
https://www.novartis.com/news/novartis-update-following-who-solidarity-trial-announcement
2021-09-09T09:49:43+02:00
daily
1.0
https://www.novartis.com/news/novartis-announces-plan-initiate-clinical-trial-canakinumab-patients-covid-19-pneumonia
2021-09-09T09:50:01+02:00
daily
1.0
https://www.novartis.com/news/leading-performance-sustainability
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-heart-day-2020-from-our-heart-yours
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/50-climate-leaders
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/new-report-shows-how-ai-health-critical-covid-19-response-and-recovery
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-coronavirus-update-remote-working-business-travel-restrictions
2021-09-14T13:02:17+02:00
daily
1.0
https://www.novartis.com/news/expanding-car-t-manufacturing-europe-serve-more-patients
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/committed-increasing-access
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/pride-novartis-2020-inspired-make-difference
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-sickle-cell-day-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-asco
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/pride-novartis-2019
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-chagas-disease-day-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-covid-19-response-fund-provides-support-healthcare-workers-and-communities
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-esmo
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-launches-new-preferred-firm-program-legal-services
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/day-african-child-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-cancer-day-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-world-economic-forum-annual-meeting-davos-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/sustaining-momentum-toward-universal-health-coverage-africa
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/discussing-innovative-solutions-address-unmet-healthcare-needs-asia
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-joins-accelerating-covid-19-therapeutic-interventions-and-vaccines-activ-initiative
2021-09-09T09:50:17+02:00
daily
1.0
https://www.novartis.com/news/novartis-announces-further-steps-protect-and-support-its-associates-during-covid-19-pandemic
2021-09-14T12:59:55+02:00
daily
1.0
https://www.novartis.com/news/novartis-ranks-4-patientviews-2019-corporate-reputation-survey-patient-organizations
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/behind-research-driving-our-data-medical-conferences
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/uncovering-profound-and-under-reported-effects-people-living-sickle-cell-disease
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/amazon-web-services-aws-announces-strategic-collaboration-novartis-accelerate-digital-transformation-its-business-operations
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-opens-facility-innovative-cell-and-gene-therapies-switzerland
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-sight-day-2019
2022-02-10T11:47:38+01:00
daily
1.0
https://www.novartis.com/news/novartis-and-microsoft-announce-collaboration-transform-medicine-artificial-intelligence
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/health-experts-explore-response-chronic-illness-poor-countries
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-malaria-day-2019
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/global-equal-parental-leave-policy-all-novartis-parents
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-moves-address-superbug-threat
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/celebrating-community-partnership-day
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-recognized-global-leader-sustainable-water-and-climate-management
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/biosimilar-drugs-have-potential-save-more-usd-54-billion
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-foundation-joins-global-partnership-zero-leprosy
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-sickle-cell-day-2019
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/exploring-future-access-healthcare-lower-income-countries
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/alcon-survey-reveals-people-are-happier-and-more-satisfied-their-lives-after-cataract-surgery
2021-08-23T10:08:22+02:00
daily
1.0
https://www.novartis.com/news/car-t-therapies-are-manufactured-each-individual-patient
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/asthma-and-exercise-why-patients-can-and-should-stay-active
2021-07-28T14:09:59+02:00
daily
1.0
https://www.novartis.com/news/beyond-pill-precision-medicine-practice
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/improving-diabetes-awareness-and-treatment-adherence-india
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/how-digital-technologies-are-creating-new-normal-people-living-copd
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/when-innovation-draws-new-future-patient-treatments
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/taking-action-psoriasis-patients-who-psoriasis-resolution
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-medikidz-and-copd-foundation-partnership-superhero-proportions
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/innovation-practice-how-we-form-partnerships-pharma
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-evolving-business-practices-better-educate-medical-community
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/medical-researchers-using-new-tools-turn-science-fiction-science-fact
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/students-take-challenges-digital-medicine
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/fighting-high-blood-pressure-vietnam
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-asthma-day-2021
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/nurturing-next-generation-scientists
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-and-red-cross-partner-tackle-chronic-diseases-refugee-populations
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/essential-consultants-updates
2021-10-14T09:40:24+02:00
daily
1.0
https://www.novartis.com/news/avxs-101-managed-access-program
2021-10-13T11:51:31+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q1-2020
2023-05-22T11:17:09+02:00
daily
1.0
https://www.novartis.com/news/world-malaria-day-2021
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q2-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-dialogue-explore-solutions-rise-chronic-diseases-developing-world
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q3-2020
2023-12-06T10:23:10+01:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q1-2018
2024-02-01T12:01:47+01:00
daily
1.0
https://www.novartis.com/news/novartis-2020-financial-results
2023-01-31T12:03:28+01:00
daily
1.0
https://www.novartis.com/news/novartis-2017-financial-results
2023-02-01T08:45:22+01:00
daily
1.0
https://www.novartis.com/news/novartis-host-stakeholder-dialogue-ways-improve-access-healthcare-lower-income-countries
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q3-2018
2024-02-01T12:06:39+01:00
daily
1.0
https://www.novartis.com/news/european-patient-innovation-summit-recommends-increasing-impact-digital-technologies
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/alcon-becomes-separately-traded-standalone-company
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-rd-day
2022-12-15T11:16:56+01:00
daily
1.0
https://www.novartis.com/news/novartis-2018-financial-results
2024-02-01T12:10:03+01:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q1-2019
2023-01-18T11:33:52+01:00
daily
1.0
https://www.novartis.com/news/novartis-jp-morgan-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-2015-financial-results
2021-10-07T15:34:53+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q2-2019
2023-06-19T14:27:07+02:00
daily
1.0
https://www.novartis.com/news/novartis-2019-financial-results
2023-04-17T16:27:05+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q3-2019
2023-06-19T14:28:41+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q2-2018
2024-02-01T12:04:02+01:00
daily
1.0
https://www.novartis.com/news/co-creating-impact-summit-society-and-planet
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-2016-financial-results
2022-02-02T08:45:07+01:00
daily
1.0
https://www.novartis.com/news/life-science-companies-and-bill-melinda-gates-foundation-joint-communique
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/european-patient-innovation-summit-publishes-call-action-ensure-greater-patient-involvement-digital-health-solution-development
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-research-shows-technology-talent-increasingly-drawn-pharma-industry-covid-19
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/world-malaria-day-2020
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/impact-measurement-and-valuation
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/ai-nurse-set-transform-standards-care-heart-failure-patients-china
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/meet-novartis-management-2020
2023-12-06T10:37:20+01:00
daily
1.0
https://www.novartis.com/news/novartis-announces-discontinuation-cirrus-1-study-cfz533-iscalimab-kidney-transplant-patients
2021-10-04T08:25:52+02:00
daily
1.0
https://www.novartis.com/news/novartis-receives-fda-fast-track-designation-lna043-osteoarthritis-knee
2021-10-04T08:28:19+02:00
daily
1.0
https://www.novartis.com/news/novartis-sabatolimab-receives-orphan-drug-designation-from-european-commission-myelodysplastic-syndromes
2021-10-14T13:31:54+02:00
daily
1.0
https://www.novartis.com/news/fda-accelerates-review-novartis-stamp-inhibitor-asciminib-abl001-patients-chronic-myeloid-leukemia-cml
2021-10-04T08:26:24+02:00
daily
1.0
https://www.novartis.com/news/novartis-receives-fda-orphan-drug-designation-nis793-pancreatic-cancer
2021-10-04T08:28:06+02:00
daily
1.0
https://www.novartis.com/news/novartis-announces-complete-response-resubmission-inclisiran-new-drug-application
2021-10-04T08:26:03+02:00
daily
1.0
https://www.novartis.com/news/novartis-receives-fda-breakthrough-therapy-designation-investigational-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc
2023-04-11T16:10:26+02:00
daily
1.0
https://www.novartis.com/news/novartis-entresto-indicated-treatment-hypertension-china
2021-10-04T08:25:43+02:00
daily
1.0
https://www.novartis.com/news/novartis-receives-fda-fast-track-designation-sabatolimab-mbg453-myelodysplastic-syndromes
2021-10-04T08:28:13+02:00
daily
1.0
https://www.novartis.com/news/industry-and-academia-collaborating-innovate-patients
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/fda-grants-priority-review-investigational-targeted-radioligand-therapy-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc
2021-10-14T10:02:25+02:00
daily
1.0
https://www.novartis.com/news/one-billion-antimalarial-treatments-delivered-extraordinary-partnership-journey
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/asia-pacific-patient-innovation-summit-examines-capability-building-gaps-patient-organizations
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/enabling-our-associates-work-safely-our-sites
2021-10-07T13:13:01+02:00
daily
1.0
https://www.novartis.com/news/beacon-hope-addressing-health-disparities-through-holistic-community-based-collective-action
2021-10-11T12:14:00+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q2-2021
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-hematology-relentless-pursuit-cure
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/two-decades-pioneering-innovation-cml-and-beyond
2023-03-13T10:41:16+01:00
daily
1.0
https://www.novartis.com/news/covid-19-news-archive
2023-07-03T16:14:31+02:00
daily
1.0
https://www.novartis.com/news/world-sight-day-2021
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q3-2021
2021-10-26T13:22:41+02:00
daily
1.0
https://www.novartis.com/news/sound-up
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/raising-awareness-prostate-cancer-during-movember
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-receives-fda-fast-track-designation-branaplam-lmi070-treatment-huntingtons-disease
2021-12-16T10:00:12+01:00
daily
1.0
https://www.novartis.com/news/2021-global-managed-access-program-community-update
2022-01-31T14:36:51+01:00
daily
1.0
https://www.novartis.com/news/novartis-2021-financial-results
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-co-creating-impact-summit-2021
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-announces-european-patent-office-orders-grant-european-gilenya-fingolimod-05mg-daily-dose-patent
2022-02-15T10:02:38+01:00
daily
1.0
https://www.novartis.com/news/novartis-condemns-war-ukraine-and-commits-supporting-humanitarian-efforts
2022-03-15T08:49:19+01:00
daily
1.0
https://www.novartis.com/news/novartis-expands-humanitarian-efforts-ukraine-through-donation-essential-medicines
2022-03-08T16:49:12+01:00
daily
1.0
https://www.novartis.com/news/novartis-condemns-war-ukraine-update-march-22
2022-03-22T08:11:41+01:00
daily
1.0
https://www.novartis.com/news/novartis-provides-more-usd-25-million-medical-aid-patients-ukraine-and-bordering-countries
2022-04-19T14:32:46+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q1-2022
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-asco-and-eha-2022
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-resumes-business-ukraine
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q2-2022
2022-07-28T12:22:49+02:00
daily
1.0
https://www.novartis.com/news/from-the-heart
2022-11-07T09:58:07+01:00
daily
1.0
https://www.novartis.com/news/zolgensma-acute-liver-failure-update
2022-08-16T17:30:22+02:00
daily
1.0
https://www.novartis.com/news/branaplam-vibrant-hd-study-update
2022-08-25T16:01:23+02:00
daily
1.0
https://www.novartis.com/news/novartis-hematology-working-help-ensure-patients-are-getting-access-they-need
2022-10-25T09:27:45+02:00
daily
1.0
https://www.novartis.com/news/world-sight-day-2022
2022-10-13T09:44:32+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q3-2022
2022-10-24T21:19:13+02:00
daily
1.0
https://www.novartis.com/news/creating-positive-social-change-through-volunteering
2022-11-29T13:07:09+01:00
daily
1.0
https://www.novartis.com/news/zolgensma-global-managed-access-program-2023
2023-01-09T08:36:49+01:00
daily
1.0
https://www.novartis.com/news/world-economic-forum-2023
2023-01-23T10:37:02+01:00
daily
1.0
https://www.novartis.com/news/novartis-shares-strategy-insights-and-highlights-key-pipeline-catalysts-jp-morgan-healthcare-conference-2023
2023-01-09T17:18:36+01:00
daily
1.0
https://www.novartis.com/news/novartis-2022-financial-results
2023-02-20T16:20:56+01:00
daily
1.0
https://www.novartis.com/news/novartis-provides-update-phase-iii-stand-trial-assessing-crizanlizumab
2023-02-01T12:36:05+01:00
daily
1.0
https://www.novartis.com/news/novartis-announces-support-people-affected-earthquake-turkey-and-syria
2023-02-07T19:10:01+01:00
daily
1.0
https://www.novartis.com/news/novartis-releases-emergency-funding-usd-1-million-people-turkey-and-syria-and-launches-employee-donation-and-volunteering-programs
2023-02-09T16:14:57+01:00
daily
1.0
https://www.novartis.com/news/novartis-unwavering-support-one-year-from-start-war-ukraine
2023-02-28T17:30:32+01:00
daily
1.0
https://www.novartis.com/news/novartis-completes-fda-filing-approval-millburn-facility-support-pluvicto-launch
2023-03-03T08:56:35+01:00
daily
1.0
https://www.novartis.com/news/fda-approves-novartis-millburn-facility-us-commercial-production-pluvicto
2023-04-21T17:17:29+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q1-2023
2023-04-25T06:06:47+02:00
daily
1.0
https://www.novartis.com/news/chmp-recommends-revoking-conditional-marketing-authorization-adakveo-crizanlizumab
2023-05-26T14:28:49+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q2-2023
2023-10-23T18:16:18+02:00
daily
1.0
https://www.novartis.com/news/european-commission-ec-adopts-decision-endorsing-chmp-recommendation-revoke-conditional-marketing-authorization-adakveo-crizanlizumab
2023-08-04T14:29:20+02:00
daily
1.0
https://www.novartis.com/news/novartis-statement-about-entresto-sacubitrilvalsartan-selection-medicare-drug-price-negotiation-program
2023-08-29T14:51:15+02:00
daily
1.0
https://www.novartis.com/news/novartis-statement-filing-inflation-reduction-act-lawsuit
2023-09-01T20:47:26+02:00
daily
1.0
https://www.novartis.com/news/novartis-giving-volunteering-wins-accps-2023-corporate-social-impact-team-year-award
2023-10-11T14:26:30+02:00
daily
1.0
https://www.novartis.com/news/gt005-ppy988-development-program-geographic-atrophy
2023-09-11T16:14:11+02:00
daily
1.0
https://www.novartis.com/news/novartis-provides-support-moroccan-earthquake-victims
2023-09-13T15:52:00+02:00
daily
1.0
https://www.novartis.com/news/novartis-statement-collaboration-and-license-agreement-tislelizumab-beigene-ltd
2023-09-19T14:36:00+02:00
daily
1.0
https://www.novartis.com/news/novartis-condemns-terrorist-actions-against-people-israel-and-loss-innocent-lives
2023-10-13T13:31:56+02:00
daily
1.0
https://www.novartis.com/news/violence-against-innocent-people-runs-counter-our-work-improve-human-health
2023-10-19T07:57:08+02:00
daily
1.0
https://www.novartis.com/news/novartis-financial-results-q3-2023
2023-10-23T19:43:20+02:00
daily
1.0
https://www.novartis.com/news/our-next-era
2023-12-04T06:31:45+01:00
daily
1.0
https://www.novartis.com/news/jp-morgan-healthcare-conference-2024
2024-01-15T08:40:58+01:00
daily
1.0
https://www.novartis.com/news/novartis-shares-strategy-and-growth-update-jp-morgan-healthcare-conference-2024
2024-01-08T17:33:04+01:00
daily
1.0
https://www.novartis.com/news/novartis-2023-financial-results
2024-01-31T14:18:01+01:00
daily
1.0
https://www.novartis.com/news/novartis-appoints-sloan-simpson-global-head-investor-relations
2024-02-29T08:59:50+01:00
daily
1.0
https://www.novartis.com/stories/artificial-intelligence-decodes-cancer-pathology-images
2022-02-10T13:40:05+01:00
daily
1.0
https://www.novartis.com/stories/african-experts-call-renewed-global-drive-beat-malaria
2021-10-12T14:51:02+02:00
daily
1.0
https://www.novartis.com/stories/10-big-questions-dissect-science-papers
2021-10-18T14:17:21+02:00
daily
1.0
https://www.novartis.com/stories/abcdes-melanoma-prevention-and-detection
2021-10-18T07:50:01+02:00
daily
1.0
https://www.novartis.com/stories/challenging-young-scientist-focus-patients
2021-10-14T07:38:35+02:00
daily
1.0
https://www.novartis.com/stories/biological-battle-bulge
2021-10-07T10:20:50+02:00
daily
1.0
https://www.novartis.com/stories/building-boot-camps-immune-cells-near-tumors
2021-10-08T14:58:49+02:00
daily
1.0
https://www.novartis.com/stories/bringing-gene-therapy-focus
2022-02-11T14:53:34+01:00
daily
1.0
https://www.novartis.com/stories/can-we-unlock-bodys-ability-regenerate-lost-hearing
2021-10-07T10:28:25+02:00
daily
1.0
https://www.novartis.com/stories/building-collaborations-fight-pandemic
2021-10-07T12:27:31+02:00
daily
1.0
https://www.novartis.com/stories/breaking-vicious-cycle-inflammation
2021-10-07T15:54:28+02:00
daily
1.0
https://www.novartis.com/stories/bringing-real-change-people
2021-10-07T12:17:22+02:00
daily
1.0
https://www.novartis.com/stories/cancer-cocktails-abl001-hitting-one-target-twice
2021-10-07T10:25:55+02:00
daily
1.0
https://www.novartis.com/stories/cancer-cocktails-come-age
2021-10-07T10:25:26+02:00
daily
1.0
https://www.novartis.com/stories/bringing-science-and-medicine-together-help-patients-cancer
2021-10-08T14:54:04+02:00
daily
1.0
https://www.novartis.com/stories/cancer-cocktails-lee011-popular-combination-partner
2021-09-14T11:23:06+02:00
daily
1.0
https://www.novartis.com/stories/cancer-cocktails-ljm716-closing-common-release-valve
2021-09-14T12:38:16+02:00
daily
1.0
https://www.novartis.com/stories/cancer-researchers-ready-aim-cures
2021-10-07T07:10:36+02:00
daily
1.0
https://www.novartis.com/stories/chan-zuckerberg-initiative-friends-novartis-scientist-mission-conquer-disease
2021-10-15T13:20:59+02:00
daily
1.0
https://www.novartis.com/stories/clinical-trial-comes-together-weeks-address-coronavirus
2021-10-15T13:51:13+02:00
daily
1.0
https://www.novartis.com/stories/cellular-drama-heart-researchers-family
2021-10-15T12:06:55+02:00
daily
1.0
https://www.novartis.com/stories/clinical-trials-make-move-toward-mice
2021-10-15T13:48:39+02:00
daily
1.0
https://www.novartis.com/stories/close-look-cryo-electron-microscopy
2021-10-15T14:00:33+02:00
daily
1.0
https://www.novartis.com/stories/collaborating-explore-new-gene-regulation-therapies
2021-10-18T14:29:32+02:00
daily
1.0
https://www.novartis.com/stories/collaborating-unlock-secrets-microbiome
2021-10-08T06:30:33+02:00
daily
1.0
https://www.novartis.com/stories/compound-designed-fight-alzheimers-disease-shows-promise-lab
2021-10-07T14:27:10+02:00
daily
1.0
https://www.novartis.com/stories/compounds-spur-insulin-producing-cells-replicate-lab
2021-10-15T15:20:55+02:00
daily
1.0
https://www.novartis.com/stories/combination-therapies-seeking-block-cancers-pathways-growth
2021-10-15T14:43:44+02:00
daily
1.0
https://www.novartis.com/stories/counting-combos-complex-liver-diseases
2022-06-08T10:16:00+02:00
daily
1.0
https://www.novartis.com/stories/confidence-led-researcher-swim-against-current
2021-10-11T11:47:55+02:00
daily
1.0
https://www.novartis.com/stories/covid-19-answering-your-top-questions
2021-10-01T06:28:14+02:00
daily
1.0
https://www.novartis.com/stories/data42-program-shows-novartis-intent-go-big-data-and-digital
2021-10-11T14:30:46+02:00
daily
1.0
https://www.novartis.com/stories/could-umbilical-cords-yield-more-stem-cells-life-saving-transplants
2021-10-15T15:31:20+02:00
daily
1.0
https://www.novartis.com/stories/digital-health-ecosystem-gets-boost-novartis-biome
2022-01-07T09:15:56+01:00
daily
1.0
https://www.novartis.com/stories/embracing-big-data-understand-complex-diseases
2021-10-18T14:31:42+02:00
daily
1.0
https://www.novartis.com/stories/decades-long-journey-blood-cancer-research
2021-10-15T15:46:52+02:00
daily
1.0
https://www.novartis.com/stories/drug-development-gets-big-data-analytics-boost
2021-10-07T10:45:05+02:00
daily
1.0
https://www.novartis.com/stories/evolution-scientist
2021-10-07T10:43:41+02:00
daily
1.0
https://www.novartis.com/stories/experimental-gene-therapy-discovered-house-enters-clinical-testing
2021-10-18T14:37:43+02:00
daily
1.0
https://www.novartis.com/stories/experimental-treatment-clears-malaria-infections-small-clinical-study
2021-10-15T16:01:23+02:00
daily
1.0
https://www.novartis.com/stories/exploring-longstanding-questions-about-heart-disease
2021-10-07T08:08:20+02:00
daily
1.0
https://www.novartis.com/stories/eye-fastest-muscle-human-body
2021-07-21T14:12:47+02:00
daily
1.0
https://www.novartis.com/stories/dna-encoded-molecules-provide-new-edge-cancer-drug-hunts
2021-10-01T06:43:44+02:00
daily
1.0
https://www.novartis.com/stories/factory-foreman-keeps-livers-line-workers-task
2021-10-07T08:39:15+02:00
daily
1.0
https://www.novartis.com/stories/eyewitness-healer-pursues-new-treatments-patients
2021-10-18T14:42:38+02:00
daily
1.0
https://www.novartis.com/stories/fresh-look-fighting-glaucoma
2021-10-07T08:40:37+02:00
daily
1.0
https://www.novartis.com/stories/from-patient-patient-advocate-how-cancer-diagnosis-fueled-new-career-path
2021-10-01T07:13:00+02:00
daily
1.0
https://www.novartis.com/stories/getting-down-roots-alzheimers-disease
2021-10-07T14:25:16+02:00
daily
1.0
https://www.novartis.com/stories/going-global-meet-local-needs-china
2021-10-15T16:50:12+02:00
daily
1.0
https://www.novartis.com/stories/how-love-sport-led-scientific-breakthrough
2021-10-07T08:59:33+02:00
daily
1.0
https://www.novartis.com/stories/heart-failure-leading-cause-hospitalizations-it-doesnt-have-be
2023-04-11T16:04:59+02:00
daily
1.0
https://www.novartis.com/stories/eye-patients-mind-innovation
2021-10-01T07:09:42+02:00
daily
1.0
https://www.novartis.com/stories/helping-clinical-trial-patients-during-lockdown
2021-10-18T09:37:02+02:00
daily
1.0
https://www.novartis.com/stories/how-scientists-aim-expand-immunotherapy-options-cancer-patients
2022-06-07T17:03:01+02:00
daily
1.0
https://www.novartis.com/stories/immuno-oncology-researchers-seek-build-smart-drug-combos
2021-10-18T14:45:39+02:00
daily
1.0
https://www.novartis.com/stories/innovating-trusted-class-antibiotics-attack-superbugs
2021-10-18T09:55:14+02:00
daily
1.0
https://www.novartis.com/stories/investigating-myopia-mystery
2022-06-21T15:35:00+02:00
daily
1.0
https://www.novartis.com/stories/it-takes-rd-village-fight-pandemic
2021-10-18T14:47:58+02:00
daily
1.0
https://www.novartis.com/stories/intractable-tumor-cells-crippled
2021-10-18T10:15:06+02:00
daily
1.0
https://www.novartis.com/stories/keeping-heart-patients-heart-everything-we-do
2023-07-04T14:59:31+02:00
daily
1.0
https://www.novartis.com/stories/let-there-be-sight
2021-10-07T09:08:43+02:00
daily
1.0
https://www.novartis.com/stories/loss-friend-liver-cancer-sharpens-focus-experimental-therapy
2021-09-29T07:49:04+02:00
daily
1.0
https://www.novartis.com/stories/killing-three-diseases-one-stone-lab
2021-09-29T08:11:16+02:00
daily
1.0
https://www.novartis.com/stories/leveraging-livers-ability-heal-scarred-tissue
2021-10-18T12:01:21+02:00
daily
1.0
https://www.novartis.com/stories/making-possible-stepping-toward-future-cell-and-gene-therapy
2022-01-14T16:58:56+01:00
daily
1.0
https://www.novartis.com/stories/meet-achim-leading-data42-program
2021-10-07T09:14:48+02:00
daily
1.0
https://www.novartis.com/stories/mutant-protein-spreads-through-neural-circuit-huntingtons-disease
2021-10-07T09:49:48+02:00
daily
1.0
https://www.novartis.com/stories/moving-from-speculation-science-during-pandemic
2021-10-01T08:06:31+02:00
daily
1.0
https://www.novartis.com/stories/not-your-grandparents-nuclear-medicine
2022-01-11T09:30:42+01:00
daily
1.0
https://www.novartis.com/stories/machine-learning-poised-accelerate-drug-discovery
2022-06-21T17:07:09+02:00
daily
1.0
https://www.novartis.com/stories/neuroscientists-restore-cell-cell-signaling-and-sociability-autism-models
2021-10-07T14:50:04+02:00
daily
1.0
https://www.novartis.com/stories/new-drug-manufacturing-tools-change-pharma-chemistry
2021-10-07T09:54:51+02:00
daily
1.0
https://www.novartis.com/stories/new-recruit-has-big-dreams-cancer-immunotherapy
2021-10-18T15:02:03+02:00
daily
1.0
https://www.novartis.com/stories/new-hope-treating-inflammatory-diseases-kidney
2022-01-11T09:27:11+01:00
daily
1.0
https://www.novartis.com/stories/novartis-and-pfizer-join-forces-upend-oncology-dogma
2021-10-18T15:13:48+02:00
daily
1.0
https://www.novartis.com/stories/novartis-cancer-researchers-advance-precision-medicine
2021-10-18T15:59:25+02:00
daily
1.0
https://www.novartis.com/stories/novartis-researches-smas-genetic-roots
2021-10-07T10:05:11+02:00
daily
1.0
https://www.novartis.com/stories/open-science-demystified
2021-10-19T08:44:12+02:00
daily
1.0
https://www.novartis.com/stories/novartis-scientists-target-resistance-threat-malaria
2021-10-07T10:09:33+02:00
daily
1.0
https://www.novartis.com/stories/organic-dealmaker-drug-discovery
2021-10-11T11:55:22+02:00
daily
1.0
https://www.novartis.com/stories/open-resources-novartis-help-drive-innovation
2022-01-14T15:56:41+01:00
daily
1.0
https://www.novartis.com/stories/physician-scientist-donald-ganem-takes-reins-infectious-disease
2021-10-07T10:21:16+02:00
daily
1.0
https://www.novartis.com/stories/potential-weight-loss-treatment-takes-shape-help-from-patients
2021-10-19T08:56:04+02:00
daily
1.0
https://www.novartis.com/stories/predictive-analytics-could-bring-medicines-patients-faster
2021-10-19T09:01:12+02:00
daily
1.0
https://www.novartis.com/stories/reaping-cancer-clues-from-blood
2021-09-28T11:25:16+02:00
daily
1.0
https://www.novartis.com/stories/rare-speed-rare-disease
2021-10-19T09:23:22+02:00
daily
1.0
https://www.novartis.com/stories/researchers-overcome-hurdles-test-experimental-malaria-drug
2021-10-07T14:36:23+02:00
daily
1.0
https://www.novartis.com/stories/researchers-aim-beat-trick-play-tumors-drug-combo
2021-10-19T09:28:15+02:00
daily
1.0
https://www.novartis.com/stories/quest-new-measure-mental-health
2021-10-19T09:04:18+02:00
daily
1.0
https://www.novartis.com/stories/researcher-races-find-new-treatment-his-progressive-disease
2021-10-18T08:18:59+02:00
daily
1.0
https://www.novartis.com/stories/researchers-phd-leads-medical-breakthrough-rare-skin-disease
2021-10-07T10:40:50+02:00
daily
1.0
https://www.novartis.com/stories/researcher-seeks-roots-plants-healing-power
2021-10-19T09:32:29+02:00
daily
1.0
https://www.novartis.com/stories/respiratory-clinical-trials-putting-patients-heart-research
2023-07-04T16:27:20+02:00
daily
1.0
https://www.novartis.com/stories/rewriting-playbook-clinical-testing-rare-disease
2021-10-07T10:42:50+02:00
daily
1.0
https://www.novartis.com/stories/saving-tumor-suppressors-from-shredder
2021-10-07T10:44:12+02:00
daily
1.0
https://www.novartis.com/stories/shaping-future-sickle-cell-disease
2021-10-07T10:46:16+02:00
daily
1.0
https://www.novartis.com/stories/search-differences-make-difference
2021-10-07T10:45:02+02:00
daily
1.0
https://www.novartis.com/stories/specter-malaria-resists-treatment
2021-10-07T10:49:09+02:00
daily
1.0
https://www.novartis.com/stories/stepping-toward-regenerative-medicine-diabetes
2021-10-18T08:21:01+02:00
daily
1.0
https://www.novartis.com/stories/small-viruses-could-accelerate-cell-and-gene-therapy-research
2021-10-18T15:24:48+02:00
daily
1.0
https://www.novartis.com/stories/stopping-alzheimers-disease-it-starts
2021-10-07T10:52:35+02:00
daily
1.0
https://www.novartis.com/stories/stifling-danger-signals-rheumatoid-arthritis
2021-10-07T10:51:16+02:00
daily
1.0
https://www.novartis.com/stories/tackling-common-denominator-liver-disease
2021-10-07T10:55:11+02:00
daily
1.0
https://www.novartis.com/stories/systematically-exposing-vulnerabilities-cancer-cells
2022-01-11T09:33:46+01:00
daily
1.0
https://www.novartis.com/stories/taking-clinical-trials-next-level-through-technology
2021-10-07T10:59:00+02:00
daily
1.0
https://www.novartis.com/stories/taking-obesity
2021-10-18T15:26:11+02:00
daily
1.0
https://www.novartis.com/stories/tracking-patients-progress-radio-signals-and-machine-learning
2021-10-07T11:30:50+02:00
daily
1.0
https://www.novartis.com/stories/talking-bruno-strigini-why-were-entering-transformative-time-cancer-care
2021-10-07T11:26:16+02:00
daily
1.0
https://www.novartis.com/stories/teaming-academia-discover-medicines
2021-10-07T11:28:03+02:00
daily
1.0
https://www.novartis.com/stories/turning-research-advances-innovative-medicines
2021-11-23T16:15:54+01:00
daily
1.0
https://www.novartis.com/stories/women-science-cathryn-clary
2021-10-19T06:42:09+02:00
daily
1.0
https://www.novartis.com/stories/visualizing-immuno-oncology-research
2023-04-11T15:58:47+02:00
daily
1.0
https://www.novartis.com/stories/women-science-kristen-harrington-smith
2021-10-07T11:42:54+02:00
daily
1.0
https://www.novartis.com/stories/women-science-annie-martin
2021-10-07T11:39:50+02:00
daily
1.0
https://www.novartis.com/stories/women-science-mimi-huizinga
2021-10-07T11:56:55+02:00
daily
1.0
https://www.novartis.com/stories/women-science-hannah-mosca
2021-10-19T06:34:41+02:00
daily
1.0
https://www.novartis.com/stories/women-science-lauren-abrey
2021-10-07T11:43:54+02:00
daily
1.0
https://www.novartis.com/stories/women-science-sandrine-piret-gerard
2021-10-07T11:58:35+02:00
daily
1.0
https://www.novartis.com/stories/women-science-renee-rodgers
2021-10-07T11:57:43+02:00
daily
1.0
https://www.novartis.com/stories/women-science-lilli-petruzzelli
2021-10-07T11:45:02+02:00
daily
1.0
https://www.novartis.com/stories/women-science-shilpa-shah-mehta
2021-09-28T12:36:21+02:00
daily
1.0
https://www.novartis.com/stories/women-science-shannon-campbell
2021-10-07T11:59:29+02:00
daily
1.0
https://www.novartis.com/stories/women-science-susanne-schaffert
2021-10-07T12:00:55+02:00
daily
1.0
https://www.novartis.com/stories/women-science-medy-attalla
2021-10-07T11:51:41+02:00
daily
1.0
https://www.novartis.com/stories/word-street-what-cell-and-gene-therapy
2021-10-07T12:03:47+02:00
daily
1.0
https://www.novartis.com/stories/women-science-tania-small
2021-10-07T12:02:01+02:00
daily
1.0
https://www.novartis.com/stories/3-d-printing-scientists-reinvent-research-tools
2021-10-07T12:05:57+02:00
daily
1.0
https://www.novartis.com/stories/women-science-virginia-lazala
2021-10-18T14:39:45+02:00
daily
1.0
https://www.novartis.com/stories/bringing-virtual-reality-lab
2022-01-11T09:54:21+01:00
daily
1.0
https://www.novartis.com/stories/brain-dish-researchers-take-neurological-disorders
2021-10-07T12:08:17+02:00
daily
1.0
https://www.novartis.com/stories/5-tips-making-smart-decisions-research-projects
2021-10-07T12:06:40+02:00
daily
1.0
https://www.novartis.com/stories/building-brain-organoids-shed-light-disease
2021-10-07T12:09:56+02:00
daily
1.0
https://www.novartis.com/stories/cancer-spies-find-drug-beating-covert-cells
2021-07-21T14:55:17+02:00
daily
1.0
https://www.novartis.com/stories/can-we-edit-our-genes-fight-disease
2021-09-13T11:20:18+02:00
daily
1.0
https://www.novartis.com/stories/chemical-genetics-sleuthing-behind-modern-drug-discovery
2021-10-07T12:14:12+02:00
daily
1.0
https://www.novartis.com/stories/could-digital-technology-drive-clinical-research-africa
2021-10-07T12:15:19+02:00
daily
1.0
https://www.novartis.com/stories/disease-pathways-key-new-drug-discovery
2021-10-07T12:18:57+02:00
daily
1.0
https://www.novartis.com/stories/electrical-brainstorms-traced-genetic-mutations
2021-10-07T12:43:58+02:00
daily
1.0
https://www.novartis.com/stories/crispr-genome-editing-fuels-cancer-drug-discovery
2021-10-18T09:44:31+02:00
daily
1.0
https://www.novartis.com/stories/countering-genome-reprogramming-cancer-cells
2021-10-18T08:26:48+02:00
daily
1.0
https://www.novartis.com/stories/eye-disease-tracked-glitch-starburst-cells
2021-10-07T12:45:00+02:00
daily
1.0
https://www.novartis.com/stories/five-things-look-scientific-mentor
2021-10-07T12:48:50+02:00
daily
1.0
https://www.novartis.com/stories/hooked-science-jay-bradner-becomes-top-researcher-novartis
2021-10-07T13:02:26+02:00
daily
1.0
https://www.novartis.com/stories/hardwiring-future
2021-10-07T13:01:34+02:00
daily
1.0
https://www.novartis.com/stories/giraffes-have-high-blood-pressure-why-dont-they-drop-dead
2021-10-07T13:00:25+02:00
daily
1.0
https://www.novartis.com/stories/fixing-whats-lost-translation
2021-10-07T12:59:32+02:00
daily
1.0
https://www.novartis.com/stories/how-address-culture-gap-between-academia-and-industry-biomedicine
2021-10-07T14:46:10+02:00
daily
1.0
https://www.novartis.com/stories/improving-science-communication-3-easy-steps
2021-10-07T13:07:35+02:00
daily
1.0
https://www.novartis.com/stories/mhealth-revolution-healthcare
2021-10-07T13:09:14+02:00
daily
1.0
https://www.novartis.com/stories/how-i-built-mini-gut-next-no-biology-training
2021-10-07T13:05:22+02:00
daily
1.0
https://www.novartis.com/stories/how-zika-infects-growing-brain
2021-10-07T13:06:08+02:00
daily
1.0
https://www.novartis.com/stories/minion-challenges-assumptions-about-genome
2021-10-07T13:10:05+02:00
daily
1.0
https://www.novartis.com/stories/molecular-glue-kills-cancer-cells-mice
2022-01-07T09:04:45+01:00
daily
1.0
https://www.novartis.com/stories/letters-my-younger-self-female-scientists-share-their-wisdom
2021-10-07T13:08:20+02:00
daily
1.0
https://www.novartis.com/stories/neuroscientists-target-alzheimers-silent-stage
2021-10-07T13:12:17+02:00
daily
1.0
https://www.novartis.com/stories/nurturing-life-science-ecosystem
2021-10-07T13:14:24+02:00
daily
1.0
https://www.novartis.com/stories/opening-chemistry-education-world
2021-10-07T13:15:17+02:00
daily
1.0
https://www.novartis.com/stories/rebuilding-blood
2021-10-07T13:16:18+02:00
daily
1.0
https://www.novartis.com/stories/rediscovering-power-natures-exquisite-complexity
2021-10-07T13:17:33+02:00
daily
1.0
https://www.novartis.com/stories/reigniting-passion-science
2021-10-07T13:17:40+02:00
daily
1.0
https://www.novartis.com/stories/reimagining-protein-sequencing
2021-10-07T13:16:50+02:00
daily
1.0
https://www.novartis.com/stories/robots-speed-pace-modern-drug-discovery
2022-01-07T08:53:12+01:00
daily
1.0
https://www.novartis.com/stories/stopping-free-radicals-their-source
2021-10-18T10:44:53+02:00
daily
1.0
https://www.novartis.com/stories/novartis-antibody-increases-muscle-growth-mice-and-human-cell-cultures
2021-10-18T08:13:19+02:00
daily
1.0
https://www.novartis.com/stories/surfing-wave-big-data-analytics
2021-10-18T15:31:43+02:00
daily
1.0
https://www.novartis.com/stories/three-lessons-ive-learned-industry-postdoc
2021-10-07T11:12:25+02:00
daily
1.0
https://www.novartis.com/stories/turning-heat-tumors
2021-10-07T11:21:04+02:00
daily
1.0
https://www.novartis.com/stories/visual-tour-scientific-strategies-combating-coronavirus
2022-01-10T09:20:55+01:00
daily
1.0
https://www.novartis.com/stories/vision-hacker
2021-10-07T11:28:09+02:00
daily
1.0
https://www.novartis.com/stories/tuning-drugs-succeed-cells-surface
2021-10-18T10:16:57+02:00
daily
1.0
https://www.novartis.com/stories/women-science-alexandra-bach-weidmuller
2021-10-07T11:46:01+02:00
daily
1.0
https://www.novartis.com/stories/what-goes-wrong-window-soul-glaucoma
2021-10-18T10:23:58+02:00
daily
1.0
https://www.novartis.com/stories/when-tiny-brains-are-best-brain-research
2021-10-07T11:33:33+02:00
daily
1.0
https://www.novartis.com/stories/women-science-jean-silveri
2021-10-07T12:43:01+02:00
daily
1.0
https://www.novartis.com/stories/women-science-cyndy-grosskreutz
2021-10-07T12:41:30+02:00
daily
1.0
https://www.novartis.com/stories/turning-power-nuclear-technology-medical-force
2021-11-25T16:08:34+01:00
daily
1.0
https://www.novartis.com/stories/women-science-jennifer-allport-anderson
2021-10-07T12:44:38+02:00
daily
1.0
https://www.novartis.com/stories/young-talent-emerging-technologies-come-together-biocamp
2021-10-07T12:52:48+02:00
daily
1.0
https://www.novartis.com/stories/2-million-kids-receive-malaria-medicine
2021-11-16T11:53:01+01:00
daily
1.0
https://www.novartis.com/stories/women-science-wendy-winckler
2021-10-11T15:39:31+02:00
daily
1.0
https://www.novartis.com/stories/women-science-marjorie-eiref
2021-10-18T08:19:57+02:00
daily
1.0
https://www.novartis.com/stories/ai-changing-face-healthcare
2021-10-07T12:57:25+02:00
daily
1.0
https://www.novartis.com/stories/asian-health-experts-call-final-push-wipe-out-deadliest-form-malaria
2023-07-03T17:16:31+02:00
daily
1.0
https://www.novartis.com/stories/bringing-chagas-disease-peoples-attention
2021-10-13T08:24:01+02:00
daily
1.0
https://www.novartis.com/stories/bringing-modern-medicine-rural-vietnam
2022-06-08T10:29:09+02:00
daily
1.0
https://www.novartis.com/stories/cancer-didnt-stop-covid-19
2021-10-18T11:08:06+02:00
daily
1.0
https://www.novartis.com/stories/collaboration-strengthening-care-chronic-illness-ethiopia
2021-10-07T13:11:18+02:00
daily
1.0
https://www.novartis.com/stories/chagas-disease-breaking-silence
2021-10-07T13:12:12+02:00
daily
1.0
https://www.novartis.com/stories/confronting-global-spread-chronic-disease
2021-10-07T13:06:03+02:00
daily
1.0
https://www.novartis.com/stories/tackling-rare-disease-working-toward-treatment-sma
2021-10-07T10:56:23+02:00
daily
1.0
https://www.novartis.com/stories/sleuths-use-hi-tech-sensors-fight-pharmaceutical-crime
2021-10-18T10:49:49+02:00
daily
1.0
https://www.novartis.com/stories/dealing-spread-chronic-disease-africa
2021-10-07T13:02:28+02:00
daily
1.0
https://www.novartis.com/stories/fighting-malaria-africa
2022-06-10T10:21:56+02:00
daily
1.0
https://www.novartis.com/stories/ensuring-medicine-supply-patients-during-covid-19
2021-10-13T09:10:15+02:00
daily
1.0
https://www.novartis.com/stories/fighting-respiratory-disease-source
2021-10-07T12:54:29+02:00
daily
1.0
https://www.novartis.com/stories/delivering-access-first-launch-kenya
2023-07-04T12:04:14+02:00
daily
1.0
https://www.novartis.com/stories/health-collaboration-russia-helped-reduce-blood-pressure-deaths
2021-10-18T11:32:58+02:00
daily
1.0
https://www.novartis.com/stories/fighting-pneumonia-biggest-killer-young-children
2021-10-07T12:55:38+02:00
daily
1.0
https://www.novartis.com/stories/kenya-confronts-chronic-diseases-building-progress-against-aids
2021-10-13T10:25:07+02:00
daily
1.0
https://www.novartis.com/stories/helping-people-sickle-cell-disease-painful-and-life-threatening-blood-disorder
2021-10-07T11:53:32+02:00
daily
1.0
https://www.novartis.com/stories/helping-syrian-refugees-manage-chronic-diseases
2021-10-07T11:52:45+02:00
daily
1.0
https://www.novartis.com/stories/improving-lives-through-community-based-care
2023-04-11T16:06:58+02:00
daily
1.0
https://www.novartis.com/stories/sight-savers-jet-rescue
2021-10-14T12:13:48+02:00
daily
1.0
https://www.novartis.com/stories/streamlining-systems-respond-covid-19
2021-10-14T12:21:47+02:00
daily
1.0
https://www.novartis.com/stories/tailoring-tactics-tackle-chronic-disease-low-income-countries
2021-10-14T12:39:12+02:00
daily
1.0
https://www.novartis.com/stories/talking-ann-aerts-head-novartis-foundation
2023-07-04T16:34:31+02:00
daily
1.0
https://www.novartis.com/stories/life-dedicated-fighting-malaria
2021-11-17T15:28:51+01:00
daily
1.0
https://www.novartis.com/stories/living-breast-cancer-uganda
2021-10-13T11:00:21+02:00
daily
1.0
https://www.novartis.com/stories/living-hypertension-cameroon-few-dollars-day
2021-09-28T14:41:19+02:00
daily
1.0
https://www.novartis.com/stories/malaria-fighter-rides-bicycle-battle-disease
2021-10-13T12:26:09+02:00
daily
1.0
https://www.novartis.com/stories/malaria-still-disrupting-lives-despite-progress
2021-10-13T13:19:02+02:00
daily
1.0
https://www.novartis.com/stories/talking-juergen-brokatzky-geiger-global-head-corporate-responsibility-novartis
2021-10-11T13:40:12+02:00
daily
1.0
https://www.novartis.com/stories/talking-patrice-matchaba-global-head-corporate-responsibility-novartis
2021-10-07T10:49:27+02:00
daily
1.0
https://www.novartis.com/stories/telemedicine-taking-health-care-worlds-far-corners
2022-05-24T16:12:47+02:00
daily
1.0
https://www.novartis.com/stories/text-messages-africa-help-fight-malaria
2021-11-18T16:25:22+01:00
daily
1.0
https://www.novartis.com/stories/treating-cataracts-leading-cause-preventable-blindness-worldwide
2021-10-07T10:46:15+02:00
daily
1.0
https://www.novartis.com/stories/women-science-fionnuala-doyle
2021-10-07T10:44:52+02:00
daily
1.0
https://www.novartis.com/stories/fighting-ms-through-innovation
2021-10-11T13:33:22+02:00
daily
1.0
https://www.novartis.com/stories/from-melanoma-survivor-front-line-nurse
2021-09-29T07:18:25+02:00
daily
1.0
https://www.novartis.com/stories/ai-nurse-evolving-heart-failure-patients-china
2021-12-14T12:32:41+01:00
daily
1.0
https://www.novartis.com/stories/body-painter-captures-anguish-those-who-suffer-from-psoriasis
2023-07-04T09:30:26+02:00
daily
1.0
https://www.novartis.com/stories/changing-landscape-cancer-treatment
2023-07-04T11:43:33+02:00
daily
1.0
https://www.novartis.com/stories/caring-someone-heart-failure
2023-07-24T13:42:04+02:00
daily
1.0
https://www.novartis.com/stories/choosing-right-care
2021-10-07T10:22:32+02:00
daily
1.0
https://www.novartis.com/stories/conversations-patient-advocates-ron-hollander-president-inca
2021-10-07T10:21:12+02:00
daily
1.0
https://www.novartis.com/stories/coping-eye-disease-and-fading-vision-late-life
2021-10-07T10:07:58+02:00
daily
1.0
https://www.novartis.com/stories/meet-manuel-cobos-transplant-surgeon-and-researcher
2021-10-13T14:51:37+02:00
daily
1.0
https://www.novartis.com/stories/creative-ways-help-kids-understand-rare-diseases
2021-10-11T13:15:33+02:00
daily
1.0
https://www.novartis.com/stories/dealing-psoriasis
2022-02-14T15:53:07+01:00
daily
1.0
https://www.novartis.com/stories/debunking-myths-about-multiple-sclerosis
2021-10-07T10:03:44+02:00
daily
1.0
https://www.novartis.com/stories/digital-innovation-looks-set-dominate-2021-healthcare-agenda
2023-07-04T12:08:30+02:00
daily
1.0
https://www.novartis.com/stories/digital-health-providing-opportunities-advocacy-groups-and-community-patients
2021-10-07T10:02:05+02:00
daily
1.0
https://www.novartis.com/stories/meet-martin-grobusch-malaria-fighter
2021-10-13T15:53:46+02:00
daily
1.0
https://www.novartis.com/stories/experts-call-new-approach-patient-and-physician-management-type-2-diabetes
2021-10-07T09:59:01+02:00
daily
1.0
https://www.novartis.com/stories/giving-small-community-big-voice
2021-10-15T15:57:22+02:00
daily
1.0
https://www.novartis.com/stories/fitness-trainer-strives-keep-his-mothers-mind-limber
2021-10-11T11:48:50+02:00
daily
1.0
https://www.novartis.com/stories/from-nurse-patient-facing-aggressive-blood-cancer
2021-10-18T06:19:36+02:00
daily
1.0
https://www.novartis.com/stories/glaucoma-silently-steals-sight
2021-10-15T15:53:20+02:00
daily
1.0
https://www.novartis.com/stories/meet-visionary-who-beat-odds-realize-his-vision-inclusive-eye-care
2023-07-04T15:38:55+02:00
daily
1.0
https://www.novartis.com/stories/groundskeeper-tackles-cancer-several-ways
2021-10-15T15:50:32+02:00
daily
1.0
https://www.novartis.com/stories/heart-failure-coping-one-worlds-biggest-killers
2021-10-15T15:45:59+02:00
daily
1.0
https://www.novartis.com/stories/importance-caregivers
2021-10-15T15:39:28+02:00
daily
1.0
https://www.novartis.com/stories/inside-cancer-diagnosis
2021-10-15T14:51:02+02:00
daily
1.0
https://www.novartis.com/stories/patients-perspective-biomarker-testing
2021-10-15T11:46:39+02:00
daily
1.0
https://www.novartis.com/stories/led-steven-taylor-sjogrens-syndrome-foundation-raising-awareness-little-known-autoimmune-disease
2021-10-08T10:39:04+02:00
daily
1.0
https://www.novartis.com/stories/lessons-from-blind-chef
2022-01-07T09:19:03+01:00
daily
1.0
https://www.novartis.com/stories/living-heart-failure
2021-10-15T11:45:48+02:00
daily
1.0
https://www.novartis.com/stories/living-hfpef-patients-story
2021-11-17T17:37:31+01:00
daily
1.0
https://www.novartis.com/stories/longevity-vitality-japanese-elders-provide-examples-healthy-aging
2021-10-15T12:09:23+02:00
daily
1.0
https://www.novartis.com/stories/lung-cancer-test-or-not-test
2021-10-14T14:28:13+02:00
daily
1.0
https://www.novartis.com/stories/meet-tj-sharpe
2023-07-04T15:36:44+02:00
daily
1.0
https://www.novartis.com/stories/most-europeans-have-limited-awareness-about-heart-failure
2022-01-07T09:11:28+01:00
daily
1.0
https://www.novartis.com/stories/migraine-one-worlds-most-common-diseases
2021-10-14T14:11:18+02:00
daily
1.0
https://www.novartis.com/stories/new-years-resolution-copd
2021-10-14T13:51:17+02:00
daily
1.0
https://www.novartis.com/stories/no-longer-living-fear
2021-10-15T12:22:53+02:00
daily
1.0
https://www.novartis.com/stories/one-boys-quest-battle-cancer
2023-07-04T16:05:46+02:00
daily
1.0
https://www.novartis.com/stories/parenting-child-rare-disease
2023-07-04T16:10:37+02:00
daily
1.0
https://www.novartis.com/stories/patient-advocacy-work-one-mans-contributions-copd-community
2021-10-14T13:01:39+02:00
daily
1.0
https://www.novartis.com/stories/psoriasis-story-hidden-condition
2021-10-11T11:09:07+02:00
daily
1.0
https://www.novartis.com/stories/putting-patients-first
2022-02-14T11:58:04+01:00
daily
1.0
https://www.novartis.com/stories/rare-every-day-experiences-challenges-and-victories-rare-disease-community
2021-09-30T09:08:16+02:00
daily
1.0
https://www.novartis.com/stories/protecting-our-tomorrows-portraits-meningococcal-disease
2021-10-14T11:41:25+02:00
daily
1.0
https://www.novartis.com/stories/realities-living-premenopausal-metastatic-breast-cancer
2021-11-17T11:46:58+01:00
daily
1.0
https://www.novartis.com/stories/reimagining-asthma-care-how-data-and-digital-could-bring-asthma-management-goals-within-reach
2023-07-04T16:15:04+02:00
daily
1.0
https://www.novartis.com/stories/surviving-heart-failure
2022-06-21T15:49:35+02:00
daily
1.0
https://www.novartis.com/stories/speaking-cml
2021-09-29T10:00:07+02:00
daily
1.0
https://www.novartis.com/stories/targeting-roots-sjogrens-syndrome
2021-09-29T10:18:29+02:00
daily
1.0
https://www.novartis.com/stories/tj-sharpe-why-clinical-trials-matter
2023-07-04T16:36:55+02:00
daily
1.0
https://www.novartis.com/stories/visionary-silke-mader-has-vision-care-premature-infants-and-their-parents
2021-10-11T10:30:01+02:00
daily
1.0
https://www.novartis.com/stories/why-research-rare-diseases-matters
2021-08-25T13:31:50+02:00
daily
1.0
https://www.novartis.com/stories/turning-sound-patient-voices-lung-cancer-research-and-development
2021-10-01T07:49:32+02:00
daily
1.0
https://www.novartis.com/stories/flexibility-novartis-ana-graf
2021-09-29T11:17:57+02:00
daily
1.0
https://www.novartis.com/stories/enabling-130000-employees-grow-organization-committed-continuous-learning
2021-09-29T10:38:57+02:00
daily
1.0
https://www.novartis.com/stories/your-genes-your-melanoma
2021-09-29T10:27:17+02:00
daily
1.0
https://www.novartis.com/stories/flexibility-novartis-deepti-mittal
2021-09-29T11:20:57+02:00
daily
1.0
https://www.novartis.com/stories/flexibility-novartis-christine-sturchler-and-aileen-wrynn
2021-10-14T07:23:16+02:00
daily
1.0
https://www.novartis.com/stories/flexibility-novartis-janneke-van-der-kamp
2021-09-29T11:22:04+02:00
daily
1.0
https://www.novartis.com/stories/flexibility-novartis-peter-canavan
2021-10-14T06:37:46+02:00
daily
1.0
https://www.novartis.com/stories/flexibility-novartis-linda-karpiak
2021-09-29T11:23:23+02:00
daily
1.0
https://www.novartis.com/stories/flexibility-novartis-robert-gschwentner-and-stefan-lackner
2021-10-14T06:27:54+02:00
daily
1.0
https://www.novartis.com/stories/going-extra-mile-keep-clinical-trials-track-during-covid-19-pandemic
2021-09-29T12:37:53+02:00
daily
1.0
https://www.novartis.com/stories/flexibility-novartis-shamsah-kazani
2021-11-16T11:15:40+01:00
daily
1.0
https://www.novartis.com/stories/novartis-social-business-careers-improving-health-lower-income-countries
2022-01-07T09:00:43+01:00
daily
1.0
https://www.novartis.com/stories/oncology-careers-life-changing-purpose
2021-09-29T12:46:25+02:00
daily
1.0
https://www.novartis.com/stories/parental-leave-novartis-alfreds-story
2022-05-24T16:23:14+02:00
daily
1.0
https://www.novartis.com/stories/parental-leave-novartis-michaels-story
2021-11-23T16:50:24+01:00
daily
1.0
https://www.novartis.com/stories/nudging-bias-out-organization
2021-09-23T11:39:01+02:00
daily
1.0
https://www.novartis.com/stories/qa-new-nibr-cio-dimitris-agrafiotis
2021-09-30T14:50:31+02:00
daily
1.0
https://www.novartis.com/stories/reimagining-cancer-workplace
2021-09-29T12:52:28+02:00
daily
1.0
https://www.novartis.com/stories/teaching-daughter-power-purpose
2021-10-14T10:09:52+02:00
daily
1.0
https://www.novartis.com/stories/two-decades-volunteering-novartis
2021-10-11T10:18:12+02:00
daily
1.0
https://www.novartis.com/stories/making-healthcare-sustainable-developing-world
2021-10-06T07:37:52+02:00
daily
1.0
https://www.novartis.com/stories/positive-gains-are-needed-accelerate-change-women-lung-disease
2021-10-01T10:03:00+02:00
daily
1.0
https://www.novartis.com/stories/new-drugs-could-offer-hope-malaria-patients
2021-10-03T16:01:27+02:00
daily
1.0
https://www.novartis.com/stories/partnering-improved-cancer-care-around-globe
2021-10-07T11:03:23+02:00
daily
1.0
https://www.novartis.com/stories/pioneering-business-approach-expands-healthcare-indian-villages
2021-10-14T11:57:33+02:00
daily
1.0
https://www.novartis.com/stories/novartis-joins-pharma-wide-effort-meet-global-demand-covid-19-vaccines
2022-05-20T15:35:45+02:00
daily
1.0
https://www.novartis.com/stories/new-orbis-flying-eye-hospital-helps-fight-blindness-china
2021-10-14T08:54:03+02:00
daily
1.0
https://www.novartis.com/stories/novartis-access-impact-evaluation-progress-update-our-work-boston-university
2021-10-01T10:07:32+02:00
daily
1.0
https://www.novartis.com/stories/novartis-invites-scrutiny-effort-improve-access-medicine
2022-06-07T17:08:17+02:00
daily
1.0
https://www.novartis.com/stories/artificial-intelligence-decodes-cancer-pathology-images-without-image-gallery
2021-08-24T11:51:26+02:00
daily
1.0
https://www.novartis.com/stories/can-data-from-heart-disease-trial-lead-potential-cancer-treatment
2021-09-30T14:48:46+02:00
daily
1.0
https://www.novartis.com/stories/cancer-research-drives-breast-cancer-treatment-forward
2021-09-30T09:47:34+02:00
daily
1.0
https://www.novartis.com/stories/discovery-gives-cystic-fibrosis-researchers-new-direction
2021-10-11T10:39:37+02:00
daily
1.0
https://www.novartis.com/stories/guidance-system-lights-path-drug-discovery
2021-10-18T09:03:23+02:00
daily
1.0
https://www.novartis.com/stories/need-new-heart-disease-medicines-drives-wave-potential-therapies
2021-09-30T11:20:32+02:00
daily
1.0
https://www.novartis.com/stories/researchers-boost-understanding-t-cell-therapy-blood-cancer
2021-09-30T11:41:44+02:00
daily
1.0
https://www.novartis.com/stories/novartis-and-uc-berkeley-take-undruggable-proteins-new-collaboration
2022-05-24T16:17:59+02:00
daily
1.0
https://www.novartis.com/stories/striving-vanquish-leukemia
2021-09-27T11:08:05+02:00
daily
1.0
https://www.novartis.com/stories/sourcing-innovation-strategically
2021-09-30T12:12:06+02:00
daily
1.0
https://www.novartis.com/stories/take-visual-tour-medicines-target-rna
2022-06-21T17:13:21+02:00
daily
1.0
https://www.novartis.com/stories/toward-improving-health-and-longevity-transplanted-organs
2021-09-30T15:13:47+02:00
daily
1.0
https://www.novartis.com/stories/using-super-resolution-microscopy-see-neurodegeneration
2021-09-30T15:30:39+02:00
daily
1.0
https://www.novartis.com/stories/visualizing-molecular-glues
2021-09-30T15:43:23+02:00
daily
1.0
https://www.novartis.com/stories/advancing-medicine-through-collaboration
2021-09-30T16:00:24+02:00
daily
1.0
https://www.novartis.com/stories/how-19th-century-technology-speeding-drug-discovery
2021-09-30T16:13:22+02:00
daily
1.0
https://www.novartis.com/stories/seeing-through-knees-quest-alleviate-osteoarthritis
2021-09-30T16:17:25+02:00
daily
1.0
https://www.novartis.com/stories/why-novartis-scouts-disruptive-technology
2021-09-30T16:30:01+02:00
daily
1.0
https://www.novartis.com/stories/future-chronic-myeloid-leukemia-evolving
2021-10-15T16:05:57+02:00
daily
1.0
https://www.novartis.com/stories/inspiring-daughter-make-her-own-path
2021-10-15T12:05:00+02:00
daily
1.0
https://www.novartis.com/stories/being-and-becoming-data-science-company
2021-09-30T14:30:36+02:00
daily
1.0
https://www.novartis.com/stories/doing-right-thing-good-business
2021-10-11T08:41:26+02:00
daily
1.0
https://www.novartis.com/stories/discover-how-inflammation-could-fan-flames-cancer
2021-10-11T10:42:18+02:00
daily
1.0
https://www.novartis.com/stories/your-neighborhood-community-based-approach-health-equity-us
2021-10-26T16:09:50+02:00
daily
1.0
https://www.novartis.com/stories/search-new-options-patients-lung-cancer
2021-10-01T12:27:18+02:00
daily
1.0
https://www.novartis.com/stories/toward-regrowing-cartilage
2023-07-04T16:46:35+02:00
daily
1.0
https://www.novartis.com/stories/blood-cancer-patients-long-road-diagnosis
2021-10-15T12:02:17+02:00
daily
1.0
https://www.novartis.com/stories/photographer-captures-patients-around-world-persevering-itp
2021-10-08T08:09:48+02:00
daily
1.0
https://www.novartis.com/stories/expanding-new-digital-healthcare-solution-across-chronic-heart-disease-management
2021-10-11T08:39:32+02:00
daily
1.0
https://www.novartis.com/stories/restoring-vision-and-hope-thousands-southeast-asia
2023-02-06T10:13:26+01:00
daily
1.0
https://www.novartis.com/stories/demystifying-science-myelodysplastic-syndromes
2023-02-06T10:13:06+01:00
daily
1.0
https://www.novartis.com/stories/breaking-down-barriers-patients-sickle-cell-disease
2023-02-06T10:12:35+01:00
daily
1.0
https://www.novartis.com/stories/make-difference-start-patients
2023-02-06T10:12:51+01:00
daily
1.0
https://www.novartis.com/stories/solving-puzzle-immunotherapy
2023-04-11T15:57:36+02:00
daily
1.0
https://www.novartis.com/stories/stopping-coronavirus-and-next-one
2023-02-06T10:11:58+01:00
daily
1.0
https://www.novartis.com/stories/art-drug-design-technological-age
2023-02-06T10:11:41+01:00
daily
1.0
https://www.novartis.com/stories/when-it-comes-cancer-theres-power-good-partner
2023-02-06T10:11:08+01:00
daily
1.0
https://www.novartis.com/stories/prioritizing-needs-patients
2023-02-06T10:10:30+01:00
daily
1.0
https://www.novartis.com/stories/understanding-hidradenitis-suppurativa-through-jasmines-eyes
2022-03-25T10:27:19+01:00
daily
1.0
https://www.novartis.com/stories/tackling-health-toll-climate-change
2022-04-06T15:38:18+02:00
daily
1.0
https://www.novartis.com/stories/staying-one-step-ahead-malaria-parasite
2022-04-19T18:16:06+02:00
daily
1.0
https://www.novartis.com/stories/boosting-access-cancer-care-where-its-needed-most
2022-06-13T09:30:28+02:00
daily
1.0
https://www.novartis.com/stories/how-emilys-act-bravery-inspired-wave-continued-innovation
2023-02-06T10:09:32+01:00
daily
1.0
https://www.novartis.com/stories/prostate-cancer-collective-commitment-serving-underserved-communities
2022-06-13T09:12:51+02:00
daily
1.0
https://www.novartis.com/stories/shared-mission-take-impossible-cancer-research
2022-06-15T08:37:00+02:00
daily
1.0
https://www.novartis.com/stories/sickle-cell-screening-urged-newborns-africa
2023-02-06T09:22:58+01:00
daily
1.0
https://www.novartis.com/stories/renewing-our-commitment-neglected-tropical-disease-and-malaria-elimination
2022-06-23T07:30:04+02:00
daily
1.0
https://www.novartis.com/stories/lets-talk-about-c-word-navigating-cancer-diagnosis-and-life-beyond-it-leanne-pero
2022-10-12T16:02:31+02:00
daily
1.0
https://www.novartis.com/stories/neuroscience-inflection-point-knowledge-and-technology
2022-10-13T22:47:12+02:00
daily
1.0
https://www.novartis.com/stories/scientist-from-start-qa-nibr-president-fiona-marshall
2022-11-01T12:41:44+01:00
daily
1.0
https://www.novartis.com/stories/prostate-cancer-and-support-care-partner-carl-and-arlenes-story
2023-02-16T15:34:10+01:00
daily
1.0
https://www.novartis.com/stories/compassionate-use-providing-access-much-needed-treatments
2023-02-06T09:19:07+01:00
daily
1.0
https://www.novartis.com/stories/when-you-think-word-cancer-what-are-first-words-spring-mind
2023-04-24T15:44:38+02:00
daily
1.0
https://www.novartis.com/stories/qa-addressing-unmet-needs-people-living-pnh-rare-and-chronic-blood-disorder
2023-08-29T14:32:50+02:00
daily
1.0
https://www.novartis.com/stories/future-medicine-here
2023-05-30T09:55:27+02:00
daily
1.0
https://www.novartis.com/stories/treatments-blood-cancers-and-serious-blood-disorders-are-advancing-rapidly-novartis-helping-lead-way
2023-09-08T15:13:36+02:00
daily
1.0
https://www.novartis.com/stories/how-i-found-my-true-purpose-novartis
2023-11-28T08:16:01+01:00
daily
1.0
https://www.novartis.com/stories/belonging-here-how-novartis-helped-me-come-out-transgender-woman
2023-11-28T08:16:49+01:00
daily
1.0
https://www.novartis.com/stories/mentoring-matters-how-we-grow-together-novartis
2023-11-28T08:14:32+01:00
daily
1.0
https://www.novartis.com/stories/beacon-hope-lights-way-more-equitable-future
2023-11-30T18:38:42+01:00
daily
1.0
https://www.novartis.com/stories/shoulder-to-shoulder
2023-12-08T17:10:45+01:00
daily
1.0
https://www.novartis.com/stories/innovation-fueled-compassion
2023-12-14T09:16:07+01:00
daily
1.0
https://www.novartis.com/stories/balancing-family-life-legal-career
2024-02-07T13:56:41+01:00
daily
1.0
https://www.novartis.com/stories/facing-fear-breast-cancer-recurrence
2024-02-05T10:04:04+01:00
daily
1.0
https://www.novartis.com/stories/partnership-against-epilepsy
2024-02-05T10:10:58+01:00
daily
1.0
https://www.novartis.com/stories/water-project-revives-rural-community-india
2024-02-05T09:59:30+01:00
daily
1.0
https://www.novartis.com/stories/giving-voice-people-misunderstood-disease
2024-02-05T10:08:14+01:00
daily
1.0
https://www.novartis.com/stories/cancer-patient-gets-new-lease-life
2024-01-29T15:21:43+01:00
daily
1.0
https://www.novartis.com/stories/empowering-next-generation-healthcare-leaders
2024-01-29T15:23:04+01:00
daily
1.0
https://www.novartis.com/stories/going-upstream-improve-heart-health-philadelphia
2024-01-26T11:32:14+01:00
daily
1.0
https://www.novartis.com/stories/colombia-researcher-works-against-devastating-disease
2024-01-26T11:32:56+01:00
daily
1.0
https://www.novartis.com/stories/how-collaboration-can-enhance-your-science-career
2024-02-08T09:23:38+01:00
daily
1.0
https://www.novartis.com/stories/listening-cml-patient-community
2024-02-14T08:13:45+01:00
daily
1.0